Document:

Development and Supply Agreement with Dynal S.A.

 Exhibit 10.34 
  
 Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the
confidentiality request. Omissions are designated as [*]. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 
  
 EXECUTION COPY 
  
 DEVELOPMENT AND SUPPLY AGREEMENT 
  
 This Development and Supply Agreement (the “Agreement”) is made and entered into as of the 1st day of August, 1999 (the “Effective
Date”) by and between XCYTE THERAPIES, INC., a Delaware corporation with offices at 1124 Columbia Street. Suite 130 Seattle, Washington 98104 (hereinafter referred to as “Xcyte”), and DYNAL A.S., a Norwegian corporation,
with offices at P.O. Box 158, Skøyen, N-0212 Oslo, Norway (hereinafter referred to as “Dynal”). 
  
 WITNESSETH: 
  
 WHEREAS Dynal has substantial knowledge and a proprietary position and expertise relating to research, development, manufacture and distribution of
products and technology for biomagnetic separation and handling of cells, microorganisms, bacteria, proteins and nucleic acids; 
  
 WHEREAS Xcyte has substantial knowledge and a proprietary position and expertise relating to the ex vivo expansion and activation of
T-cells; 
  
 WHEREAS prior to entering into this Agreement
the parties executed a Letter Agreement dated October 27, 1999 (the “Letter Agreement”) whereby Xcyte paid Dynal the sum of one hundred thousand U.S. dollars (U.S.$100,000) in consideration for certain development activities
conducted by Dynal prior to the Signing Date; and 
  
 WHEREAS
Dynal and Xcyte wish to establish a development and supply agreement whereby Dynal will develop, manufacture and supply certain products that will incorporate certain paramagnetic particles (with and without antibodies) to be commercialized by
Xcyte in one or more therapies in the Field (as such term is defined below), as set forth in this Agreement. 
  
 NOW, THEREFORE, in consideration of the mutual covenants and promises contained herein, and for other good and valuable consideration, the receipt
and sufficiency of which is hereby acknowledged, the parties agree as follows: 
  
 SECTION 1: DEFINITIONS OF TERMS 
  
 1.1 “Affiliate” shall mean a person or entity that, directly or indirectly through one or more intermediaries controls, is controlled by, or is under common control with, a party to this Agreement. As used in this
definition, “control” means owning more than fifty percent (50%) of such an entity or party to this Agreement. 

 EXECUTION COPY 
  
 1.2 “Antibodies” shall mean the antibodies described in the antibody specifications set forth in Attachment
A hereto. The antibody specifications set forth in Attachment A may be modified from time to time by the mutual agreement of the parties (including modifications as may be appropriate to include the release criteria for Phase III) and
neither party shall unreasonably withhold its consent to modifications proposed by the other party. 
  
 1.3 “Assays” shall mean the assays determined mutually by the parties (except that Xcyte shall determine the functional Assays performed
and paid for by Xcyte pursuant to Section 2.8, with Dynal’s acceptance (such acceptance not to be unreasonably withheld)) and set forth in a Work Plan to be required for the completion of the work called for in such Work Plan, including
all existing or to-be-developed standards, specifications, validation protocols and reports related thereto. 
  
 1.4 “Nascent Beads” shall mean any beads or paramagnetic particles that are not conjugated with antibodies or any other materials or
substances or coated with any materials or substances. 
  
 1.5
“CD3x28 Beads” shall mean any paramagnetic particles or beads that are doubly conjugated with antibodies to CD3 and antibodies to CD28 and that are not conjugated with any other antibodies. 
  
 1.6 “cGMP” shall mean current Good Manufacturing Practices,
as defined in 21 CFR Part 210, Part 211, Part 610 and Part 680. 
  
 1.7 “Development Phase” shall mean and refer to, as the context indicates the period during the term of this Agreement starting on the Effective Date and ending when Xcyte receives final marketing approval from the U.S.
Food and Drug Administration or any successor thereto (the “FDA”) to use the Products in the Field for the first indication under this Agreement. 
  
 1.8 “DMF” shall mean a drug master file or device master file, as the context indicates (or the non-U.S.
equivalent as appropriate in each country of the Territory) or any related regulatory filing. 
  
 1.9 “Dynabeads® M-450 CD3/CD28 T” shall mean the Dynabeads® M-450 CD3/CD28 beads consisting of Dynabeads® M-450 epoxy beads conjugated with the Antibodies, to be developed and manufactured pursuant to this Agreement in accordance with the Dynabeads® M-450 CD3/CD28 T Specifications. 
  
 1.10 “Dynabeads® M-450 Epoxy T” shall mean Dynabeads® M-450 epoxy beads, to be developed and manufactured pursuant to this Agreement in
accordance with the Dynabeads® M-450 Epoxy T
Specifications. 
  
 1.11 “Field” shall mean ex
vivo expansion and/or activation of T-cells using CD3x28 Beads (whether or not in conjunction with one or more other beads, paramagnetic particles, steps or procedures) for Therapeutic Use; provided, however, that the Field shall
exclude the following: 
  
  

 - 2 - 

 EXECUTION COPY 
  
 (a) any and all uses in multiarray microfluidic chip format analyzers; and 
  
 (b) any use in process or multiarray chip format that
comprises general or special applications in DNA/RNA-technology, including isolation of DNA/RNA fragments (DNA/RNA probes), peptide nucleic acids (PNA), plasmids, oligonucleotides, or any other subcellular components (Mitochondria, Endoplasmic
reticulum, Golgi apparatus, etc.) 
  
 1.12 “Patents”
shall mean all patents and patent applications, and all additions, divisions, continuations, continuations in-part, pipeline protection, substitutions, reissues, extensions, registrations, patent term extensions, supplementary protection
certificates and renewals of any of the above. 
  
 1.13
“Products” shall mean, collectively, the Dynabeads® M-450 Epoxy T and the Dynabeads® M-450 CD3/CD28 T. 
  
 1.14
“Signing Date” shall mean December 7, 1999, the date this Agreement was signed by the parties. 
  
 1.15 “Specifications” shall mean: 
  
 (i) the release criteria and specifications for the Dynabeads® M-450 Epoxy T as set forth in Attachment C hereto, and as the same may be refined and amended from time to time
by Dynal (the “Dynabeads® M-450 Epoxy T
Specifications”); and 
  
 (ii) the
release criteria and specifications for the Dynabeads® M-450 CD3/CD28 T as set forth in draft form in Attachment D hereto, and as the same may be refined, amended and finalized in the course of the development activities under this Agreement by the mutual agreement
of Dynal and Xcyte (the “Dynabeads® M-450
CD3/CD28 T Specifications”). 
  
 Neither party shall unreasonably
withhold its consent to an alteration or supplementation to the Dynabeads® M-450 CD3/CD28 T Specifications. 
  
 1.16 “Territory” shall mean the world. 
  
 1.17 “Therapeutic Use” shall mean the attempt to cure, improve, mitigate, treat and/or prevent disease and/or other conditions in humans. 
  
 1.18 “Third Party” shall mean any person or entity other than a party to this Agreement or an Affiliate of
a party to this Agreement. 
  
 1.19 “Work Plans”
shall mean the work plans which detail the parties’ respective tasks and responsibilities with respect to the development work to be conducted during the Development Phase in connection with the Dynabeads® M-450 CD3/CD28 T under this Agreement in connection with filing and obtaining final
marketing approval from the FDA in the United States as set forth in Attachment B, and as may be amended or modified from time to time, by mutual agreement of the parties. Subject to Section 2.5, neither party shall unreasonably
withhold its consent to amendments or modifications of the Work Plans proposed by the other party. 
  

 - 3 - 

 EXECUTION COPY 
  
 1.20 “Year” shall mean a calendar year. 
  
 SECTION 2: DEVELOPMENT PHASE AND REGULATORY FILINGS 
  
 2.1    During the Development Phase, Dynal shall
use its good faith and commercially reasonable efforts to complete its responsibilities under the Work Plans in accordance with the standards and time frames stated therein and the terms and conditions of this Agreement. If Xcyte does not complete
its responsibilities under the Work Plans in accordance with the standards and time frames stated therein and/or the terms and conditions of this Agreement, Dynal shall not be entitled to terminate this Agreement therefor, but Dynal shall be
afforded additional time to accomplish such activity to the extent necessary to account for any such delay caused by or as a result of actions or inactions of Xcyte or its Affiliates or agents. As of the Signing Date, the Work Plans detail
the development activities to be conducted through Phase I of the Development Phase, but only provide a general outline of the development activities to be conducted during Phase III of the Development Phase, and therefore, the parties shall after
the Signing Date, amend the Work Plans to detail the Phase III activities during the Development Phase, as mutually agreed by the parties. The parties shall use commercially reasonable efforts to so amend the Work Plans to detail the Phase III
activities by April 1, 2000. 
  
 2.2    The parties shall, promptly after the Signing Date, each designate a representative to act as a contact person for the other party and to coordinate and communicate between the parties with respect to each
party’s respective development activities under this Agreement during the Development Phase. A party may change its designee at any time by written notice to the other party. During the Development Phase, each party shall prepare and provide to
the other party written reports on a quarterly basis detailing its development activities and progress under the Work Plans under this Agreement, and each party shall also keep the other party generally updated on a monthly basis of its development
activities and progress under this Agreement. 
  
 2.3    As part of Dynal’s activities under the Work Plans, Dynal, at its cost, shall duly file with the FDA and the regulatory agencies in the countries included in the European Union (the
“EU”), and shall own, all DMFs that are to be filed in connection with the Products. With respect to countries in the Territory outside of the United States and the EU, Dynal shall, at Xcyte’s cost, if and as requested by
Xcyte, duly file with the regulatory agencies in such countries, and shall own, all DMFs for the Products. During the term of this Agreement and after the term of this Agreement upon non-renewal of this Agreement or termination of this Agreement
pursuant to Section 8.3 by Xcyte, Xcyte shall have the right to cross-reference all DMFs filed during the term of this Agreement by Dynal in the Territory as necessary to enable Xcyte to obtain or maintain marketing approval for use of the
Products in the Field. Xcyte or its Antibody suppliers shall duly file with the FDA and the applicable regulatory agencies in the Territory outside the United States and shall own all regulatory filings for the Antibodies. If Xcyte makes any
regulatory filings in the Territory relating to the Products and/or their use in the Field, Dynal shall have the right to cross-reference such regulatory filings in the Territory as necessary in connection with Dynal’s obligations under this
Agreement, including with respect to accomplishing activities under the Work Plans, making DMF filings for the Products and manufacturing and supplying the Products to Xcyte under this Agreement. If a regulatory agency in the Territory will not
grant marketing approval to Xcyte for use of the Products in the Field based upon a cross-reference to a DMF for the Products made by Dynal or its agent for the Field, and requires that Xcyte submit the information that is (or if not yet filed in
such country, would be) included in Dynal’s DMF for the Products in such country for the Field, Dynal shall provide the information that is (or if not yet filed in such country, would be) included in Dynal’s DMF for the Products for the
Field solely for Xcyte to include such information in its filing to the regulatory agency to obtain marketing approval for use of the Products in the Field in such country and for no other use or purpose; provided that Xcyte provides Dynal
with written confirmation from the regulatory agency in such country that the regulatory agency will not allow a cross-reference to Dynal’s DMF for the Product, and requires the information that is (or if not yet filed in such country, would
be) included in Dynal’s DMF for the Products. 
  
 2.4    In order to fund Dynal’s work directed toward the accomplishment of the development activities under the Work Plans as well as for activities undertaken by Dynal prior to the Signing Date, Xcyte shall
make the following non-creditable and non-refundable milestone payments to Dynal as follows: 
  
 (i) Xcyte shall pay to Dynal five hundred thousand U.S. dollars (U.S.$500,000), one hundred thousand U.S. dollars (U.S.$100,000) of which
was paid by Xcyte to Dynal prior to the Signing Date pursuant to the Letter Agreement, and the remaining four hundred thousand U.S. dollar (U.S.$400,000) of which shall be paid to Dynal on January 3, 2000 (“Milestone Payment 1”);

  

 - 4 - 

 EXECUTION COPY 
  
 (ii) When [*] Xcyte shall pay to Dynal five hundred thousand U.S. dollars (U.S.$ 500,000)
(“Milestone Payment 2”) (Dynal shall have no obligation to [*] prior to receiving Milestone Payment 2 from Xcyte); 
  
 (iii) On and as of April 1, 2000, Xcyte shall be obligated to pay Dynal one million U.S. dollars (U.S.$ 1,000,000), five hundred thousand
U.S. dollars (U.S.$500,000) of which (“Milestone Payment 3”) shall be paid to Dynal on April 1, 2000 and the five hundred thousand U.S. dollar (U.S.$500,000) balance of which (“Milestone Payment 4”) shall be paid to
Dynal on October 1, 2000; 
  
 (iv) When
[*] Xcyte shall pay to Dynal five hundred thousand U.S. dollars (U.S.$ 500,000) (“Milestone Payment 5”) (Dynal shall have no obligation to [*] prior to receiving Milestone Payment 5 from Xcyte); and 
  
 (v) When (a) the [*] (Xcyte shall notify Dynal when
to commence the production of such [*]); and (b) Dynal has [*] Xcyte shall pay to Dynal five hundred thousand U.S. dollars (U.S.$ 500,000) (“Milestone Payment 6”) (Dynal shall have no obligation to [*] prior to
receiving Milestone Payment 6 from Xcyte). 
  
 The milestone
payments set forth in this Section 2.4 shall be paid by Xcyte by wire transfer to an account designated by Dynal. 
  
 2.5 Notwithstanding anything contained in this Agreement, in no event shall Dynal be obligated to perform any activities under this Agreement that
would require efforts or expenditures in excess of the scope reasonably contemplated by the parties as of the Signing Date, as reflected from time to time in Work Plans, to complete the development of the Dynabeads® M-450 CD3/CD28 T Product during the Development Phase in connection with
obtaining marketing approval from the FDA to use the Products in the Field for the first indication under this Agreement, and as contemplated to make the regulatory filings pursuant to Section 2.3. 
  
 2.6 Xcyte shall, at its discretion and at its expense, apply for
marketing approval in the United States and in the other countries in the Territory, as determined by Xcyte, and shall conduct and control all Phase I, Phase II (or Phase I/II), and Phase III clinical trials in the Field using the Products as Xcyte
considers necessary and appropriate, in light of applicable regulatory requirements and the results obtained to date. Except as otherwise expressly set forth in this Agreement, including Sections 2.3 and 6, Xcyte shall own all clinical
protocols, all results of such clinical tests, all other clinical data required for regulatory submissions and approvals, all such regulatory filings, and any and all regulatory approvals. 
  
 2.7 Dynal shall inform Xcyte of any amendments to the Dynabeads® M-450 Epoxy T Specifications. 
  
 2.8 Xcyte shall own any and all proprietary rights relating to the
functional Assays, provided that Xcyte shall develop the functional Assays (including the inter-lab validation of the functional Assays) and shall pay for all costs and expenses associated therewith. 
  
 SECTION 3: SUPPLY AND DISTRIBUTION 
  
 3.1 During the term of this Agreement, and subject to the terms and
conditions set forth herein, (a) Xcyte shall, as ordered by Dynal, supply Dynal with the Antibodies, at Xcyte’s 
  
  
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities & Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 - 5 - 

 EXECUTION COPY 
  
 cost, for use by Dynal solely for use in the production of the Dynabeads® M-450 CD3/CD28 T in accordance with the specifications for the Antibodies set forth in
Attachment A and the Specifications; and (b) Dynal, subject to Xcyte’s obligation to supply Antibodies to Dynal, shall supply to Xcyte, and Xcyte shall purchase from Dynal, all of Xcyte’s and its Affiliates’ requirements (i)
for Dynabeads® M-450 CD3/CD28 T for use in clinical
trials and other product research, development, certification or regulatory activities conducted in connection with either or both of the Products in the Field in the Territory; and (ii) for Dynabeads® M-450 CD3/CD28 T for use, marketing, distribution, sale and import by Xcyte and its
Affiliates in the Field in the Territory; and (iii) to be held in reasonable inventories associated with any of the foregoing. 
  
 3.2 During the term of this Agreement, Dynal shall supply to Xcyte, and Xcyte shall purchase from Dynal, all of Xcyte’s and its
Affiliates’ requirements (a) for Dynabeads®
M-450 Epoxy T for use in clinical trials and other product research, development, certification or regulatory activities conducted in connection with either or both of the Products in connection with the Dynabeads® M-450 CD3/CD28 T in the Field in the Territory; (b) for Dynabeads® M450 Epoxy T for use, marketing, distribution, sale,
and import by Xcyte and its Affiliates in connection with the Dynabeads® M-450 CD3/CD28 T in the Field in the Territory; and (c) to be held in reasonable inventories associated with any of the foregoing. For the avoidance of doubt, to the extent that Dynal has to conduct any development
activities with respect to the Dynabeads® M-450
Epoxy T, Dynal shall ensure that it conducts such activities in a timely manner so that it will be able to supply Xcyte the Dynabeads® M-450 Epoxy T Product when it supplies Xcyte the Dynabeads® M-450 CD3/CD28 T Product, as provided under this Agreement. 
  
 3.3 Xcyte shall ensure that any Products to be sold or otherwise distributed by Xcyte or its Affiliates or any of
their distributors, licensees or agents, for use in the Field shall be appropriately labeled to state that the use thereof is limited to use solely within the Field. If either party becomes aware that Products are being used outside the Field or
outside the Territory, it shall promptly notify the other party hereto. Xcyte shall and shall ensure that its Affiliates and each of their distributors, licensees and agents shall, use its reasonable commercial efforts to preserve the quality of the
Products and shall act in accordance with any applicable quality control guidelines for the Products provided to Xcyte by Dynal. 
  
 3.4 Xcyte shall not, and shall ensure that its Affiliates and that their respective distributors, licensees and agents shall not, sell or use any
Products or perform any treatments utilizing the Products not in compliance with applicable laws, regulations and orders. If either party becomes aware that Products are being used, or that treatments are being performed using the Products, not in
compliance with applicable laws, regulations and orders, it shall promptly notify the other party hereto. 
  
 3.5 Xcyte shall, and shall ensure that its Affiliates and/or its and its Affiliates’ distributors, licensees and agents shall, only sell and
distribute the Products for use in the Field in the Territory pursuant to the terms and conditions of this Agreement, and in doing so neither Xcyte nor its Affiliates shall use or sell or otherwise distribute, and shall ensure that their respective
distributors, licensees and agents shall not use or sell or otherwise distribute, the 
  

 - 6 - 

 EXECUTION COPY 
  
 Dynabeads® M-450 Epoxy T for any use except in connection with the Dynabeads® M-450 CD3/CD28 T and only in the Field. Xcyte shall remain primarily liable and responsible for the performance and
observance of all of its and its Affiliates’ and each of their consultants, distributors’ and licensees’ and agents’ duties and obligations in accordance with the terms and conditions of this Agreement. Any agreement between
Xcyte and any of its Affiliates or any of their consultants, distributors, licensees or agents shall be consistent with the terms and conditions of this Agreement and shall include appropriate obligations of confidentiality and a limitation to use
of the Products solely within the Field. 
  
 3.6 During the
term of this Agreement, Xcyte shall purchase all of its requirements for CD3x28 Beads and Nascent Beads for use in the Field; however, if Xcyte must substitute another CD3x28 Bead for the Dynabeads® M-450 CD3/CD28 T and/or another Nascent Bead for the Dynabeads® M-450 Epoxy T for medical (e.g., adverse medical
reaction arising from use of the Dynabeads® M-450
CD3/CD28 T Product and/or the Dynabeads® M-450
Epoxy T Product) or regulatory (e.g., rejection of the Dynabeads® M-450 CD3/CD28 T Product and/or the Dynabeads® M-450 Epoxy T Product by a regulatory agency) reasons for use in the Field in any country or countries of the Territory, Xcyte shall promptly notify Dynal and provide Dynal with sufficient information and documentation
to evidence the medical and/or regulatory reason or reasons that require Xcyte to substitute the Dynabeads® M-450 CD3/CD28 I Product and/or the Dynabeads® M-450 Epoxy T Product. After such notice and provision of information and documentation have been provided to Dynal by Xcyte, the parties shall discuss in good faith what would be an
acceptable substitute CD3x28 Bead and/or substitute Nascent Bead, and after the parties mutually identify, or a party identifies, in writing, an acceptable substitute, unless Dynal notifies Xcyte in writing that it does not wish (as determined by
Dynal in its sole discretion) to supply Xcyte with the substitute CD3x28 Bead and/or substitute Nascent Bead, the parties shall negotiate in good faith the terms and conditions of a development and/or supply agreement for the substitute CD3x28 Bead
and/or substitute Nascent Bead for such country or countries upon commercially reasonable terms and conditions (subject to the limitations on Dynal’s obligations set forth in Section 2.5). If the parties do not execute a full agreement
which covers such development and/or supply arrangement within one hundred and twenty (120) days of commencing such good faith negotiations, Xcyte may obtain the substitute CD3x28 Bead and/or the substitute Nascent Bead from a Third Party;
provided that Xcyte may not offer terms or conditions to any such Third Party which are more favorable in the aggregate to those offered to Dynal hereunder, unless such new terms and conditions have first been offered to Dynal and
Dynal has not accepted such terms and conditions (or terms and conditions substantially similar thereto) in writing within sixty (60) days of such offer by Xcyte. If Dynal notifies Xcyte in writing at any time during the discussions or negotiations
set forth in this Section above that it does not wish to supply Xcyte with the substitute CD3x28 Bead and/or substitute Nascent Bead as provided in this Section above, Xcyte may obtain the substitute CD3x28 Bead and/or the substitute Nascent Bead
from a Third Party. 
  
 3.7 In the event that Xcyte plans
to acquire, use, develop, sell or distribute any beads or paramagnetic particles (other than the Products, CD3x28 Beads and Nascent Beads) for use in the Field in addition to either or both of the Products, Xcyte shall promptly notify Dynal
detailing the beads or paramagnetic particles that Xcyte requires and thereafter the parties shall in good 
  
  

 - 7 - 

 EXECUTION COPY 
  
 faith attempt to negotiate the terms and conditions of a development and/or supply agreement for such beads and/or paramagnetic particles
for the Territory. If the parties do not execute an agreement which covers such development and/or supply arrangement within ninety (90) days of commencing such good faith negotiations, Xcyte may obtain such beads or paramagnetic particles from a
Third Party. 
  
 3.8 Notwithstanding anything contained in
this Agreement, if Xcyte undergoes a change of control during the Development Phase, such that Xcyte is directly or indirectly controlled by any person or entity that derives at least fifty percent (50%) of its revenue from the development and/or
manufacture of beads and/or paramagnetic particles, Xcyte hereby agrees that it shall not, and hereby agrees to ensure that any such person or entity shall not, until the non-renewal of this Agreement or three (3) years after such change of control
(whichever occurs first), disclose to such person or entity any information relating to the Products, or supply any Products to such person or entity. Notwithstanding anything contained in this Agreement, both during and after the term of this
Agreement, such person or entity shall be treated as a Third Party for all purposes of this Agreement, regardless of whether such person or entity may be an “Affiliate” of Xcyte after such change of control. As used in this clause,
“change of control” means any event (whether in one or more transactions) which results in a transfer of direct or indirect ownership of more than fifty percent (50%) of the voting stock of Xcyte to a previously unaffiliated third
party. 
  
 3.9 For the avoidance of doubt and without
limiting either party’s development and supply obligations under this Agreement, in no event shall this Agreement restrict: [*] 
  
 SECTION 4: PRICE, PAYMENT AND DELIVERY 
  
 4.1 Dynal shall supply to Xcyte reasonable quantities of samples of the Dynabeads® M-450 Epoxy T and of the Dynabeads® M-450 CD3/CD28 T, in quantities and supply schedules as are more fully described in the
Work Plans for use by Xcyte and Xcyte’s consultants during the Development Phase. During the Development Phase and prior to the point at which the Products being supplied will be used in Phase I clinical trials, the Products shall be provided
by Dynal without charge to Xcyte. 
  
 4.2 Starting at the
point during the Development Phase at which the Products being supplied to Xcyte by Dynal will be used in Phase I clinical trials, the initial price of Products sold to Xcyte shall be the applicable price set forth on Attachment E hereto
(regardless of the concentration of beads in each vial, which concentration shall be determined by Xcyte, provided that no such concentration shall be in excess of 4 x 108 beads/ml in a 10 ml vial). All such prices are quoted FCA, Oslo, Norway (Incoterms 1990). Such prices shall not be increased until [*] and thereafter,
Dynal may raise such prices no more often than [*] Anything in this Section 4.2 to the contrary notwithstanding, no annual increase shall have the effect of raising the previous year’s price by [*] 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities & Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 - 8 - 

 EXECUTION COPY 
  
 4.3 Dynal shall deliver the Products ordered by Xcyte pursuant to this Agreement to Xcyte, FCA Oslo, Norway
(Incoterms 1990). Risk of loss shall pass to Xcyte on delivery of the Products to the carrier selected by Xcyte. Dynal shall include the information as described in Attachment F with each shipment of the Products. Upon delivery of the
Products to Xcyte’s carrier, Dynal shall invoice Xcyte, and Xcyte shall make payment to Dynal within thirty (30) days from the date of the invoice. Upon request by Xcyte, Dynal shall transmit invoices by facsimile or by any other means mutually
agreed to by the parties. Notwithstanding the foregoing, or anything contained in this Agreement, with respect to Dynabeads® M-450 CD3/CD28 T Product ordered by Xcyte and delivered to Xcyte hereunder that is part of a batch of the Dynabeads® M-450 CD3/CD28 T produced by Dynal for Phase I clinical trials and/or other
development work to be performed during such period of the Development Phase, Xcyte may make payment to Dynal for such Dynabeads® M-450 CD3/CD28 T Product so ordered by Xcyte within twelve (12) months (instead of thirty (30) days) from the date of the invoices for such Product.

  
 4.4 Xcyte shall pay interest to Dynal on any overdue
payments under this Agreement at a rate of [*] per month overdue from the date due until payment. 
  
 4.5 Dynal reserves the right to alter the payment procedures set forth in this Agreement in the event that Xcyte has previously (within the
then-most recent three-month period) failed to conform to the payment provisions hereof and if and for so long as Dynal is reasonably concerned about Xcyte’s financial condition. Such alterations in payment terms shall be either a requirement
of an irrevocable, confirmed letter of credit or a requirement of cash prior to delivery. 
  
 4.6 Xcyte shall not require a delivery date of earlier than ninety (90) days after the date of receipt of an order for Products by Dynal. Orders by Xcyte for Products shall be sent to Dynal at P.O. Box 158,
Skøyen N-0212, Oslo, Norway, or as otherwise may be directed by Dynal from time to time. Dynal shall use its reasonable efforts to fill orders from Xcyte which are in accordance with this Section 4 by the delivery date requested by
Xcyte. Dynal shall acknowledge each Xcyte purchase order in writing and notify Xcyte of the estimated delivery date. Dynal shall promptly notify Xcyte if at any time Dynal has reason to be concerned that Dynal will not be able to fill any Xcyte
order on time or as estimated or agreed. 
  
 4.7 Xcyte
shall, starting at the thirtieth (30th) day following the end of the Development Phase and thereafter on a quarterly
basis (by March 31st, June 30th, September 30th, and December 31st) of each Year, provide to Dynal a forecast of Xcyte’s requirements for the Products for the ensuing twelve (12) month period for the Territory. The amount of Products specified
for the first quarter of such twelve (12) month period shall be binding on Xcyte, and Dynal shall supply, and Xcyte shall be required to take delivery and pay for such amount of the Products. All amounts specified for succeeding quarters of a twelve
(12) month period are considered a non-binding but good faith forecast. 
  
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities & Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 - 9 - 

 EXECUTION COPY 
  
 4.8 In addition to the forecasts provided pursuant to Section 4.7, Xcyte shall provide to Dynal good faith
non-binding three (3) Year forecasts for the Products for capacity and long-term manufacturing planning purposes. This three (3) Year forecast shall be provided by Xcyte to Dynal on or before the thirtieth (30th) day following the end of the
Development Phase, and thereafter by August 31st of each Year, covering the succeeding three-Year period. In the event that the manufacture of the volumes of Dynabeads® M-450 CD3/CD28 T indicated by such three-Year forecast would require Dynal to make any capital expansions (including
entering into any leases), the parties may meet to discuss in good faith how to proceed and whether Xcyte would be willing to commit to such forecasts if Dynal decides to make any capital expansion and/or enter into any leases (as Dynal shall decide
in its sole discretion). Subject to the provisions of Section 4.10, in no event shall Dynal be required to meet any such forecast for the Dynabeads® M-450 CD3/CD28 T (beyond the levels stated therein that would not require Dynal to make such capital expansions) nor to obtain such capital expansions
unless the parties agree in writing how to proceed and without Xcyte agreeing to purchase sufficient volumes of the Products and to amend this Agreement to increase the minimums set forth in Section 8.5. 
  
 4.9 All sales of Products to Xcyte shall be controlled by the terms
and conditions of this Agreement and the standard terms and conditions of the business forms of the parties shall not form part of the agreement of the parties. 
  

4.10 During the term of this Agreement, Dynal shall notwithstanding Section 4.8, fill any order (or series of orders) for any calendar
quarter which are in accordance with this Article 4 and that is (or are) not in excess of one hundred twenty five percent (125%) of the volumes specified for such calendar quarter in Xcyte’s most recent good faith quarterly estimate for such
calendar quarter (i.e., that was not a binding order for such calendar quarter under Section 4.7), and Dynal shall not be required to fill any order or series of orders that are for any calendar quarter in excess of one hundred twenty five
percent (125%) of the volumes specified for such calendar in Xcyte’s most recent good faith quarterly estimate for such calendar quarter. However, Dynal shall nevertheless exert commercially reasonable efforts to fill all Xcyte orders and to
supply all requested volumes to the extent the same may be done without extra cost to Dynal, and in doing so Dynal would not be in violation of any other agreement. 
  
 4.11 Notwithstanding anything contained herein, in no event shall Dynal be liable for any delay or failure to deliver
Products for reasons beyond the control of Dynal, provided, however, that Dynal shall notify Xcyte promptly of anticipated delays and shall use all commercially reasonable efforts to fill such orders as soon as possible. 
  
 4.12 If Dynal is not able to manufacture the Products in the
quantities ordered by Xcyte in accordance with the terms and conditions of this Agreement either itself or through its Affiliates, Dynal shall undertake to engage and qualify a Third Party contract manufacturer to manufacture those quantities of the
Products that Dynal and/or its Affiliates are unable to supply to Xcyte, for supply to Xcyte subject to and in accordance with the terms and conditions of this Agreement (including the terms and conditions of this Agreement relating to
Specifications, quality control and assurance, price, ordering, delivery, indemnities and warranties) and Xcyte shall continue to pay Dynal for the Products in accordance with Section 4. The parties recognize 
  

 - 10 - 

 EXECUTION COPY 
  
 that use of such a Third Party contract manufacturer would constitute a “Major Change” as such term defined in
Attachment F, and that it will be handled in accordance with and shall be governed by the requirements in that Attachment. 
  
 4.13 All payments due to Dynal under this Agreement shall be paid in full, regardless of whether Xcyte or its Affiliates or their distributors or
licensees are required to withhold taxes, levies or other duties on payments made under this Agreement. If Xcyte is required to withhold taxes, levies or other duties on payments made under this Agreement, then Xcyte shall gross up such payments so
that Dynal receives the payment in full regardless of any withholdings, and if Dynal obtains any credit for the amount of the withholding, such amount shall be repaid by Dynal to Xcyte when it is received by Dynal. 
  
 SECTION 5: WARRANTY AND DISCLAIMER 
  
 5.1 Dynal warrants that the Products shall conform to the
Specifications upon delivery to Xcyte’s carrier, provided that in no event shall Dynal be responsible or liable for any failure of the Products to meet the Specifications as a result of defects in the Antibodies (other than any defect in the
Antibodies caused solely because of a failure of Dynal or its Affiliates to act in conformity with any applicable quality control guidelines provided to Dynal by Xcyte). Xcyte shall promptly inspect the Products upon receipt and in accordance with
any applicable quality control guidelines provided to Xcyte by Dynal, and shall promptly notify Dynal of any discovered failure of the Products to conform to the Specifications, but in no event later than thirty (30) days after Xcyte’s receipt
of the Products. Upon request by Dynal, Xcyte shall promptly return the non-conforming Products to Dynal. Upon verification that the Products failed to comply with the Specifications upon delivery to Xcyte’s carrier other than because of
defects in the Antibodies (other than any defect in the Antibodies caused solely because of a failure of Dynal or its Affiliates to act in conformity with any applicable quality control guidelines provided to Dynal by Xcyte), Xcyte shall receive, at
Dynal’s sole option, a credit, refund or replacement for such non-conforming Products. In the event that Dynal decides to replace such non-conforming Products with conforming Products, Dynal shall use reasonable commercial efforts to do so
within sixty (60) days of such confirmation by Dynal, and Dynal shall in such event bear the cost of delivery and risk of loss or damage to the replacement Products during delivery. Notwithstanding anything to the contrary contained in this
Agreement, Dynal shall not be responsible for any Products if such Products are removed from their original vials prior to inspection by Xcyte or are modified in any manner not in conformity with any applicable quality control guidelines provided to
Xcyte by Dynal, nor for any use or misuse or actions or inactions by any person or entity after delivery of the Products to Xcyte’s carrier. 
  
 THE FOREGOiNG WARRANTY IS IN LIEU OF ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, AND DYNAL EXPRESSLY DISCLAIMS ANY IMPLIED WARRANTIES INCLUDING, BUT NOT LIMITED TO, THE
IMPLIED WARRANTIES OF NON-INFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. EXCEPT AS SET FORTH IN SECTION 10, XCYTE’S EXCLUSIVE REMEDY FOR ANY DEFECT IN THE PRODUCTS OR BREACH OF WARRANTY SHALL AT DYNAL’S OPTION BE
CREDIT, REFUND OR REPLACEMENT AS SET FORTH IN THIS SECTION 5. 
  

 - 11 - 

 EXECUTION COPY 
  
 EXCEPT AS SET FORTH IN SECTION 10, IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR ANY SPECIAL, CONSEQUENTIAL OR INCIDENTAL DAMAGES BASED UPON
BREACH OF WARRANTY, BREACH OF CONTRACT, NEGLIGENCE, STRICT TORT OR ANY OTHER LEGAL THEORY. 
  
 SECTION 6: INTELLECTUAL PROPERTY 
  
 6.1    Except as provided in Section 6.2, ownership of any and all inventions or other proprietary rights (“Inventions”) developed in connection with activities under or performed in connection with this
Agreement, including in connection with development and acceptance testing of the Dynabeads® M-450 Epoxy T and the Dynabeads® M-450 CD3/CD28 T or during or in connection with work performed under the Work Plans, shall be determined by reference to United States laws pertaining to inventorship. For example, (a)
if Inventions is developed in connection with the development activities hereunder by one (1) or more employees or consultants of each party, it shall be jointly owned (“Joint Inventions”), and if one (1) or more claims included in an
issued Patent or pending Patent application which is filed in a patent office in the Territory claim such Joint Inventions such claims shall be jointly owned (“Joint Patent Rights”); and (b) if Inventions is developed in connection with
development activities hereunder solely by an employee or consultant of a party, it shall be solely owned by such party, and any Patent filed claiming such solely owned Inventions shall also be solely owned by such party. Each party shall ensure
that its employee and consultant inventors of Inventions developed in connection with this Agreement shall assign his/her interest in such Inventions to his/her respective party employer (e.g., Dynal or Xcyte, as the case may be), and such rights
shall therefore vest in the respective party employer to whom the inventor assigns his/her rights. The parties shall discuss and consult with each other in good faith as to the filing and prosecution of any joint patent applications covering Joint
Inventions, the maintenance of any ensuing Joint Patent Rights covering such Joint Inventions, and the enforcement, defense and protection of any such Joint Patent Rights. 
  
 6.2    Notwithstanding anything contained in this Agreement, including Section 6.1: (a) any
Inventions, including any know-how and data relating to any Dynabeads®, including the Dynabeads® M-450 and/or coupling to Dynabeads® and/or the coating of Dynabeads®, shall be owned solely by Dynal regardless of inventorship and Xcyte shall assign any and all such rights that Xcyte and/or its Affiliates or any of their agents may have in or to any such Inventions to Dynal, and such
rights shall therefore vest in Dynal; and (b) any Inventions, including any know-how and data relating to the Antibodies shall be owned solely by Xcyte regardless of inventorship and Dynal shall assign any and all such rights that Dynal and/or its
Affiliates or any of their agents may have in or to any such Inventions to Xcyte, and such rights shall therefore vest in Xcyte. 
  
 6.3    This Agreement contains no grants to either party under any intellectual property of the other party, except as expressly set
forth in this Agreement. 
  
 6.4    Xcyte
retains all right, title and interest in and to the Antibodies delivered or to be delivered to Dynal hereunder. Unless otherwise agreed by the parties, Dynal shall not at any time 
  

 - 12 - 

 EXECUTION COPY 
  
 during the term of this Agreement, divert or use any of the Antibodies for any other purpose or in support of any other product or service
than the Dynabeads® M-450 CD3/CD28 T to be
developed and manufactured hereunder solely for supply to Xcyte, and Dynal shall not authorize anyone else to do so. 
  
 SECTION 7: TRADEMARK, LABELING AND PACKAGING 
  
 7.1 Xcyte shall use the registered trademark “Dynabeads®” in the package inserts, labels and packaging and, to the extent appropriate, promotion and marketing materials, used in connection with
the sale of the Products or the performance of the treatments using the Products, and each such package insert, label and packing and promotion and marketing materials that uses such trademark shall state: “Dynabeads® is a registered trademark of Dynal A.S., Oslo Norway, licensed to Xcyte”
or equivalent language approved by Dynal. Xcyte and Dynal shall cooperate reasonably in the use by Xcyte of Dynal’s trademark, so that such use will be consistent with applicable regulations, including any concerning or affecting the
designation of Xcyte as the manufacturer. Subject to the terms and conditions of this Agreement, during the term of this Agreement, Dynal hereby grants to Xcyte a non-exclusive license to use the Dynabeads® trademark to such limited extent. The registered trademark “Dynabeads®” is and shall remain the sole and exclusive
property of Dynal and all goodwill arising from the use of the Dynabeads® trademark shall enure to the benefit of Dynal. If necessary in any market to maintain Dynal’s rights in Dynal’s trademarks, Xcyte shall enter into a reasonable separate royalty-free license or registered user
agreement regulating its use of the Dynal trademarks. Approval of such material by Dynal shall not be unreasonably withheld. Approval shall be deemed given in the event that Dynal does not otherwise so notify Xcyte within twenty-one (21) days after
receipt of such material from Xcyte. During any periods in which Xcyte is so using any Dynal trademark(s), Xcyte shall periodically and upon reasonable request, provide Dynal with samples of any products and packages that bear, or that have been
associated with, copies of all product literature, promotional material, advertising, product inserts, labeling and packaging and other printed materials that use, the “Dynabeads®” trademark, in order that Dynal may monitor the quality of products associated
with such trademark(s). 
  
 7.2 The Products shall be labeled and
packaged for delivery to Xcyte as provided in Attachment F. 
  
 SECTION 8: TERM AND TERMINATION 
  
 8.1
This Agreement shall come into effect on the Effective Date and unless terminated earlier as provided herein shall continue for a period often (10) years. Either party shall have the option to extend the term of this Agreement for an additional five
(5) years after the initial ten (10) year term, by written notice to the other at any time at least one hundred and eighty (180) days prior to the end of the initial ten (10) year term. Following the end of the initial ten (10) year term (if it is
not so renewed for an additional five (5) years), or the end of such five (5) year renewal term (if the ten (10) year initial term is so renewed), this Agreement shall be automatically renewed for successive one (1) year terms unless either party
gives the other party 
  

 - 13 - 

 EXECUTION COPY 
  
 written notice of termination of the term at least ninety (90) days prior to the conclusion of the then-current term, to be effective at the
end of such current term. 
  
 8.2 This Agreement may be terminated
by either party upon the happening of any of the following events: 
  
 (i) if the other party shall generally cease to pay debts as they come due; or 
  
 (ii) if the other party shall cease to do business, enter into liquidation, or become subject to any bankruptcy law or enter into any
agreement with its creditors or commit any similar act. 
  
 8.3 If
either party shall fail to perform its material obligations under this Agreement, the other party shall have the right to terminate this Agreement upon ninety (90) days written notice to the defaulting party, provided, however, that if: 

 
 (i) such default is cured within the notice period, this
Agreement shall not be terminated therefor; or 
  
 (ii) such failure is a failure by Dynal to accomplish an activity under the Work Plans or an obligation under this Agreement that is the responsibility of Dynal, within the time frame established in the applicable Work Plan or otherwise
under this Agreement for such accomplishment or obligation, Dynal shall be afforded additional time to accomplish such activity to the extent necessary to account for any factors beyond its reasonable control (such as, without limitation, as a
result of any action or inaction of the FDA) or as a result of any delay caused by or as a result of actions or inactions of Xcyte or its Affiliates or agents. 
  

8.4 Either party may terminate this Agreement upon written notice to the other party at any time prior to the first filing by Xcyte with the FDA for a
marketing approval of the treatments and/or products utilizing the Products in the Field, if the parties mutually agree in writing that the Products cannot, for scientific, regulatory or technical reasons not due to a breach hereof by the party
seeking such a termination, be developed and certified for commercial use in the Field. Neither party shall unreasonably withhold its consent to any such mutual agreement. 
  
 8.5 Dynal may terminate this Agreement upon at least one hundred and eighty (180) days advance written notice to Xcyte:

  
 (i) if Xcyte does not order from Dynal at
least [*] of Dynabeads® M-450 CD3/CD28 T
(measured by the [*] pursuant to Section 4.2) prior to end of the first twelve-month period following the end of the Development Phase and Dynal gives Xcyte its notice of such termination no later than sixty (60) days following the end
of such twelve (12) month period; or 
  
 (ii) if
Xcyte does not order from Dynal at least [*] pursuant to Section 4.2) in any twelve (12) month period that begins after the end of the first twelve-month period described 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities & Exchange Commission. Confidential treatment has been requested to the omitted
portions. 

  

 - 14 - 

 EXECUTION COPY 
  
 above in clause (i) of this section and Dynal gives its notice of such termination no later than sixty (60) days following the end of such
twelve (12) month period. 
  
 8.6    No
termination or non-renewal of this Agreement shall extinguish any right or obligation that has accrued prior thereto, or that is a post-termination or post-non-renewal right or obligation under the terms and conditions of this Agreement, including
those set forth in Section 11. Upon termination or non-renewal of this Agreement: 
  
 (i)    Xcyte shall cease all use of Dynal’s trademarks and other intellectual property rights and shall cooperate
with Dynal in terminating any separate license or registered user agreement or recordal thereof; except that upon non-renewal of this Agreement or termination of this Agreement pursuant to Section 8.3 by Xcyte, Xcyte may continue to use the
Dynabeads® trademark, subject to the terms and
conditions of this Agreement, until the occurrence of the earlier of: (a) receipt by Xcyte of all applicable regulatory approvals to alter labeling, packaging, and promotional materials (which regulatory approvals Xcyte shall use reasonably
commercial efforts to obtain as soon as possible after any such non-renewal or termination of this Agreement), and (b) one (1) year after such non-renewal or termination, and thereafter Xcyte shall cease all use of Dynal’s trademarks and other
intellectual property rights and shall cooperate with Dynal in terminating any separate license or registered user agreement or recordal thereof 
  
 (ii)    all sums accrued hereunder prior to such termination or non-renewal shall become immediately due and payable;
and 
  
 (iii)    Xcyte shall
continue after such termination or non-renewal to have the right to cross-reference the DMFs as provided in Section 2.3. 
  
 SECTION 9: QUALITY ASSURANCE 
  
 9.1    Certain obligations and responsibilities of Dynal and Xcyte with respect to the manufacture and quality control analysis of the
Products under the Agreement shall be set forth in the applicable quality assurance guidelines set forth in Attachment F. 
  
 9.2    Certain obligations and responsibilities of Dynal and Xcyte with respect to the manufacture and quality control analysis of the
Antibodies under the Agreement shall be set forth in the applicable quality assurance guidelines set forth in Attachment G. 
  
 SECTION 10: WARRANTIES; INDEMNIFICATION’S; INSURANCE 
  
 10.1    Each of Xcyte and Dynal represents and warrants to the other that: 
  
 (i)    it has the full right, power and
authority to enter into and perform this Agreement; 
  
 (ii) the execution and performance of this Agreement by it does not and will not violate any law or regulation, or any agreement to which it is a party or by which it is bound; 
  

 - 15 - 

 EXECUTION COPY 
  
 (iii) when executed and delivered, this Agreement will constitute the legal, valid and binding obligation of such party,
enforceable against it in accordance with its terms; and 
  
 (iv)
it has obtained, and shall at all times during the term of this Agreement hold and comply with, all licenses, permits and authorizations necessary to perform this Agreement as now or hereafter required under any applicable statutes, laws,
ordinances, rules and regulations of the United States and any applicable foreign, state, and local governments and governmental entities. 
  
 10.2 Dynal hereby indemnifies and agrees to defend and to hold Xcyte, its successors and its Affiliates and each of their employees, directors, officers
and agents harmless from and against all Third Party claims, liabilities, losses and expenses (other than lost profits) (including reasonable attorneys’ fees) arising out of: 
  
 (i) the failure of the Products to meet the warranty set forth in Section 5; provided that in no event shall Dynal be
responsible or liable for any failure of the Products to meet the Specifications as a result of: (a) defects in the Antibodies (other than any defect in the Antibodies caused solely because of a failure of Dynal or its Affiliates to act in
conformity with any applicable quality control guidelines provided to Dynal by Xcyte) or (b) actions or inactions by any person or entity after delivery of the Products to Xcyte; 
  
 (ii) any Third Party claims for infringement or misappropriation of any intellectual property rights based on the method of
manufacture or composition of the Dynabeads®
included in the Product (but not for any other claims for infringement or misappropriation based on the use or sale of Dynabeads® or the Products, for which Xcyte shall indemnify and defend Dynal, its successors and its Affiliates and each of their employees, directors, officers
and agents pursuant to Section 10.3) or 
  
 (iii) any
breach or inaccuracy of any of Dynal’s representations or warranties made herein. 
  
 10.3 Xcyte hereby indemnifies and agrees to defend and to hold Dynal, its successors and its Affiliates and each of their employees, directors, officers and agents harmless from and against all Third Party claims,
liabilities, losses and expenses (other than lost profits) (including reasonable attorneys’ fees) arising out of: 
  
 (i) the development, use, promotion, marketing, manufacture, distribution, sale or import of any of the Products and performance of treatments using any
of the Products, including any actual or alleged infringement or misappropriation of any Intellectual Property of any Third Party, except for any Third Party claims expressly covered by Dynal’s indemnification of Xcyte pursuant to Section
10.2 or 
  
 (ii) any breach or inaccuracy of any of
Xcyte’s representations or warranties made herein. 
  

 - 16 - 

 EXECUTION COPY 
  
 10.4 Each party shall communicate to the other notice of all claims falling within the indemnity provided by the other
pursuant to Sections 10.2 and 10.3, as soon as possible after their receipt. The indemnified party shall cooperate fully with the indemnifying party in defending or otherwise resolving such claims. The indemnifying party shall have full
control of the defense and settlement of all litigation brought against the indemnified party arising out of such claims, provided that any settlement or voluntary consent judgment shall require the consent of the indemnified party, such consent not
to be unreasonably withheld. The indemnified party, at its expense, shall be entitled to participate in such defense through its own counsel, subject to the retention of control of such defense by the indemnifying party. 
  
 10.5 Each party shall obtain and keep in force during the term of this
Agreement, and for a period of three (3) years after the non-renewal or termination of this Agreement, comprehensive general liability insurance covering bodily injury and property damage in amounts of not less than [*] per year combined
single limit; covering completed operations liability and contractual liability in amounts of not less than [*] and, [*] Each party shall provide written proof of the existence of such insurance to the other party upon request.

  
 SECTION 11: CONFIDENTIALITY AND PRESS RELEASES

  
 11.1 It is understood by both Dynal and Xcyte that misuse
or disclosure of Confidential Information of the other party could irreparably harm the business of the disclosing party or that party’s Affiliates. As used herein, “Confidential Information” shall mean, subject to the exceptions set
forth in Section 11.2, all confidential and proprietary information (including all other technology, know-how, data and records, whether written or oral or obtained through inspection of facilities or samples), which is obtained by a
receiving party (Xcyte or Dynal, as the case may be) from a disclosing party (Xcyte or Dynal, as the case may be), where either it is identified by the disclosing party as being confidential at the time of disclosure or the circumstances of
disclosure otherwise reasonably put the recipient on notice that the information or materials are treated as confidential or which receiving party should reasonably know should be treated as confidential. The parties agree: 
  
 (i) not to use such Confidential Information for any purpose other than for
the purpose of this Agreement or as may otherwise be agreed by the parties in writing; 
  
 (ii) to use the same degree of care to maintain such Confidential Information in confidence as it applies to confidential information of its own of the same type, but in no event less than a reasonable standard of
care, and not to disclose any portion of such Confidential Information to any person or entity other than as needed for the purposes of this Agreement; 
  
 (iii) to cause its Affiliates and each of its and its Affiliates’ employees, Affiliates, licensees and consultants (and the employees of any thereof)
who are to be given access to such Confidential Information to agree to be bound by the provisions of this Section 11 or by other provisions at least as protective as those set forth in this Section 11. 
  
  
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities & Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 - 17 - 

 EXECUTION COPY 
  
 11.2 The provisions of this Section 11 shall not apply to: 
  
 (i) Information that can be demonstrated by the receiving party by credible
evidence to be in the public domain at the time of disclosure. 
  
 (ii) Information that, after disclosure, can be demonstrated by the receiving party by credible evidence to have subsequently become part of the public domain other than as a consequence of a breach of this Agreement by the receiving party
or its employees or agents. 
  
 (iii) Information that can be
demonstrated by the receiving party by credible evidence to have been known or otherwise available to the receiving party prior to the disclosure by the disclosing party. 
  
 (iv) Information that, after disclosure, can be demonstrated by the receiving party by credible evidence to have been
subsequently provided to the receiving party by a Third Party having the right to disclose such information and without obligations of confidentiality if the receiving party reasonably believes such disclosure does not violate any obligations of the
Third Party to the disclosing party. 
  
 (v) Information that has
been independently developed without the benefit of any reference to any disclosure hereunder from the other party. 
  
 (vi) Information that is required to be disclosed by law or regulation, provided that the party required to make such disclosure shall, to the extent
practicable under such law or regulation and the circumstances, give the other party prior notice of such requirement and afford it an opportunity to seek restrictions or limitations on such disclosure. 
  
 11.3 Upon non-renewal or termination of this Agreement. the receiving party
shall, upon the disclosing party’s written request, promptly return to the disclosing party, all copies of Confidential Information received from the disclosing party, and shall return or destroy, and document the destruction of, all summaries,
abstracts, extracts or other documents that contain any Confidential Information of the disclosing Party; except that the receiving party may retain copies of Confidential Information (including summaries, abstracts, extracts or other
documents that contain any Confidential Information) received from the disclosing party if the retention of the same is necessary for regulatory purposes or is otherwise required by law or regulation, and in any event the receiving party may retain
one (1) copy of Confidential Information received from the disclosing party for archival purposes. 
  
 11.4 The provisions of this Section 11 shall not terminate upon non-renewal or termination of this Agreement, but shall continue for a period of
seven (7) years following the termination or non-renewal of this Agreement. 
  
 11.5 Unless otherwise agreed by the parties, the parties agree to issue, within thirty (30) days from the Signing Date, a mutually agreed upon press release. Neither party to this Agreement shall otherwise issue any
press release or other publicity materials, or make any public presentation with respect to the terms or conditions of this Agreement without the prior 
  

 - 18 - 

 EXECUTION COPY 
 written consent of the other party (such consent not to be unreasonably withheld or delayed). This restriction shall not apply to disclosures required by law or regulation, including as may be required in connection with any filings made
with the Securities and Exchange Commission or similar non-U.S. regulatory authority, or by the disclosure policies of a major stock exchange; provided, however, that if reasonably possible, the party making such disclosures shall
inform the other party prior to any such disclosures. 
  
 SECTION 12: DISPUTE RESOLUTION 
  
 12.1 The
parties intend that they shall resolve disputes and differences regarding the performance of their respective obligations under this Agreement in a spirit of cooperation and common purpose. In cases in which that does not occur (other than as to a
question relating to patent validity), any differences between the parties arising from or in connection with this Agreement shall be resolved in accordance with the procedures set forth in this Section 12. 
  
 12.2 Any dispute arising from or in connection with this Agreement during the
Development Phase shall be first presented to a senior executive of each party (with each party designating its own senior executive that shall handle such dispute) for resolution. If the designated senior executives are unable to resolve the
dispute within thirty (30) days, then either party may initiate arbitration pursuant to Section 12.3. 
  
 12.3 Subject to Section 12.2, any and all disputes or legal proceedings to enforce this Agreement (other than as to a question relating to patent
validity and except for any action to compel arbitration hereunder or an action to enforce any award or judgment rendered thereby) or in any way related to this Agreement shall be governed by this Section 12.3. Both the agreement of the
parties to arbitrate any and all claims and disputes under this Agreement as provided in this Section 12.3, and the results, determination, finding, judgment and/or award rendered through such arbitration, shall be final and binding on the
parties thereto and may be specifically enforced by legal proceedings in a court having jurisdiction over the party in question. Arbitration proceedings under this Agreement shall be conducted under the auspices of the International Arbitration
Rules of the American Arbitration Association (the “AAA”) in New York. Dynal shall appoint one (1) arbitrator, and Xcyte one (1) arbitrator, within a term of thirty (30) days from the date arbitration is required or invoked by the parties,
and the two (2) arbitrators so appointed shall appoint the third arbitrator within a term of thirty (30) days from the date on which the later of the two (2) arbitrators have been selected, all in accordance with the rules of the AAA. If either
party fails to select its arbitrator within the term mentioned above, or in the event that the two (2) selected arbitrators are unable or unwilling to select a third arbitrator within thirty (30) days, one shall be appointed in accordance with the
rules of the AAA, and the three (3) arbitrators so selected shall constitute the arbitration panel for purposes of the dispute. Unless agreed otherwise by the parties, the parties shall have thirty (30) days thereafter to submit their position to
the arbitrators, and the arbitrators shall be instructed and required to render their decision within thirty (30) days following completion of the arbitration. In any arbitration, the prevailing party shall be entitled to reimbursement of its
reasonable attorneys’ fees and the parties shall use all reasonable efforts to keep arbitration costs to a minimum. 
  

 - 19 - 

 EXECUTION COPY 
  
 12.4 Notwithstanding anything in this Section 12 to the contrary, if either party shall reasonably determine the need
to seek injunctive or other expedited relief in connection with this Agreement, such party may do so in a court of competent jurisdiction. 
  
 SECTION 13: OTHER PROVISIONS 
  
 13.1 This Agreement contains the entire agreement between the parties relating to the subject matter hereof and all prior understandings, representations
and warranties between the parties (including the Letter Agreement) are superseded by this Agreement. 
  
 13.2 None of the terms of this Agreement shall be deemed to be waived or amended by either party unless such a waiver or amendment specifically references
this Agreement and is in writing signed by the party to be bound. 
  
 13.3 Notwithstanding anything contained herein, in no event shall either party be liable for any delay or failure hereunder for reasons beyond the control of such party, provided, however, that such party shall notify the
other promptly of anticipated delays and shall use all reasonable efforts to perform as soon as possible. 
  
 13.4 All notices and demands required or permitted to be given or made pursuant to this Agreement shall be deemed effective upon receipt, in English and
in writing (which term shall include telecopy) addressed to the people named below and shall be personally delivered or mailed by prepaid air mail, or sent by international courier requiring signed receipt for delivery, or sent by telecopy, provided
such telecopy is promptly confirmed by electronic return receipt, addressed as follows: 
  

	 If to Xcyte:
	  	If to Dynal:
		
	 Xcyte Therapies, Inc.
	  	Dynal A.S.
	 1124 Columbia St., Suite 130
	  	P.O. Box 158 Skøyen
	 Seattle, WA 98104
	  	N-0212 Oslo, Norway
	 Telecopy: 206-262-0900
	  	Telecopy: 011-47-22-50-7015
	 Attn: President, CEO
	  	Attn: President, CEO

  
 or to such other address or person
which either party may notify the other in writing. 
  
 13.5 This
Agreement shall be binding upon and inure to the benefit of the parties and their permitted successors and assigns. This Agreement shall be assignable by either party (i) with the written consent of the other party, such consent not to be
unreasonably withheld; or (ii) to an Affiliate; or (iii) to any successor by merger or upon sale of all or substantially all of its assets. Any attempted assignment which does not comply with the terms of this Section 13.4 shall be void.

  
 13.6 This Agreement shall be governed by the laws of the State
of New York, and all rights and remedies shall be governed by such laws without regard to principles of conflicts of 
  

 - 20 - 

 EXECUTION COPY 
  
 law. The Convention on Contracts for the International Sale of Goods shall not apply to this Agreement. 
  
 13.7 The parties do not intend to violate any public policy or statutory or
common law. However, if any sentence, paragraph, clause or combination of this Agreement is in violation of any law or is found to be otherwise unenforceable by a court from which there is no appeal, or no appeal is taken, such sentence, paragraph,
clause, or combination of the same shall be deleted and the remainder of this Agreement shall remain binding, provided that such deletion does not alter the basic structure of this Agreement. The parties shall negotiate in good faith to substitute
for any such invalid or unenforceable provision, a valid and enforceable provision that achieves to the greatest extent possible the economic, legal and commercial objectives of the invalid or unenforceable provision. In the event the basic
structure of this Agreement is altered as a result of such deletion, the parties shall renegotiate this Agreement in good faith, but should such negotiations not result in a new Agreement within ninety (90) days of the initiation of such
negotiations, then this Agreement may be terminated by either party by thirty (30) days notice to the other. 
  
 13.8 The titles to sections of this Agreement are intended for the purpose of assisting the parties when working with this Agreement, and are not intended
to have any effect on the interpretation of this Agreement. Where appropriate herein, singular terms shall be interpreted in the plural and plural terms interpreted as singular. 
  
 13.9 Dynal acknowledges that it is not an agent of Xcyte and has no authority to speak for, represent, or obligate Xcyte in
any way, without first receiving written authorization from Xcyte. Xcyte acknowledges that it is not an agent of Dynal and has no authority to speak for, represent, or obligate Dynal in any way, without first receiving written authorization from
Dynal. This Agreement does not and shall not be deemed to create any relationship of a joint venture or a partnership. 
  
 13.10 This Agreement may be executed in one or more counterparts, each of which shall be deemed an original but all of which together shall constitute one
and the same instrument. 
  
 * * * 
  
  

 - 21 - 

 EXECUTION COPY 
  
 IN WITNESS WHEREOF, the parties have executed this Agreement by their duly authorized representatives. 
  

	 XCYTE THERAPIES, INC.
	 	 	 	 DYNAL A.S.

					
	By:	 	/s/    Ronald Jay Berenson        	 	 	 	By:	 	/s/    Jeff Bork        
	 	
	 	 	 	 	

			
	Name:             Ronald Jay
Berenson                             	 	 	 	Name:             Jeff
Bork                                        
        
			
	Title: President &
CEO                                        
        	 	 	 	Title:
CEO/President                                      
              
			
	7 December 1999	 	 	 	7 December 1999

  

 EXECUTION COPY 
  
 Attachment List 
  

		
	 Attachment A
	  	The Antibodies
		
	 Attachment B
	  	Work Plans
		
	 Attachment C
	  	Dynabeads® M-450 Epoxy T Specifications
		
	 Attachment D
	  	Dynabeads® M-450 CD3/CD28 T Specifications
		
	 Attachment E
	  	Per Vial Prices
		
	 Attachment F
	  	Quality Assurance — Products
		
	 Attachment G
	  	Quality Assurance — Antibodies

 EXECUTION COPY 
  
 EXECUTION COPY 
  
 [*] 
  
  
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities & Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

 EXECUTION COPY 
  
 Attachment A 
 to

 Development and Supply Agreement dated as of August 1, 1999 between 
 Xcyte Therapies, Inc. and Dynal A.S. (the “Agreement”) 
  
 (Terms used herein and not otherwise defined below 
 have the meanings defined in the Agreement) 
  
 The
Antibodies 
  
 [*] 
  
  
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities & Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

 EXECUTION COPY 
  
 Attachment B 
  
 to 
  
 Development and Supply Agreement dated as of August 1, 1999 between 
 Xcyte Therapies,
Inc. and Dynal A.S. (the “Agreement”) 
  
 (Terms used
herein and not otherwise defined below 
 have the meanings defined in the Agreement) 
  
 Work Plans 
  
 Work Plans attached hereto. 
  

 EXECUTION COPY 
  
 [Attachment B-1 to B-4] 
  
 [illustrations/graphs] 
  
 [*] 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities & Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 EXECUTION COPY 
  
 Attachment C 
  
 [*] 
  
  
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities & Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

 EXECUTION COPY 
  
 Attachment D 
  
 [*] 
  
  
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities & Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

 EXECUTION COPY 
  
 Attachment E 
 to 
 Development and Supply Agreement dated as of August 1, 1999 between 
 Xcyte Therapies, Inc. and Dynal A.S. (the “Agreement”) 
 (Terms used herein and not otherwise defined below 
 have the meanings defined in the Agreement) 

 
 [*] 
  
  
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities & Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

 EXECUTION COPY 
  
 Attachment F 
  
 to 
  
 Development and Supply Agreement 
  
 dated as of August 1, 1999 between 
  
 Xcyte Therapies, Inc. and Dynal A.S. (the “Agreement”) 
  
 (Terms used herein and not otherwise defined below 
  
 have the meanings defined in the Agreement) 
  
 Quality Assurance — Products 
  
 General 
  
 The
purpose of this Attachment is to detail the obligations and responsibilities of Dynal and Xcyte with respect to the manufacture and quality control analysis of the Products under this Agreement in accordance with cGMP and NS-ISO 9001:1994 from Phase
III forward. The obligations and responsibilities of the parties prior to Phase III will be consistent with the product development continuum of cGMP. 
  
 Procedures 
  
 Dynal shall establish, document and maintain a quality assurance procedure system which meets cGMP and all other requirements of relevant regulatory
authorities. 
  
 Raw Materials 
  
 Dynal shall be responsible for acquiring all raw materials used in the
manufacture of the Products and for analyzing and confirming compliance with the respective raw materials specifications. 
  
 Manufacturing 
  
 Dynal shall be responsible for manufacturing the Products in accordance with cGMP and the Specifications and, to the extent consistent with the
Specifications, Dynal’s standard manufacturing techniques and procedures. Dynal shall be responsible for performing the necessary process and method validations for the Products. 
  
 Packaging, Labeling and Storage 
  
 Dynal shall be responsible for packaging and labeling the Products in accordance with cGMP and the Specifications. Xcyte shall provide Dynal with all the
information to be included on the labels of the Products except the batch specific data, and Dynal shall order such labels based upon information provided to Dynal by Xcyte. Upon receipt of the blue print labels, Dynal shall send a sample of each to
Xcyte for review and final approval. If Xcyte has any revisions to such samples, Xcyte shall notify Dynal promptly of such revisions, but in no event later than twenty-one (21) days after Xcyte’s receipt of each such sample from Dynal. If Xcyte
does not provide Dynal with comments within such 21-day period, Dynal shall label the Products using the form of such labels as in the sample provided to Xcyte. Xcyte shall be solely responsible for ensuring that all labels for the Products are in
compliance with applicable laws and regulations. 
  
 Dynal shall
store the Products in accordance with cGMP and the Specifications. 
  
 All shipment of the Products will follow the cGMP requirements regarding the (i) packaging (ii) monitoring of the shipment in terms of temperature and time (iii) documentation. Xcyte is responsible for shipment validation. 
  
 Documentation 
  
 Dynal shall include the following information with each shipment of the Products: (i) Xcyte purchase order number, (ii) part
number, (iii) Dynal lot number, (iv) lot number of the Antibodies used in manufacture of the Dynabeads® M-450 CD3/CD28, and (v) a Certificate of Analysis. 
  
 All batch manufacturing records shall be stored at Dynal’s facilities. The batch manufacturing records and the Products shall be inspected prior to
release by the Quality Assurance Department at Dynal. Xcyte shall have the right to inspect such records at Dynal’s site and to conduct quality assurance audits upon reasonable notice at Dynal no more than once a year unless otherwise required
by law or a regulatory agency. 
  
 Dynal shall confirm and
document the shelf life of the Products in accordance with cGMP and the Specifications. 
  
 Complaint Handling 
  
 Dynal shall be
responsible for the accuracy, sensitivity, specificity, purity and identity of the Products and shall conduct any investigations which are necessary in connection with a third party complaint concerning the Products; provided, however, that: (i)
Dynal shall not be responsible or liable for any failure of the Products to meet the Specifications as a result of defects in the Antibodies not caused by any act or omission of Dynal or its Affiliates not in conformity with cGMP or any applicable
quality control guidelines provided to Dynal by Xcyte with respect to the Antibodies; and (ii) Xcyte will conduct any investigations which are necessary in connection with a third party complaint, to the extent it concerns the Antibodies. Dynal
shall retain samples of the Products at its facilities in accordance with cGMP and its standard procedures in case any complaint concerning the Products should result in an investigation. 
  
 In the event that either party receives any complaint regarding the Products involving a potential patient safety or other
liability issue, it shall notify the other party promptly by telephone and facsimile and discuss the situation to the extent possible within the time available. The parties shall cooperate fully with each other, to the extent possible, in effecting
any follow-up and communications with the customer. With respect to all other complaints, the receiving party shall notify the other party promptly by telephone and facsimile. 
  
 Major Changes 
  
 Major Changes with respect to the Antibodies are defined in, and shall be handled as provided in, Attachment G to the Agreement. Otherwise, each party
shall inform the other party in writing prior to making any “Major Changes” to the Products (as defined below), and discuss its plan to implement such Major Changes with the other party. Such notification shall be sent from the Quality
Assurance Manager or Regulatory Affairs Manager of such party to the Quality Assurance Manager or Regulatory Affairs Manager of the other party. Each party shall have no more than thirty (30) days from the date of such party’s receipt of such
notice to evaluate such Major Changes. Each party shall notify the other party of the time it needs to make such evaluation no later than thirty (30) days from the date it received such notice. Each party must obtain the written consent of the other
party (such consent not to be unreasonably withheld or delayed) to any Major Changes prior to such party making such Major Changes to the Products. 
  
 As used herein, “Major Changes” are defined as: 
  

	 	•	Changes in raw material specifications. 

  

	 	•	Changes in production equipment. 

  

	 	•	Changes in production processes. 

  

	 	•	Changes in production scale. 

  

	 	•	Changes in quality control methods. 

  

	 	•	Changes in quality control specifications. 

  

	 	•	Changes in packaging and labeling. 

  

	 	•	Changes in storage and/or shipping requirements. 

  
 Inspection by Regulatory Agencies 
  
 Dynal shall notify Xcyte of any inspection of its facilities related to the Products by any regulatory agency, and, if it is able and has the right to do
so, Dynal shall send Xcyte copies of any material written reports relating to such inspection within seven days after receipt or preparation of such reports. 
  
 Inspection by Regulatory Agencies 
  
 Xcyte shall notify Dynal, and shall require the Antibody Manufacturers to notify Xcyte, of any inspection of any of Xcyte’s or Antibody
Manufacturer’s facilities related to the Antibodies by any regulatory agency, and, if it is able and has the right to do so, Xcyte shall send Dynal copies of any material written reports relating to such inspection within seven days after
receipt or preparation of such reports. 

 EXECUTION COPY 
  
 Attachment G 
 to 
 Development and Supply Agreement dated as of August 1, 1999 between 
 Xcyte Therapies, inc. and Dynal A.S. (the “Agreement”) 
  
 (Terms used herein and not otherwise defined below 
 have the meanings defined in the Agreement) 
  
 Quality Assurance—Antibodies 
  
 General 
  
 The purpose of this Attachment
is to detail the obligations and responsibilities of Dynal and Xcyte with respect to the manufacture and quality control analysis of the Antibodies from Phase Ill forward. The obligations and responsibilities of the parties prior to Phase lU will be
consistent with the product development continuum of cGMP. 
  
 Xcyte will obtain the Antibodies to be used in the manufacture of the Dynabeads® M-450 CD3/CD28 from one or more suppliers of Xcyte’s choosing (the “Antibody Manufacturers”), and contract with Antibody Manufacturers for the manufacture of Antibodies in accordance with cGMP.

  
 Procedures and Investigations 
  
 Xcyte shall require that the Antibody Manufacturers shall establish,
document the Quality Assurance System which meets cGMP, including the utility, process and method validation. In the event of any third party complaint concerning the Antibodies, Xcyte shall be responsible in accordance with cGMP to require and to
give the proper notifications (including without limitation all proper notice to Dynal), and to conduct any necessary investigations. 
  
 Packaging, Labeling and Storage 
  
 The Antibodies will be filled aseptically in sterile containers by the Antibody Manufacturer and labeled with the description of the Antibody, including
the lot number from the Antibody Manufacturer, volume and expiry date. 
  
 Antibodies will be at all times stored under controlled, validated conditions according to the Specifications, and following the cGMP requirements. 
  
 All shipment of Antibodies (from the Manufacturer to Xcyte and from Xcyte to Dynal) will follow the cGMP requirements regarding the (i) packaging (ii)
monitoring of the shipment in terms of temperature and time (iii) documentation. Xcyte is responsible for shipment validation. The Antibodies will be shipped to Dynal CIP Oslo, Norway (Incoterms 1990). 
  
 Documentation 
  
 Xcyte shall include the following documentation with each shipment of the Antibodies to Dynal: (i) description of the
Antibody including the lot number from the Antibody Manufacturer and expiry date, (ii) Certificate of Analysis issued by the unit responsible for testing and compliance with Quality Control Specifications, (iii) releasing document (Certificate of
Compliance) from the responsible Regulatory and/or QA Department(s), confirming the compliance with Quality Standards and Specifications. 
  
 All batch manufacturing production records shall be stored at the Antibody Manufacturers’ or their agents’ facilities. Xcyte shall require that
the batch manufacturing production records and Antibodies shall be inspected prior to release by the Quality Assurance Department at Antibody Manufacturer in accordance with cGMP, and that the Antibody Manufacturers so certify. Dynal shall have the
right to conduct quality assurance audits with respect to the Antibodies at Xcyte’s facilities upon reasonable notice to Xcyte, and at the Antibody Manufacturers’ facilities, in each case no more than once a year unless otherwise required
by law or the FDA. 
  
 Major Changes 
  
 Xcyte shall inform Dynal in writing prior to making or authorizing any
“Major Changes” (as defined below) to the Antibodies or their production or provision, and discuss its plan to implement such Major Changes with Dynal. Such notification shall be sent from the Regulatory Manager of Xcyte to the Quality
Assurance Manager of Dynal. Dynal shall have no more than thirty (30) days from the date of receipt of such notice to evaluate such Major Changes and to raise any reasonable objections it may have thereto. 
  
 As used herein, “Major Changes” are defined as: 
  

	 	•	Changes in Antibody Manufacturer. 

  

	 	•	Changes in production equipment. 

  

	 	•	Changes in production processes. 

  

	 	•	Changes in quality control methods. 

  

	 	•	Changes in quality control specifications. 

  

	 	•	Changes in packaging and labeling. 

  

	 	•	Changes in storage and/or shipping requirements. 

  
 Inspection by Regulatory Agencies 
  
 Xcyte shall notify Dynal, and shall require the Antibody Manufacturers to notify Xcyte, of any inspection of any of Xcyte’s or Antibody
Manufacturer’s facilities related to the Antibodies by any regulatory agency, and, if it is able and has the right to do so, Xcyte shall send Dynal copies of any material written reports relating to such inspection within seven days after
receipt or preparation of such reportsLicense Agreement with Genetics Institute, Inc. dated July 8, 1998.

 Exhibit 10.35 
  
 Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information
subject to the confidentiality request. Omissions are designated as [*****]. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 
  
 LICENSE AGREEMENT 
  
 THIS LICENSE AGREEMENT (together with the attached Exhibits, the (“Agreement”) is made as of July 8 (the “Effective Date”) by and between Genetics
Institute, Inc., a Delaware corporation with a business address at 87 Cambridge Park Drive, Cambridge, Massachusetts 02140 (“GI”) and Xcyte Therapies, Inc., a Delaware corporation with a business address at 2203 Airport Way South, Suite
300, Seattle, Washington 98134 (“Xcyte”). 
  

	1.	Background. 

  

	 	1.1	GI. GI has acquired and/or licensed the rights to certain patents, as set forth in Exhibit D to this Agreement (the “Patents”), pursuant to agreements between GI
and third parties (defined below as the “Licensors”). 

  

	 	1.2	Xcyte. Xcyte desires to license and/or sublicense the Patents from GI, to make, use and sell Products (defined below) in the Field (defined below). GI is Willing, for the
consideration and on the terms set forth herein, to license and/or sublicense the Patents to Xcyte for such purposes. 

  

	 	1.3	Agreement. In consideration of the mutual covenants and promises contained in this Agreement and other good and valuable consideration, the Parties agree as follows:

  

	2.	Definitions. As used in this Agreement, the following terms shall have the meanings set forth below. 

  

	 	2.1	“Affiliate” means any corporation, company, partnership, joint venture and/or firm which controls, is controlled by or is under common control with a Party. For
purposes of this Section 2.1, “control” means (a) in the case of corporate entities, direct or indirect ownership of at least fifty percent (50%) of the stock or shares entitled to vote for the election of directors; and (b) in the case of
non-corporate entities, direct or indirect ownership of at least fifty percent (50%) of the equity interest with the power to direct the management and policies of such noncorporate entities. 

  

	 	2.2	“Combination Product” means any Product sold in combination with one or more other products which are not Products. 

  

	 	2.3	“Confidential Information” shall mean(i) any proprietary or confidential information or material in tangible form disclosed hereunder that is marked as
“Confidential” at the time it is delivered to the receiving party, or (ii) proprietary or confidential information disclosed orally hereunder which is identified as confidential or proprietary when disclosed and such disclosure of
confidential information is confirmed in writing within thirty (30) days by the disclosing party. 

  

	 	    	 “Confidential Information” does not include information which (a) was known to the receiving Party at the time it was disclosed, other than by previous
disclosure 

	 	 
by the disclosing Party, as evidenced by written records at the time of disclosure; (b) is at the time of disclosure or later becomes publicly known under
circumstances involving no breach of this Agreement; (c) is lawfully and in good faith made available to the receiving Party by a third party who did not derive it from the disclosing Party and who imposes no obligation of confidence on the
receiving Party; or (d) is developed by the receiving Party independent of any disclosure by the disclosing Party. 

  

	 	2.4	“Distributor” means a third party which is not a Xcyte Affiliate or Sublicensee and which is a distributor, wholesaler or other entity purchasing Products from
Xcyte or its Affiliate or Sublicensee for resale. 

  

	 	2.5	“Field” means ex vivo activation or expansion of human T-cells (including T-cells modified through gene transfer (except as indicated below) or otherwise)
for treatment and/or prevention of infectious diseases (including, without limitation, AIDS), cancer and immunodeficiency states. It is understood and agreed that the Field shall not include activation or expansion of T-cells modified through
gene transfer to specifically modify the T-cells to produce secreted or cell-surface membrane-bound proteins not normally expressed in significant levels by such T-cells, unless the cell-surface membrane-bound proteins bind the T-cell to specific
target cells. 

  

	 	2.6	“Improvements” means any invention or discovery whether or not patentable which is used commercially by Xcyte during the term of this Agreement and which directly
relates to the methods of preparing T-cells claimed in the Patents, and is within the scope thereof. It is understood and agreed that any ligand (including, without limitation, any antibody or antibody derivative) identified or used by Xcyte or its
designees for the practice of the methods claimed in the Patents shall not be an Improvement. 

  

	 	2.7	“License Agreements” means the 1995 Acquisition Agreement between GI and Repligen Corporation, together with the following agreements, pursuant to which GI licensed
the Patents which are sublicensed to Xcyte under this Agreement: 

  

	 	(a)	“Navy Agreement” means the December 10, 1996 License Agreement between GI and the Navy, a copy of which is attached as Exhibit A to this Agreement.

  

	 	(b)	“Michigan Agreement” means the May 28, 1992 License Agreement between GI and Michigan, a copy of which is attached as Exhibit B to this Agreement

  

	 	(c)	“DFCI Agreement” means the July 20, 1993 License Agreement between DFCI and Repligen, a copy of which is attached as Exhibit C to this Agreement.

  

	 	2.8	“Licensors” means the United States of America, represented by the Secretary of the Navy (the “Navy”), the University of Michigan (“Michigan”)
and the Dana Farber Cancer Institute (“DFCI”). 

  
  

 2 
  

	 	2.9	“Net Sales” means the aggregate United States dollar equivalent of gross revenues derived by or payable to Xcyte, its Affiliates and Sublicensees from or on account
of the sale or distribution of Products (including Combination Products) and Services to third parties, less (a) reasonable credits or allowances, if any, actually granted on account of price adjustments, rebates, discounts, recalls, rejection or
return of items previously sold, (b) excises, sales taxes, value added taxes, consumption taxes, duties or other taxes imposed upon and paid with respect to such sales or Services (excluding income or franchise taxes of any kind) and (c) separately
itemized insurance, packaging and transportation costs incurred in shipping Products (including Combination Products) to such third parties. No deduction shall be made for any item of cost incurred by Xcyte, its Affiliates or Sublicensees in
preparing, manufacturing, shipping or selling Products (including Combination Products) except as permitted pursuant to clauses (a), (b) and (c) of the foregoing sentence. Net Sales shall not include any transfer between Xcyte and any of its
Affiliates or Sublicensees for resale. 

  

	 	    	If Xcyte or an Affiliate or Sublicensee sells Products (including Combination Products) to a Distributor, Net Sales shall be calculated from the gross revenues received by Xcyte
and/or its Affiliate or Sublicensee from the sale of Products to the Distributor. 

  

	 	    	In the event that Xcyte or any of its Affiliates or Sublicensees shall make any transfer of Products (including Combination Products) to third parties for other than monetary value,
such transfer shall be considered a sale hereunder for accounting and royalty purposes. Net Sales for any such transfers shall be determined on a country-by-country basis and shall be the average price of “arms length” sales by Xcyte, its
Affiliates or Sublicensees in such country during the royalty reporting period in which such transfer occurs or, if no such “arms length” sales occurred in such country during such period, during the last period in which such “arms
length” sales occurred. If no “arms length” sales have occurred in a particular country, Net Sales for any such transfer in such country shall be the average price of arms length” sales in all countries in the Territory.

  

	 	    	Notwithstanding the foregoing, no transfer of Products (including Combination Products) for testing, pre-clinical, clinical or developmental purposes or as samples shall be
considered a sale hereunder. 

  

	 	    	In the event a Product or Combination Product is sold to end-users together with a Service, in calculating Net Sales the payment received by Xcyte for such Service component shall
be included in Net Sales, subject to Section 5.2(b); provided, any payment received by Xcyte for any service which is not a Service shall not be included in Net Sales. 

  

	 	2.10	“Party” means GI or Xcyte; “Parties” means GI and Xcyte. 

  

 3 

	 	2.11	“Patents” means the patents and patent applications listed in Exhibit D attached to this Agreement and shall include any foreign counterparts of the patents
and patent applications listed in Exhibit D (which for all purposes of this Agreement shall be deemed to include certificates of invention anti applications for certificates of invention and priority rights), together with any reissues
extensions or other governmental acts which effectively extend the period of exclusivity by the patent holder, substitutions, confirmations, registrations, revalidations, additions, continuations, continuations-in-pan, or divisions of or to any of
the foregoing, to the extent GI owns or controls such rights, or has acquired or licensed such rights under the License Agreements. 

  

	 	2.12	“Product” means any product developed by or on behalf of Xcyte, the manufacture, use or sale of which is covered by a Valid Claim of the Patents in the country of
manufacture, use or sale. 

  

	 	2.13	“Service” means any service provided by Xcyte in connection with a Product in the Field. By way of illustration and without limitation, services would include
apheresis conducted in connection with the use of a Product or services relating to cell testing or cell characterization or quality assurance or quality control of Products. 

  

	 	2.14	“Sublicensee” means a third party, including any Xcyte Affiliate, to which Xcyte has granted a further sublicense to make, use, import, offer for sale and/or sell
the Products. 

  

	 	2.15	“Technology” means the technology described in the Patents related to the manufacture, use or sale of the Products in the Field. 

  

	 	2.16	“Territory” means, with respect to each Patent, the area of the world in which GI has the rights to practice under such Patent, as set forth in applicable License
Agreement under which GI obtained rights to such Patent. 

  

	 	2.17	“Valid Claim” means (a) a claim of an unexpired patent which shall not have been withdrawn, canceled or disclaimed, nor held invalid or unenforceable by a court of
competent jurisdiction in an unappealed or unappealable decision or (b) a claim of a patent application which is either: (i) the subject of a pending patent interference proceeding or (ii) supported by the disclosure of such application or any prior
filed patent application for a cumulative period not exceeding seven (7) years from the earliest date of such supporting disclosure for such claim in any such patent application. 

  

	3.	License from GI to Xcyte. 

  

	 	3.1	 Grant. Subject to the fulfillment of the terms and conditions of this Agreement, including, without limitation, the conditions of sublicense set forth in
Section 3.4, below, GI grants to Xcyte exclusive, royalty-bearing licenses and/or sublicenses 

  

 4 

	 	 
under the Patents, restricted to the Field, to make and have made, to use, to offer for sale, to sell and have sold, to import and have imported, and to
export and have exported, the Products in the Territory. 

  

	 	3.2	Term. The licenses and/or sublicenses granted in Section 3.1, above, shall run to the end of the enforceable term of the Patents or License Agreements under which such
license and/or sublicense is granted. 

  

	 	3.3	Further Sublicenses. Xcyte shall have the right to grant further sublicenses under the foregoing license and/or sublicense, provided the Sublicensees agree to comply with all
terms and conditions of this Agreement. Notwithstanding any such further sublicenses, Xcyte shall remain primarily liable for all of such Affiliates’ and Sublicensees’ duties and obligations contained in this Agreement.

  

	 	3.4	Conditions of Sublicense. With respect to the applicable Patents or the applicable claim or claims of such Patents, the sublicenses granted to Xcyte under this Agreement are
subject to thc following conditions imposed on GI, as licensee, and Xcyte, as sublicensee, by the applicable Licensors: 

  

	 	(a)	Approval of Licensors. Each such sublicense shall be subject to the prior written approval of the applicable Licensor to the extent required by the License Agreements.

  

	 	(b)	Licensors’ Retained Rights. Each sublicense is subject to any and all rights retained by the applicable Licensor. 

  

	 	(c)	 Consistent with Terms of License Agreements. Each sublicense is granted pursuant to the terms of the applicable License Agreement. No provision of this
Agreement shall be in derogation of or diminish any rights of each Licensor in the applicable License Agreement. Each sublicense under this Agreement may be modified or terminated in whole or in part upon the modification or termination in whole or
in part of the applicable License Agreement; provided, GI shall not terminate or enter into any modification of any of the License Agreements if such modification or termination would affect the rights of Xcyte under this Agreement, without the
prior written consent of Xcyte, and shall notify Xcyte within ten (10) business days if GI receives any notice from any Licensor that (i) such Licensor believes that GI is in default or breach of the relevant License Agreement, or (ii) such Licensor
intends to terminate the relevant License Agreement, or (iii) such Licensor intends to modify GI’s rights under the applicable License Agreement (e.g., by converting GI’s exclusive rights under such License Agreement to non-exclusive
rights). Should any sublicense granted by Xcyte under this Agreement not comply with the requirements of any License Agreement, such sublicense of rights under this Agreement may be void. If either Party becomes aware of any potential inconsistency
of a sublicense granted by Xcyte with this 

  

 5 

	 	    	Agreement, it shall promptly notify the other Party, providing a detailed explanation of the potential inconsistency. 

  

	 	(d)	GI to Furnish Copy. Within thirty (30) days of the Effective Date, and within thirty (30) days of any modification of this Agreement, GI may be obligated to furnish to each
Licensor a true and complete copy of this Agreement and any modification hereof. 

  

	4.	Product Development. 

  

	 	4.1	Diligence Obligations. Xcyte shall exercise commercially reasonable and diligent efforts, in its scientific and business judgement, to develop at least one Product itself or
through sublicensees. Each year during the term of the Agreement until the first commercial sale of a Product, Xcyte, itself or through a sublicensee, shall expend no less than five hundred thousand dollars ($500,000) annually on research and
development activities directly relaxing to Product development. During the term of this Agreement, within sixty (60) days of each anniversary of the Effective Date, Xcyte shall issue to GI a progress report detailing Xcyte’s progress in
developing Products. 

  

	 	4.2	Conversion of License and/or Sublicense. In the event that Xcyte fails to satisfy the requirements set forth in Section 4.1, above, GI shall have the right, in its sole
discretion, upon written notice to Xcyte, to convert the licenses and/or sublicenses granted to Xcyte under this Agreement from exclusive to non-exclusive; provided Xcyte has not cured such failure within sixty (60) days following written notice
from GI of any such failure. In the event that GI converts such licenses and/or sublicense to non-exclusive, GI shall be entitled to grant additional licenses and/or sublicenses under the Patents to not more than two (2) unrelated third parties. If
GI exercises its conversion right under this Section 4.2, thereafter the royalty obligation due to GI pursuant to Section 5.2 below shall be reduced by [*] but in no event shall be less than [*] of Net Sales of Product or Combination
Product. 

  

	5.	Consideration. 

  

	 	5.1	License Fee. In partial consideration for the license granted herein, on the Effective Date Xcyte shall pay to GI a license fee in the form of 145,875 shares of Xcyte
preferred stock, subject to the terms and conditions of the Stock Purchase Agreement attached hereto as Exhibit E, and shall pay a total of fifty three thousand four hundred eighty seven U.S. dollars and fifty cents ($53,487.50) to the Licensors as
provided in the Letter Agreement of even date herewith between GI, Xcyte and the Licensors. In addition, upon the first to occur of (i) notice from GI to Xcyte of the issuance of the first Valid Claim within the Patents, (ii) the first grant of a
sublicense by Xcyte to a third party pursuant to Section 3.3, or (iii) the third anniversary of the Effective Date, GI shall have the right to purchase 194,500 additional shares of Xcyte stock, subject to the terms and conditions of the Stock
Warrant Agreement attached hereto as Exhibit F. 

  
  

 6 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

	 	5.2	Royalty Payments. 

  

	 	(a)	With respect to the sales of each Product, Xcyte shall pay GI a royalty of [*] of Net Sales of Products sold by Xcyte, its Affiliates and Sublicensees without any
Services. 

  

	 	(b)	With respect to the sales of each Product, Xcyte shall pay GI a royalty of [*] of Net Sales of Products by Xcyte, its Affiliates and Sublicensees sold together with
one or more Services. 

  

	 	(c)	With respect to the sales of each Combination Product, Xcyte shall pay GI a royalty of such Combination Product, as follows: 

  

	 	(i)	[*] of Net Sales of each Combination Product sold by Xcyte, its Affiliates and Sublicensees, if such Combination Product is sold without any Services, and

  

	 	(ii)	[*] of Net Sales of each Combination Product sold by Xcyte, its Affiliates and Sublicensees, if such Combination Product is sold together with one or more Services;

  
 provided, in each case, in determining Net
Sales of Combination Products, Net Sales shall first be calculated in accordance with the definition of Net Sales and then multiplied by a fraction, the numerator of which is the current Net Selling Price of Product and the denominator of which is
the current Net Selling Price of the Combination Product. If there is no Net Selling Price of Product, then the numerator shall be the fair market value of the Product for the quantity contained in the Combination Product and of the same class,
purity and potency, as negotiated in good faith by the parties, or, failing such agreement, as is determined by an appraisal to be conducted by an independent third party mutually agreed to by Xcyte and GI, which determination shall be binding.
However, in no event shall the royalty be less than [*] of Net Sales of each Combination Product. 
  

	 	(d)	In addition to the royalties payable under this Section 5.2, Xcyte shall pay to GI a portion of all compensation, including license fees, advances and other payments of
compensation (however characterized), which are owed to Xcyte pursuant to further sublicensing of the rights granted to Xcyte hereunder, as follows: 

  

	 Sublicense Date

	  	% of Compensation

	 Within 24 months of Effective Date
	  	 [*]

	 After 24 months after Effective Date
	  	 [*]

  
  

 7 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

	 	    	Notwithstanding the above, it is understood and agreed that Xcyte shall not be obligated to pay to GI any portion of any amounts received from any Sublicensee as payments for
research and development activities to be conducted by Xcyte on behalf of such Sublicensee, or amounts received from a Sublicensee for equity, or the license or sublicense of any intellectual property other than the Patents, or products other than
the Products, or reimbursement for patent or other expenses. 

  

	 	(e)	Xcyte and its Affiliates and Sublicensees shall be responsible for any payments due to third parties under licenses or similar agreements entered by Xcyte or its Affiliates
or Sublicensees necessary for the manufacture, use or sale of Products. Xcyte may offset one-half of any such payments made by Xcyte or its Affiliates or Sublicensees to third parties against royalties due GI pursuant to Section 5.2(a), (b) and (c)
above; provided, GI shall have the right to receive the greater of (i) [*] the amounts due pursuant to Sections 5.2(a), (b) and (c) above, or (ii) [*] of Net Sales of Product or Combination Product. 

  

	 	(f)	Payments due under this Section 5.2 shall be payable on a country-by-country and Product-by-Product basis and shall be payable until (i) with respect to Patents owned by GI, the
expiration of the last-to-expire Valid Claim, and (ii) with respect to Patents subject to the License Agreements, the expiration of the applicable license term, as set forth in Section 3.2. 

  

	 	(g)	Regardless of any credits or offsets available to Xcyte under Section 5.2(e) of this Agreement commencing on the first anniversary of the Launch of the first Product in any country,
in no year shall Xcyte pay to GI less than the greater of (i) [*] of the royalties due pursuant to Sections 5.2(a), (b) or (c) in any year with regard to any Product or (ii) [*] of Net Sales of Product or Combination Product. Any
credits or offsets not creditable against royalties in the year such credit or offset is earned may be carried forward until fully applied. 

  

	 	5.3	Reports and Payment. Xcyte shall deliver to GI, within sixty (60) days after the end of each calendar quarter, a written report showing its computation of royalties due under
this Agreement upon Net Sales by Xcyte, its Affiliates and Sublicensees during such calendar quarter. All Net Sales shall be segmented in each such report according to sales by Xcyte, each Affiliate and each Sublicensee, as well as on a
country-by-country basis, including the rates of exchange used to convert such royalties to United States Dollars from the currency in which such sales were made. Subject to the provisions of Sections 5.4 and 5.5 of this Agreement, simultaneously
with the delivery of each such report, Xcyte shall tender payment in United States Dollars of all royalties shown to be due therein. 

  

	 	    	For purposes hereof, the rates of exchange to be used for converting royalties hereunder to United States Dollars shall be the closing price published for the

  
  

 8 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

	 	 
purchase of United States Dollars in the East Coast Edition of the Wall Street Journal for the last business day of the calendar quarter for which payment is
due. 

  

	 	5.4	Foreign Royalties. Where royalties are due hereunder for sales of Products in a country where, by reason of currency regulations or taxes of any kind, it is impossible or
illegal for Xcyte, any Affiliate or Sublicensee to transfer royalty payments to GI for Net Sales in that country, such royalties shall be deposited in whatever currency is allowable by the person or entity not able to make the transfer for the
benefit or credit of GI in an accredited bank in that country that is reasonably acceptable to GI. 

  

	 	5.5	Taxes. Any and all income or similar taxes imposed or levied on account of the receipt of royalties payable under this Agreement which are required to be withheld by Xcyte
shall be paid by Xcyte, its Affiliates or Sublicensees on behalf of GI and shall be paid to the proper taxing authority. Proof of payment shall be secured and sent to GI by Xcyte, its Affiliates or Sublicensees as evidence of such payment in such
form as required by the tax authorities having jurisdiction over Xcyte, its Affiliates or Sublicensees. Such taxes shall be deducted from the royalty that would otherwise be remittable by Xcyte, its Affiliates or Sublicensees.

  

	 	5.6	Records. Xcyte shall keep, and shall require all Affiliates and Sublicensees to keep, for a period of at least two (2) years, full, true and accurate books of accounts and
other records containing all information and data which may be necessary to ascertain and verify the royalties payable hereunder. During the term of this Agreement and for a period of two (2) years following its termination, GI shall have the right
from time to time (not to exceed once during each calendar year) to inspect in confidence, or have an agent, accountant or other representative inspect in confidence, such books, records and supporting data. 

  

	6.	Representation, Warranty and Indemnity. 

  

	 	6.1	Representation and Warranty of GI. GI represents and warrants to Xcyte that, subject to the terms and conditions of this Agreement and the License Agreements, (i) it has an
interest licensable or sublicensable to Xcyte in the Patents; (ii) it has full right, power and authority to grant the licenses and / sublicense granted by it under this Agreement; (iii) GI has not previously granted, and will not grant during the
term of this Agreement, any right, license or interest in and to the Patents, or any portion thereof, inconsistent with the license granted to Xcyte herein; (iv) as of the Effective Date, there are no actions, suits, investigations, claims or
proceedings pending or threatened in any way relating to the Patents except as set forth on Schedule 6.1 to this Agreement; and (v) during the term of this Agreement, GI shall use its reasonable efforts not to breach any of the License Agreements.

  

	 	6.2	 Representation and Warranty of Xcyte. Xcyte represents and warrants to GI that, subject to the terms and conditions of this Agreement and the License 

  

 9 

	 	 
Agreements, during the term of this Agreement, Xcyte shall use its reasonable efforts not to breach any of the License Agreements.

  

	 	6.3	Indemnity of GI by Xcyte. Xcyte shall defend, indemnify and hold GI (and its agents, directors, officers and employees) harmless, at Xcyte’s cost and expense, from and
against any and all losses, costs, liabilities, damages, fees and expenses, including reasonable attorneys’ fees and expenses (collectively, “Liabilities”) arising out of or in connection with the manufacture, promotion, sale or other
disposition of the Products by Xcyte, its Affiliates and Sublicensees, and any actual or alleged injury, damage, death or other consequence occurring to any third person as a result, directly or indirectly, of the possession, consumption or use of
the Products sold by Xcyte or its Affiliates or Sublicensees, regardless of the form in which any such claim is made. 

  

	 	6.4	Effect of Representations and Warranties. It is understood that if the representations and warranties made by a party under this Article 6 are not true and accurate, the
party making such representations and warranties shall indemnify and hold the other party harmless from and against any Liabilities incurred as a result. 

  

	 	6.5	Exclusion. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY, OR ANY OF ITS OFFICERS, DIRECTORS, SHAREHOLDERS, EMPLOYEES OR AGENTS, OR ANY OTHER PERSON OR ENTITY,
FOR ANY INCIDENTAL, CONSEQUENTIAL, OR OTHER SPECIAL DAMAGES, INCLUDING WITHOUT LIMITATION, LOST PROFITS OR OPPORTUNITIES INCURRED BY SUCH PARTY, OR ANY OTHER PERSON OR ENTITY, ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE LICENSES AND RIGHTS
GRANTED HEREIN, THE PRODUCT, PATENTS OR IMPROVEMENTS, OR ACTUAL OR ALLEGED NEGLIGENCE, STRICT LIABILITY, BREACH OF REPRESENTATIONS OR WARRANTIES, OR ANY OTHER CAUSE OF ACTION. 

  

	 	6.6	Procedure. A party entitled to indemnification hereunder agrees to give prompt written notice to the indemnifying party after the receipt by such party of any written notice
of the commencement of any action, suit, proceeding or investigation or threat thereof made in writing for which such party will claim indemnification pursuant to this Agreement. Unless, in the reasonable judgment of the indemnified party, a
conflict of interest may exist between the indemnified party and the indemnifying party with respect to a claim, the indemnifying party may assume the defense of such claim with counsel reasonably satisfactory to the indemnified party. if the
indemnifying party is not entitled to, or elects not to, assume the defense of a claim, it will not be obligated to pay the fees and expenses of more than one counsel with respect to such claim. The indemnifying party will not be subject to any
liability for any settlement made without its consent, which consent shall not be unreasonably withheld or delayed. 

  

 10 

	7.	Intellectual Property. 

  

	 	7.1	Improvements. Xcyte shall own the entire right, title and interest in and to all Improvements. 

  

	 	7.2	Option; Right of First Refusal. Xcyte grants to GI an option to execute an exclusive, worldwide, royalty-bearing commercialization license, with the right to grant
sublicenses, to the Improvements, to commercialize products based on or incorporating Improvements outside the Field, on terms to be negotiated by the parties in good faith. 

  

	 	    	GI may exercise its option by written notice to Xcyte within three (3) months of notice by Xcyte to GI of such Improvement and receipt by GI of sufficient technical information to
evaluate such Improvement. If GI exercise its option, the parties will negotiate in good faith to reach agreement on a commercialization license for up to 120 days. If GI does not exercise its option, or the parties do not reach agreement within 120
days, Xcyte may commercialize such Improvement outside the Field, itself or license such Improvement to a third party, without obligation to GI. Before entering into any transaction with a third party on terms which, taken as a whole, are materially
more favorable than those offered to GI in writing to license such Improvement, Xcyte will inform GI and shall allow GI sixty (60) days in which to elect whether to license such Improvement under all the terms of the proposed transaction with the
third party. Nothing in this Section 7.2 shall imply the grant of any license under the Patents to Xcyte outside the Field. 

  

	 	7.3	 Patent Maintenance. GI shall have the right to seek or continue to seek or maintain patent protection on the Patents in any country. GI shall obtain the
advice of Xcyte concerning the countries in which to seek or maintain patent protection, and the nature and text of such patents and prosecutions matters related thereto prior to the filing thereof and provide Xcyte a reasonable opportunity to
review and comment on all proposed submissions to any patent office before submittal, and provided further that GI shall keep Xcyte reasonably informed as to the status of such patent applications by promptly providing Xcyte copies of all
communications relating to such patent applications that are received from any patent office. Xcyte shall reimburse GI for any reasonable expenses incurred by GI during the term of this Agreement in preparing, filing, prosecuting and maintaining any
Patents containing claims relating to the Field. If GI elects not to seek or continue to seek or maintain patent protection on any patent application or patent within the Patents in any country, Xcyte shall have the right, at its expense, to file,
procure and maintain in such countries such Patents. If Xcyte elects not to continue to make payments to seek or continue to seek or maintain patent protection on any patent application or patent within the Patents in any country, it may notify GI,
and its obligation to make such payments shall cease and its license with regard to such patent application or patent shall terminate. Xcyte shall have the right, at Xcyte cost and expense, to audit all 

  

 11 

	 	 
expenses relating to the preparing, filing, prosecuting and maintaining of the Patents. 

  

	 	7.4	Patent Infringement. 

  

	 	(a)	Each Party shall promptly report in writing to the other Party during the term of this Agreement any known infringement or suspected infringement of any of the Patents, and promptly
shall provide the other Party with all available evidence supporting said infringement, suspected infringement, or unauthorized use or misappropriation. 

  

	 	(b)	Except as provided in Section 7.4(c) below, Xcyte shall have the right to initiate an infringement or other appropriate suit anywhere in the Territory against any third party who at
any time has infringed, or is suspected of infringing, any of the Patents in the Field. Xcyte shall give GI sufficient advance notice of its intent to file said suit and the reasons therefor, and shall provide GI with an opportunity to make
suggestions and comments regarding such suit. Xcyte shall keep GI promptly informed, and shall from time to time consult with GI regarding the status of any such suit and shall provide GI with copies of all documents filed in, and all written
communications relating to, such suit. Xcyte shall have the sole and exclusive right to select counsel for any such suit and shall, except as provided below, pay all expenses of the suit, including without limitation attorneys’ fees and court
costs. GI, in its sole discretion, may elect, within sixty (60) days after the commencement of such litigation, to contribute to the costs incurred by Xcyte in connection with such litigation and, if it so elects, any damages, royalties, settlement
fees or other consideration received by Xcyte or any of its Affiliates for infringement as a result of such litigation shall be shared by Xcyte and GI pro rata based on their respective sharing of the costs of such litigation. In the event that GI
elects not to contribute to the costs of such litigation, Xcyte and/or its Sublicensees shall be entitled to retain any damages, royalties, settlement fees or other consideration for infringement resulting therefrom. If necessary, GI shall join as a
party to the suit but shall be under no obligation to participate except to the extent that such participation is required as the result of being a named party to the suit. GI shall offer reasonable assistance to Xcyte in connection therewith at no
charge to Xcyte except for reimbursement of reasonable out-of-pocket expenses, incurred in rendering such assistance. GI shall have the right to participate and be represented in any such suit by its own counsel at its own expense.

  

	 	(c)	 In the event that Xcyte elects not to initiate an infringement or other appropriate suit pursuant to Section 7.4(b) above, Xcyte shall promptly advise GI of
its intent not to initiate such suit, and GI shall have the right, at the expense of GI, of initiating an infringement or other appropriate suit against any third party who at any time has infringed, or is suspected of 

  

 12 

	 	    	infringing, any of the Patents in the Field. GI shall have the sole and exclusive right to select counsel for any such suit and shall, except as provided below, pay all expenses of
the suit including without limitation attorneys’ fees and court costs. Xcyte, in its sole discretion, may elect, within sixty (60) days after the commencement of such litigation, to contribute to the costs incurred by GI in connection with such
litigation and, if it so elects, any damages, royalties, settlement fee or other consideration received by GI or any of its Affiliates for infringement as a result of such litigation shall be shared by GI and Xcyte pro rata based on their respective
sharing of the costs of such litigation. In the event that Xcyte elects not to contribute to the costs of such litigation, GI and/or its Affiliates shall be entitled to retain any damages, royalties, settlement fees or other consideration for
infringement resulting therefrom. If necessary, Xcyte shall join as a party to the suit but shall be under no obligation to participate except to the extent that such participation is required as a result of being a named party to the suit. At
GI’s request, Xcyte shall offer reasonable assistance to GI in connection therewith at no charge to GI except for reimbursement of reasonable out-of-pocket expenses incurred in rendering such assistance. Xcyte shall have the right to
participate and be represented in any such suit by its own counsel at its own expense. 

  

	 	7.5	Claimed Infringement. 

  

	 	(a)	In the event that a third party at any time provides written notice of a claim to, or brings an action, suit, or proceeding against, either Party or any of their respective
Affiliates or Sublicensees, claiming infringement of its patent rights or unauthorized use or misappropriation of its know-how, based upon an assertion or claim arising out of the development, use, manufacture, distribution, or sale of Products,
such Party shall promptly notify the other Party of the claim or the commencement of such action, suit, or proceeding, enclosing a copy of the claim and/or all papers served. Each Party agrees to make available to the other Party its advice and
counsel regarding the technical merits of any such claim at no cost to the other Party. 

  

	 	(b)	THE FOREGOING STATES THE ENTIRE RESPONSIBILITY OF THE PARTIES IN THE CASE OF ANY CLAIMED INFRINGEMENT OR VIOLATION OF ANY THIRD PARTY’S RIGHTS OR UNAUTHORIZED USE OR
MISAPPROPRIATION OF ANY THIRD PARTY’S KNOW-HOW. 

  

	8.	Confidential Information. 

  

	 	8.1	 Nondisclosure of Confidential Information. Each Party shall not directly or indirectly publish, disseminate or otherwise disclose, deliver or make available
to any person outside its organization any of the other Party’s Confidential 

  

 13 

	 	 
information. Each Party may disclose the other Party’s Confidential Information to persons within its organization and to its Affiliates and
Sublicensees who/which have a need to receive such Confidential Information in order to further the purposes of this Agreement and who/which are bound to protect the confidentiality of such Confidential Information, as set forth in Section 8.4
below. Each Party may disclose the other Party’s Confidential Information to a governmental authority or by order of a court of competent jurisdiction, provided that such disclosure is subject to all applicable governmental or judicial
protection available for like material and reasonable advance notice is given to the other Party. 

  

	 	8.2	Use of Confidential Information. Each Party shall use the other Party’s Confidential Information solely for the purposes contemplated in this Agreement or for such other
purposes as may be agreed upon by the Parties in writing. 

  

	 	8.3	Physical Protection of Confidential Information. The Parties shall exercise commercially reasonable precautions to physically protect the integrity and confidentiality of the
other Party’s Confidential Information. 

  

	 	8.4	Agreements with Personnel and Third Parties. The Parties have or shall obtain agreements with all personnel and third parties who will have access to the other Party’s
Confidential Information which impose comparable confidentiality obligations as are set forth in this Agreement on such personnel and third parties. 

  

	9.	Term and Termination. 

  

	 	9.1	Term. Unless sooner terminated in accordance with the provisions of this Section 9, this Agreement shall continue in force on a country-by-country and Product-by-Product
basis for the period set forth in Section 3.2. 

  

	 	9.2	Termination for Breach. Each Party shall be entitled to terminate this Agreement by written notice to the other party in the event that the other party shall be in default of
any of its material obligations hereunder, and shall fail to remedy any such default within sixty (60) days after notice thereof by the non-breaching party. Any such notice shall specifically state that the non-breaching party intends to terminate
this Agreement in the event that the breaching party shall fail to remedy the default. 

  

	 	9.3	Permissive Termination. Xcyte may terminate this Agreement with thirty (30) days notice to GI. 

  

	 	9.4	Effect of Termination. 

  

	 	(a)	 Accrued Obligations. Termination of this Agreement for any reason shall not release any Party hereto from any liability which, at the time of such
termination, has already accrued to the other Party or which is attributable to such termination, nor shall it preclude either Party from 

  

 14 

	 	    	pursuing all rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement. 

  

	 	(b)	Return of Confidential Information. Subject to any license granted pursuant to Section 7.2, upon any termination of this Agreement each Party shall return to the other Party
all Confidential Information received from the other Party (except one copy of which may be retained for archival purposes), and neither Party shall use any such Confidential Information of the other Party for any purpose. 

 

	 	(c)	Stock on Hand. In the event this Agreement is terminated for any reason, Xcyte, its Affiliates and its Sublicensees shall have the right for six (6) months following the date
of termination to sell or otherwise dispose of the stock of any Licensed Product subject to this Agreement then on hand, subject to the right of GI to receive payment thereon as provided in Section 5. 

  

	 	9.5	Survival of Obligations. Notwithstanding any termination of this Agreement, the obligations of the Parties under Sections 5.3, 5.6, 6,7.1, 8,9.4, 9.5 and 10 shall survive and
continue to be enforceable. 

  

	10.	Miscellaneous. 

  

	 	10.1	Publicity. Neither Party shall originate any publicity, news release or other public announcement, written or oral, relating to this Agreement or the existence of an
arrangement between the Parties, without the prior written approval of the other Party, which approval shall not be unreasonably withheld, except as otherwise required by law. It is expressly understood that nothing in this Section 10.1 shall
prevent a Party from making a disclosure in connection with any required filings with the Securities and Exchange Commission or in connection with the offering of securities or any financing. 

  

	 	10.2	 Export Control. The Parties acknowledge that the export of technical data, materials, or products is subject to the exporting Party receiving the necessary
export licenses and that the Parties cannot be responsible for any delays attributable to export controls which are beyond the reasonable control of either Party. The Parties agree that regardless of any disclosure made by the Party receiving an
export of an ultimate destination of any technical data, materials, or products, the receiving Party will not reexport either directly or indirectly, any technical data, material, or products without first obtaining the applicable validated or
general license from the United States Department of Commerce, United States Food and Drug Administration, and/or any other agency or department of the United States Government, as required. The receiving Party shall provide the exporting Party with
any information, materials, certifications, or other documents which may be reasonably required in connection with such exports under the Export Administration Act of 1979, as amended, its rules and 

  

 15 

	 	 
regulations, the Federal Food, Drug and Cosmetic Act, and other applicable export laws. 

  

	 	10.3	No Implied Licenses. Only the licenses granted pursuant to the express terms of this Agreement shall be of any legal force and effect. No license tights shall be created by
implication or estoppel. 

  

	 	10.4	No Agency. Nothing herein shall be deemed to constitute either Party as the agent or representative of the other Party, or both Parties as joint venturers or partners for any
purpose. Each Party shall be an independent contractor, not an employee or partner of the other Party, and the manner in which each Party renders its services under this Agreement shall be within its sole discretion. Neither Party shall be
responsible for the acts or omissions of the other Party, and neither Party will have authority to speak for, represent or obligate the other Party in any way without prior written authority from the other Party. 

  

	 	10.5	Notice. All notices required under this Agreement to be given by one Party to the other shall be in writing and shall be given by addressing the same to the other at the
address or facsimile number set forth below, or at such other address or facsimile number as either may specify in writing to the other. All notices shall become effective when deposited in the United States Mail with proper postage for first class
registered or certified mail prepaid, return receipt requested, or when delivered personally, or, if promptly confirmed by mail as provided above, when dispatched by facsimile. 

  

	 GI:
	  	Genetics Institute, Inc.
	 	  	87 Cambridge Park Drive
	 	  	Cambridge, Massachusetts 02140
	 	  	Telecopier (617) 876-5851
	 	  	Attn: Legal Department
		
	 Xcyte:
	  	Xcyte Therapies, Inc.
	 	  	2203 Airport Way South
	 	  	Suite 300
	 	  	Seattle, Washington 98134
	 	  	Telecopier (206) 328-7316
	 	  	Attn: President and CEO

  

	 	10.6	Assignment. This Agreement, and the rights and obligations hereunder, may not be assigned or transferred, in whole or in part, by either Party without the prior written
consent of the other Party, except that neither Party shall require the other Party’s consent to assign this Agreement to any Affiliate, or to any entity acquiring such Party or substantially all of the assets of such Party as to which this
Agreement relates whether by sale, operation of law or otherwise, or to any successor entity of such Party as the result of a merger or consolidation. 

  

 16 

	 	10.7	Entire Agreement. This Agreement constitutes the entire agreement of the Parties with regard to its subject matter, and supersedes all previous written or oral
representations, agreements and understandings between the Parties. 

  

	 	10.8	No Modification. This Agreement may be changed only by a writing signed by the Parties. 

  

	 	10.9	Headings. The headings contained in this Agreement are for convenience of reference only and shall not be considered in construing this Agreement. 

 

	 	10.10	Waiver. The waiver by either Party of a breach or a default of any provision of this Agreement by the other Party shall not be construed as a waiver of any succeeding breach
of the same or any other provision, nor shall any delay or omission on the part of either Party to exercise or avail itself of any right, power or privilege that it has or may have hereunder operate as a waiver of any right, power, or privilege by
such Party. 

  

	 	10.11	Severability. In the event that any one or more of the provisions contained in this Agreement shall, for any reason, be held to be invalid, illegal or unenforceable in any
respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Agreement, and all other provisions shall remain in full force and effect. If any of the provisions of this Agreement is held to be excessively
broad or invalid, illegal or unenforceable in any jurisdiction, it shall be reformed and construed by limiting and reducing it so as to be enforceable to the maximum extent permitted by law in conformance with its original intent. In the event that
after such reformation, a Party’s rights or obligations are materially changed, then such Party may terminate this Agreement. 

  

	 	10.12	Force Majeure. Any delays in or failures of performance by either party under this Agreement shall not be considered a breach of this Agreement if and to the extent caused by
occurrences beyond the reasonable control of the party affected, including but not limited to: acts of God, acts, regulations or laws of any government; strikes or other concerted acts of workers; fires; earthquakes; floods; explosions; riots; wars;
rebellion; and sabotage. Any time for performance imposed hereunder shall be extended by the actual time of delay caused by any such occurrence. 

  

	 	10.13	LIMITATION OF LIABILITY. NEITHER. PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL OR INDIRECT DAMAGES ARISING OUT OF THIS AGREEMENT, HOWEVER
CAUSED, UNDER ANY THEORY OF LIABILITY. 

  

	 	10.14	Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the Parties hereto and their successors and permitted assigns.

  

 17 

	 	10.15	Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original but all of which together shall constitute one and the
same instrument. 

  

	 	10.16	Applicable Law. This Agreement shall in all events and for all purposes be governed by, and construed in accordance with, the law of The Commonwealth of Massachusetts without
regard to any choice of law principle that would dictate the application of the law of another jurisdiction. 

  

	 	10.17	HSR. Xcyte represents and warrants that neither Xcyte nor any ultimate parent entity of Xcyte has $10 million in sales or total assets and therefore does not meet the size of
person test under Title II of the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the regulations promulgated thereunder. 

  

 18 

 IN WITNESS WHEREOF, duly-authorized representatives of the Parties have signed this Agreement as a
document under seal as of the Effective Date. 
  

	
	 GENETICS INSTITUTE, INC.

	
	 By /s/ Egon E. Berg

	
	 Print Name

	
	 Title

	
	 XCYTE THERAPIES, INC.

	
	 By /s/ Ronald Jay Berenson

	
	 Print Name Ronald Jay Berenson

	
	 Title President & CEO

  

 19 

 Exhibit A 
  

Navy Agreement 
  
  

 Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information
subject to the confidentiality request. Omissions are designated as [*]. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 
  
 EXCLUSIVE LICENSE 
  
 Between 
  
 GENETICS INSTITUTE, INC. 
  
 And 
  
 UNITED STATES OF
AMERICA 
  
 As Represented By 
  
 THE SECRETARY OF THE NAVY 

 TABLE OF CONTENTS 
  

			
	 	  	Page

	 PREAMBLE
	  	1
	 ARTICLE I. Definitions
	  	3
	 ARTICLE II. License Grant
	  	4
	 ARTICLE III. LICENSEE’s Performance
	  	5
	 ARTICLE IV. Royalties
	  	6
	 ARTICLE V. Patent Marking and Nonendorsement
	  	8
	 ARTICLE VI. Representations and Warranties
	  	8
	 ARTICLE VII. Reports
	  	9
	 ARTICLE VIII. Modification and Termination
	  	9
	 ARTICLE IX. Officials Not to Benefit
	  	10
	 ARTICLE X. Notice
	  	10
	 ARTICLE XI. Sublicensing
	  	11
	 ARTICLE XII. Reservation of Rights
	  	12
	 ARTICLE XIII. Litigation
	  	12

  

 - i - 

 PREAMBLE 
  
 This exclusive license (hereinafter called “LICENSE”) is made and entered into by and between the United States of
America as represented by the Secretary of the Navy (hereinafter called “LICENSOR”) and Genetics Institute, Inc., a Delaware corporation (hereinafter called. “LICENSEE”) having an address at 87 CambridgePark Drive, Cambridge,
Massachusetts 02140. 
  
 WITNESSETH: 
  
 WHEREAS LICENSOR and Repligen Corporation. (“REPLIGEN”) are parties
to a Cooperative Research and Development Agreement effective December 20, 1991, as subsequently amended by REPLIGEN and LICENSOR from time to time (the “CRADA”); 
  
 WHEREAS LICENSEE and REPLIGEN are parties to a September 1, 1995 Asset Acquisition. Agreement, pursuant to which LICENSEE
acquired certain of REPLIGEN’s tangible assets, intellectual property and contractual rights related to REPLIGEN’ s immune modulation business, and thereafter, LICENSEE became REPLIGEN’s successor-in-interest to such immune modulation
business; 
  
 WHEREAS a portion of the assets, intellectual
property and contractual rights acquired by LICENSEE from REPLIGEN included REPLIGEN’s rights under the CRADA; 
  
 WHEREAS LICENSEE informed LICENSOR of its acquisition of said REPLIGEN rights pursuant to an October 16, 1995 letter, a copy of which is attached to this
LICENSE as SCHEDULE A; and LICENSOR has consented to the substitution of LICENSEE for REPLIGEN under the CRADA; 
  
 WHEREAS LICENSOR has consented to LICENSEE’S exercise of its option under the CRADA to obtain an exclusive license to certain patent applications
filed by LICENSOR (more fully defined below as the “LICENSED PATENTS”); . 
  
 WHEREAS Title 35 of the United States Code, Section 207, authorizes Federal agencies to license their patents; 
  
 WHEREAS Title 37 of the Code of Federal Regulations, Chapter IV, Part 404 entitled “Licensing of Government Owned Inventions” sets forth the
terms and conditions under which licenses may be granted; 
  
 WHEREAS the above-cited authorities provide that licensing of Government inventions will best serve the interests of the Federal Government and the public when utilization of such inventions is promoted and such inventions are brought to
practical application; 

 WHEREAS LICENSOR has an assignment of an undivided ownership interest in the inventions disclosed, and
claimed in the LICENSED PATENTS; 
  
 WHEREAS LICENSEE has supplied
LICENSOR with a plan for development and marketing of these inventions and has expressed its intention to carry out this plan upon the granting of this LICENSE; 
  

WHEREAS LICENSEE has agreed that any products embodying these inventions or produced through the use of these inventions for use or sale in the United
States will be manufactured substantially in the United States; 
  
 WHEREAS LICENSOR has determined that: 
  
 (A) The
interest of the Federal Government and the public will best be served by the proposed license, in view of the LICENSEE’s intentions, plans, and ability to bring the inventions described and claimed, in the LICENSED PATENTS to practical
application or otherwise promote the inventions’ utilization by the public; 
  
 (B) The desired practical application has not been achieved, or is not likely expeditiously to be achieved, under any non-exclusive license which has been granted, or which may be granted, on the inventions;

  
 (C) Exclusive licensing is a reasonable and necessary
incentive to call forth the investment of risk capital and expenditures to bring the inventions to practical application or otherwise promote the inventions’ utilization by the public; 
  
 (D) The proposed terms and scope of exclusivity are not greater than
reasonably necessary to provide the incentive for bringing the inventions to practical application or otherwise promote the inventions utilization by the public; 
  
 WHEREAS LICENSOR has not determined that the grant of this LICENSE will tend substantially to lessen competition or result
in undue concentration in any Section of the country in any line of commerce to which the technology to be licensed relates or to create or maintain other situations inconsistent with the antitrust laws; and 
  
 WHEREAS LICENSOR has considered the capabilities of LICENSEE to bring the
inventions to practical application and’ has found that the LICENSEE is a responsible party for negotiating this LICENSE on terms and conditions most favorable to the public interest and that to grant this exclusive LICENSE would be in the
public interest; 
  
 NOW, THEREFORE, in accordance with and to the
extent provided by the aforementioned authorities and in consideration of the foregoing premises and of the covenants and obligations hereinafter set forth to be well and truly performed, and other good and valuable consideration, the parties hereto
agree to the foregoing and as follows: 
  

 -2- 

 ARTICLE I. 
 Definitions 
  
 The
following definitions shall apply to the defined words where such words are used in this LICENSE: 
  
 a. “LICENSED PATENTS” means all patents and patent applications listed on SCHEDULE B to this LICENSE (which for all purposes of this Agreement
shall be deemed to include certificates of invention and applications for certificates of invention and priority rights), together with any reissues, extensions or other governmental acts which effectively extend the period of exclusivity by the
patent holder, substitutions, confirmations, registrations,, revalidations, additions, continuations, continuations-in-part (to the extent a claim is entitled to the benefit of one or more prior applications), or divisions of or to any of the
foregoing; 
  
 b. “LICENSED INVENTIONS” means the
inventions claimed in the LICENSED PATENTS; 
  
 c. To
“practice the LICENSED INVENTIONS” means to make, use and sell by or on behalf of LICENSEE or otherwise dispose of according to law any machine, article of manufacture or composition of matter physically embodying or made according to
LICENSED INVENTIONS; 
  
 d. “PRACTICAL APPLICATION”
means to manufacture in the case of a composition or product, to practice in the case of a process or method, or to operate in the case of a machine or system, and, in each case under such conditions as to establish that these LICENSED INVENTIONS
are being utilized and that their benefits are to the extent permitted by law and Government regulations available to the public on reasonable terms; 
  
 e. A “ROYALTY-BEARING PRODUCT” means any product defined by a VALID CLAIM of the LICENSED PATENTS or made by a method claimed in a VALID CLAIM
of, the LICENSED PATENTS; 
  
 f. The “NET SELLING PRICE”
shall mean the invoice price of a ROYALTY-BEARING PRODUCT sold and not returned. A ROYALTY-BEARING PRODUCT will be considered to be sold when shipped or delivered to a customer. If a ROYALTY-BEARING PRODUCT is sold as part of a unit, system, package
or combination product, the NET SELLING PRICE, for purposes of calculating the royalty shall be calculated by multiplying the NET SELLING PRICE of the combination product by the fraction A/ (A+B) where “A” is the average unit sales price
of the ROYALTY-BEARING PRODUCT when sold separately and “B” is the average unit sale’s price of the other product or products when sold separately. If either the ROYALTY-BEARING PRODUCT or the other product or products are not sold
separately, then the NET 
  

 -3- 

 SELLING PRICE of such ROYALTY-BEARING PRODUCTS shall be deemed to be the actual average NET SELLING PRICE per unit for
independent sales of such ROYALTY-BEARING PRODUCT over e prior calendar quarter, when sold and invoiced as a separate unit. In the event the NET SELLING PRICE cannot be calculated in the manner set forth above, the PARTIES shall discuss in good
faith and agree upon an alternative calculation for NET SELLING PRICE. 
  
 g. “UNITED STATES” means the United States of America, its territories and possessions, the District of Columbia, and the Commonwealth of Puerto Rico. 
  
 h. “SUBLICENSEE” means any third party, other than an AFFILIATE, to which LICENSEE has granted a sublicense
pursuant to the terms of this LICENSE. 
  
 i. “VALID
CLAIM” means, with respect to the manufacture, use or sale of a ROYALTY-BEARING PRODUCT, (a) a claim of an unexpired LICENSED PATENT which shall not have been withdrawn, canceled or disclaimed, nor held invalid or unenforceable by a court of
competent jurisdiction in an unappealed or unappealable decision or (b) a claim of a patent application which is either (i) the subject of a pending patent interference proceeding or (ii) supported by the disclosure of such application or any prior
filed patent application for a cumulative period not exceeding seven (7) years from the earliest date of such supporting disclosure for such claim in any such patent application. 
  
 j. “LICENSED TERRITORY” means all—countries in the world in which LICENSEE has filed a patent application, as
set forth on Attachment 1 to this AGREEMENT. 
  
 k.
“AFFILIATE” means any corporation, company, partnership, joint venture, firm and/or other entity which controls or is controlled by LICENSEE. For purposes of this Section, “control” means: (a) in the case of corporate entities,
direct or indirect ownership of, at least fifty. percent (50%) of the stock’ or shares entitled to vote for the election of directors; and (b) in the case of non-corporate entities, direct or indirect ownership of at least fifty percent (50%)
of the equity interest with the power to direct the management and policies of such noncorporate entities. 
  
 ARTICLE II. 
 License Grant 
  
 LICENSOR grants to LICENSEE an exclusive right and license in LICENSOR’s
undivided ownership interest in the LICENSED PATENTS to practice the LICENSED INVENTIONS throughout the LICENSED TERRITORY, commencing on the date of execution of this LICENSE by LICENSOR, which shall become the effective date of the LICENSE, and
ending upon the expiration of the last-to-expire of the LICENSED PATENTS which cover such LICENSED INVENTIONS, unless the LICENSE is sooner modified or terminated in whole or in part. 
  

 -4- 

 This LICENSE is nonassignable without written approval of LICENSOR except to the successor of that part
of LICENSEE’s business to which these LICENSED INVENTIONS pertain. 
  
 ARTICLE III. 
 LICENSEE’s Performance 
  
 LICENSEE agrees to carry out the plan for development and marketing of the LICENSED INVENTIONS submitted with
LICENSEE’S application for license dated June 28, 1996 to bring these LICENSED INVENTIONS to practical application as soon as commercially feasible, and LICENSEE will, thereafter, continue to make the benefits of these LICENSED INVENTIONS
reasonably accessible to the public for the remainder of the period of this LICENSE. 
  
 LICENSEE agrees to spend not less than One Million Dollars ($1,000,000) per year, either internally or through AFFILIATES or SUBLICENSEES or other collaborators, on the research, development and marketing (and
associated costs related thereto) of products in the [*], CTLA4 and/or B7 immune modulation area, which area includes, without limitation, the LICENSED INVENTIONS. 
  
 LICENSEE agrees that during the period of this LICENSE any products embodying these LICENSED INVENTIONS or produced through
the use of the LICENSED INVENTIONS for use or sale by LICENSEE or its AFFILIATES or SUBLICENSEES in the UNITED STATES will be manufactured substantially in the UNITED STATES. 
  
 LICENSEE shall pay to the LICENSOR a non-refundable licensing fee in the amount of ONE HUNDRED THOUSAND DOLLARS ($100,000)
payable, at the LICENSOR’s election, either: (a) upon the execution of this LICENSE by LICENSEE or (b) at a later date during the term of this ‘LICENSE, upon ninety (90) days prior written notice to LICENSEE. 
  
 LICENSEE agrees to pay to LICENSOR [*] of any sublicensing fee (other than
running royalty payments or research and development reimbursements for research and/or development performed after the effective date of the applicable sublicense agreement) collected from any SUBLICENSEE. If LICENSEE is required to pay a portion
of such sublicensing fee to a third party (other than the. University of Michigan (“MICHIGAN”) pursuant to a May 28, 1992 License Agreement, as amended, between MICHIGAN and GI’s predecessor in interest under such License Agreement,
Repligen Corporation), then [*] of LICENSEE’S payments to such third party shall be deducted 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities & Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 -5- 

 from the portion of the sublicensing fee payable to LICENSOR. However, in no event shall LICENSOR’S share of any
sublicensing fee be reduced below [*]. Payment will be made in the manner prescribed in Article IV. 
  
 LICENSEE agrees to report promptly-to LICENSOR any changes in mailing address, name or company affiliation during the period of this LICENSE and to report
promptly discontinuance of LICENSEE’s making the benefits of these LICENSED INVENTIONS reasonably accessible to the UNITED STATES public. 
  
 ARTICLE IV. 
 Royalties 
  
 LICENSEE shall pay a royalty to LICENSOR of (a) [*] of the NET SELLING PRICE
for each ROYALTY-BEARING PRODUCT made, used, or sold by LICENSEE or its AFFILIATES in the LICENSED TERRITORY, where LICENSOR is the sole assignee of the LICENSED PATENT covering such ROYALTY—BEARING PRODUCT, or (b) [*] of the NET SELLING PRICE
for each ROYALTY-BEARING PRODUCT made, used, or sold by LICENSEE or its AFFILIATES in the LICENSED TERRITORY, where LICENSOR is not the sole assignee of the LICENSED PATENT(S) covering such ROYALTY-BEARING PRODUCT. 
  
 During the term of this LICENSE, for each calendar year beginning with
calendar year 1998, LICENSEE shall pay LICENSOR an annual minimum royalty of Ten Thousand Dollars ($10, 000), which payment shall be due and payable for each calendar year in advance, prior to October 1st of the preceding year (for example, the
first annual minimum royalty payment (that is, for calendar, year 1998) shall be due and payable prior to October 1, 19,97). These minimum royalty payments shall be creditable against royalties owed ‘to LICENSOR by LICENSEE on account of sales
by LICENSEE or its AFFILIATES or SUBLICENSEES of ROYALTY-BEARING PRODUCTS during subsequent calendar years. 
  
 In addition, LICENSEE shall pay a royalty to LICENSOR of (a) [*] of any royalties received by LICENSEE with respect to the NET SELLING PRICE of
ROYALTY-BEARING PRODUCTS sold by LICENSEE’s SUBLICENSEES, where LICENSOR is the sole assignee of the LICENSED PATENT covering such ROYALTY-BEARING PRODUCT; or (b) [*] of any royalties received by LICENSEE with respect to the NET SELLING PRICE
of ROYALTY-BEARING PRODUCTS sold by LICENSEE’s SUBLICENSEES, where LICENSOR is not the sole assignee of the LICENSED PATENT(S) covering such ROYALTY-BEARING PRODUCT. However, in no event shall LICENSOR’S royalty be reduced below [*], such
percentage being the minimum royalty rate to LICENSOR on such NET SELLING PRICE for sales of ROYALTY-BEARING PRODUCTS by SUBLICENSEES. 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities & Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 -6- 

 Royalties will not be, paid on items sold directly to agencies of the U.S. Government or for known U.S.
Government end use. 
  
 Only one royalty obligation shall be
imposed with respect to the same unit of ROYALTY-BEARING PRODUCT regardless of the number of VALID CLAIMS of the LICENSED PATENTS covering the same. 
  
 If LICENSEE is required to pay a royalty to a third party (other than MICHIGAN pursuant to the May 28, 1992 License Agreement, as amended, between
MICHIGAN and GI’s predecessor in interest under such License Agreement, Repligen Corporation) in order to sell the ROYALTY-BEARING PRODUCTS in a particular country, then [*] of that royalty will be deducted from the royalty otherwise payable
hereunder on the NET SELLING PRICE of such ROYALTY-BEARING PRODUCTS in such country; provided, however, that in no event shall the royalty thus payable by LICENSEE on account of its sales be reduced below [*]. LICENSEE agrees that royalty deductions
under this paragraph will not be made without LICENSOR’s prior written approval, which approval shall not be unreasonably ‘withheld or delayed. When seeking LICENSOR’s prior written approval under the preceding sentence, LICENSEE,
shall submit to LICENSOR such materials as LICENSOR may reasonably request in order to evaluate LICENSEE’s , request , for such deductions, including, without limitation, a copy of the license’ with the third party, copies of the patents
licensed from the third party, identification of the patent claims on which the royalty deduction is to be made, and a sufficient description of the ROYALTY-BEARING PRODUCT to permit a comparison of the third party’s patent claims with that
ROYALTY-BEARING PRODUCT. 
  
 LICENSEE shall send to LICENSOR all
royalties which accrue between January 1 and December 31 of each year by March 1 of the following year. A royalty report shall be included with each payment setting forth, separately by Licensed Patents, the quantity and net-selling price of each
royalty-bearing product sold during the period covered by the report, to whom sold and the date of such sale, the total amount of royalties being paid for that year and the computation of the amount of royalties owed. Royalty reports are due each
calendar year. The last royalty report is due- sixty (60) days after the expiration of this LICENSE. 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities & Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 -7- 

 All payments due LICENSOR under this LICENSE shall be made payable to the Treasurer of the United States
and mailed to: 
  
 Deputy Counsel (Intellectual Property)

  
 Office of Naval Research 
 Code OOCCIP, Room 207 
 800 North Quincy Street 
 Arlington, Virginia 22217-5660 
  
 LICENSEE agrees to make and keep full, accurate and complete books and
records as are necessary to establish its compliance with this Article IV. 
  
 LICENSEE agrees that LICENSOR may, if LICENSOR so desires at a future time or times, have a duly authorized agent or representative in LICENSOR’s behalf inspect, check or verify all such books and records either
at LICENSEE’s business premises or at a place mutually agreed upon by LICENSEE and LICENSOR. 
  
 ARTICLE V. 
 Patent Marking and Nonendorsement 
  
 LICENSEE hereby agrees to mark each product manufactured or sold under this
LICENSE (or when the character of the product precludes marking, the package containing any such product) with the notation “Licensed from U.S. Navy under U.S. Patent No.
                     “(to be completed by LICENSEE, for each LICENSED PATENT, as applicable). LICENSEE agrees not to create the
appearance that LICENSOR endorses LICENSEE’s business or products. 
  
 ARTICLE VI. 
 Representations and Warranties 
  
 LICENSOR makes no representation or warranty as to validity of any of the LICENSED PATENTS or of the scope of any of the
claims contained therein or that the exercise of, this LICENSE will not result in the infringement of other patent(s). Neither LICENSOR nor its employees assume any liability whatsoever resulting from the exercise of this LICENSE. 
  
 Nothing relating to the grant of this LICENSE, nor the grant itself, shall be
construed to confer upon LICENSEE or any sub-licensee hereunder or any other person any immunity from or defenses ‘under the antitrust laws or from a charge of patent misuse, and the acquisition and use of rights pursuant to this LICENSE shall
not be immunized from the operation of State or Federal law by reason of the source of the grant. 
  

 -8- 

 Nothing contained in this LICENSE shall be interpreted to grant to LICENSEE any rights with respect to
any inventions other than the LICENSED INVENTIONS. 
  
 ARTICLE VII.

 Reports 
  
 LICENSEE agrees to submit periodic reports on its efforts to achieve practical application of the LICENSED INVENTIONS, with particular reference to
LICENSEE’S plan for development and marketing of the LICENSED INVENTIONS submitted with LICENSEE’S application for license. These reports shall contain information within LICENSEE’S knowledge, or which it may acquire under normal
business practices, pertaining to the commercial use being made of the LICENSED INVENTIONS and other information which LICENSOR may determine is pertinent to Government licensing activities. LICENSEE agrees to submit such reports to LICENSOR
annually until ‘such time that the LICENSED INVENTIONS have been brought to the point of practical application. 
  
 ARTICLE VIII. 
 Modification and Termination 
  
 This LICENSE may be terminated in whole or in part by LICENSOR if:

  
 (1) LICENSOR determines that LICENSEE is not executing the
plan submitted with the request for license dated June 28, 1996 and LICENSEE cannot otherwise demonstrate to the satisfaction of LICENSOR that it has taken or can be expected to take within a reasonable time effective steps to achieve practical
application of these LICENSED INVENTIONS; 
  
 (2) LICENSOR
determines that such action is necessary to meet requirements for public use specified by Federal regulations issued after the date of this LICENSE and such requirements are not reasonably satisfied by LICENSEE; 
  
 (3) LICENSEE willfully made a false statement of or willfully omitted a
material fact in its application for license or in any report required by this LICENSE; or 
  
 (4) LICENSEE commits a substantial breach of a covenant or agreement herein contained. 
  
 This LICENSE shall automatically terminate on September 30 of any year if the minimum annual royalty due for the subsequent calendar year, as set forth in
Article IV of this LICENSE, is not timely paid; provided, however, if the minimum annual royalty payment, together with a surcharge of five hundred dollars ($500.00) is paid prior to December 31st of such calendar year, then this LICENSE shall be
considered as not having automatically terminated. During such grace period, LICENSOR shall not take any actions which would prevent LICENSEE ‘from reinstating this LICENSE, without the LICENSEE’s prior written consent. 
  

 -9- 

 This LICENSE may be modified or terminated in whole or in part consistent with the law and applicable
regulations upon mutual agreement of LICENSOR and LICENSEE evidenced in writing and signed by both parties. 
  
 This LICENSE may be restricted to the fields of use or geographic areas, or both, in which the LICENSEE has brought the LICENSED INVENTIONS to practical
application and continues to make the benefits of the LICENSED INVENTIONS reasonably accessible to the public. However, such restriction may be made only after the expiration of TEN (10) years following the effective date of this LICENSE.

  
 LICENSEE may request modification of this LICENSE in writing
sent to LICENSOR and stating the reasons therefor. 
  
 Before
modifying or terminating in whole or in part this LICENSE for any cause other than by mutual agreement, LICENSOR shall furnish LICENSEE and each sublicensee of record a written notice of intention to modify or terminate in whole or ii part this
LICENSE, and LICENSEE and any sublicensee shall be allowed ninety (90) days after such notice or other agreed—upon time period, whichever is greater, to remedy any breach of any covenant or agreement set forth in this LICENSE or to show cause
why this LICENSE should not be modified or terminated in whole or in part. 
  
 LICENSEE has a right to appeal, in accordance with procedures prescribed by the Chief of Naval Research, any decision or determination concerning the interpretation, modification, termination in whole or in part of
this LICENSE. 
  
 Upon termination or expiration of, this LICENSE,
the parties shall continue to be responsible for any obligations (including, without limitation, royalty obligations) which have been incurred prior to such termination or expiration. 
  
 ARTICLE IX. 
 Officials Not to Benefit 
  
 No member of or
delegate, to Congress, or resident commissioner, shall be admitted to any share or part, of this LICENSE or to any benefit to arise thereupon. 
  
 ARTICLE X. 
 Notice 
  
 All communications and notices required under this LICENSE shall be
considered duly given if timely mailed by U.S. Postal Service, first class, postage prepaid and addressed as follows: 
  

 -10- 

	 	(a)	if to LICENSOR: 

  
 Deputy Counsel (Intellectual Property) 
 Office of Naval Research (Code OOCCIP) 
 800 North Quincy Street 
 Arlington, Virginia 22217-5660 
  

	 	(b)	if to LICENSEE: 

  
 General Counsel 
 GENETICS INSTITUTE, INC. 
 87 CambridgePark Drive 
 Cambridge, Massachusetts 02140 
  
 or such mailing address as either party may from time to time specify in writing. 
  
 ARTICLE XI. 
 Sublicensing 
  
 LICENSEE may grant, subject to
the approval of LICENSOR, which approval shall not be unreasonably withheld or delayed, sublicenses with the ability to grant further sublicenses, to AFFILIATES and SUBLICENSEES under this LICENSE, upon terms and conditions that LICENSEE may arrange
provided that: 
  
 a. Each sublicense shall be in writing and
make reference to this LICENSE including the rights retained by LICENSOR under this LICENSE; and 
  
 b. Each sublicense shall specify that it is granted pursuant to this LICENSE, that no provision shall be in derogation of or diminish any rights in this
LICENSE and include the condition that the sublicense shall automatically be modified or terminated in whole or in part upon the ‘modification or termination’ in whole or in part of this LICENSE; and 
  
 c. Before any sublicense is granted by LICENSEE, the written approval of
LICENSOR shall first be obtained for each sublicense; and 
  
 d.
Within thirty (30) days after the issuance or modification of any sublicense hereunder, LICENSEE shall furnish LICENSOR with a true and complete copy of the sublicense or any modification thereof; 
  
 e. The granting of any sublicense by LICENSEE shall in no way relieve
LICENSEE from any of the requirements of this LICENSE. Any sublicense granted by LICENSEE that does not comply with the requirements of this Article XI is void. 
  

 -11- 

 ARTICLE XII. 
 Reservation of Rights 
  
 LICENSOR reserves the right to require LICENSEE to and LICENSEE agrees to grant promptly sublicenses to responsible applicants on reasonable terms when necessary to fulfill health and safety needs of the public to the extent such needs are
not being reasonably satisfied by LICENSEE and its sublicensees. 
  
 This LICENSE is subject to the irrevocable, royalty-free right of the Government of the United States to practice and have practiced these LICENSED INVENTIONS throughout the world by or on behalf of the United States and by or on behalf of
any foreign government or intergovernmental or international organization pursuant to any existing or, future treaty or agreement with the Government of the United States. 
  
 This LICENSE is subject to any licenses, in force at the time of the grant of this LICENSE. 
  
 ARTICLE XIII. 
 Litigation 
  
 LICENSOR does not by entering into this LICENSE transfer the property rights in the LICENSED INVENTIONS, provided however, that LICENSEE has the right of enforcement of the LICENSED PATENTS, at no cost to the Government, pursuant to the
provisions of Chapter 29 of Title 35, United States Code, or other statutes. LICENSEE shall pay LICENSOR the lesser of (i) an amount equal to the royalty that would have been payable by LICENSEE in accordance with this LICENSE had the unlicensed
entity been licensed by LICENSEE, or (ii) one-half of the actual recovery after deduction of LICENSEE’S litigation costs and expenses. 
  
 IN WITNESS WHEREOF, the parties hereto have caused this instrument to be executed by their, duly authorized representatives. 
  

					
	UNITED STATES OF AMERICA
	For the Secretary of the Navy
			
	 	 	By:	 	  

	 	 	Title:	 	  

	 	 	Date:	 	  

  

 -12- 

			
	 GENETICS INSTITUTE, INC.

		
	 By:
	 	  

	 Title:
	 	  

	 Date:
	 	  

  

			
	 Attest:

	 	 

  

 -13- 

 SCHEDULE A 
  
 October 16, 1996 Letter 
  
 Via Telecopier 
 Original via Federal Express 
  
 Commanding Officer 
 Naval Medical Research and Development Command 
 Building One T-12 
 8901 Wisconsin Avenue 
 Bethesda, MD 20889-5606 Navy 
  
 Attention: Code 00CC44 – David Spevack 
  
 Dear Sir or Madame: 
  
 Genetics Institute, Inc. (“GI”) and The Naval Medical Research and Development Command (the “Navy”) have
signed a letter agreement dated October 16, 1995, pursuant to which the Navy consented to the substitution of GI for Repligen Corporation (“Repligen”) under a Cooperative Research and Development Agreement effective December 20, 1991, as
subsequently’ amended by Repligen and the Navy from time to time (the “CRADA”). As Repligen’s successor-in-interest under the CRADA, GI has assumed all of Repligen’s rights and obligations with respect thereto: 

 
 Pursuant to the terms of the CRADA, Or hereby exercises option to obtain
an exclusive license to the patent applications filed by the Navy within the last year. 
  
 In addition, GI respectfully requests that the Navy permit GI to exercise option to obtain an exclusive license to patent applications filed by the Navy, pursuant to option rights under the CRADA which have previously
expired. 
  
 By signing both copies of this letter and returning
one copy to me for our records, the Navy hereby acknowledges that 01 has exercised its option to obtain an exclusive license to the patent applications described above, on the terms and conditions set forth in the CRADA. 

 Commanding Officer 
 Naval
Medical Research and Development Command 
 October 16, 1995 
 Page 2 
  
 Thank you for your attention and
consideration. 
  
 Sincerely, 
  
 Thomas DesRosier 
 Vice President, 
 Chief Patent Counsel 
  
 AGREED TO AND ACCEPTED: 
  
 Naval Medical Research and Development Command 
  

			
	 By:

	 Print Name:
	 	  

	 Title:

 SCHEDULE B 
  

LICENSED PATENTS 
  

					
	 Serial Number/
Patent Number

	  	 Title and Inventor(s)

	  	Filing
Date/Issue
Date

	 USSN08/073, 223
	  	Methods for Selectively Stimulating Proliferation of T-Cells by Carl H. June, Craig B. Thompson, Gary J. Nabel and Gary S. Gray	  	06/04/93
			
	 USSN08/253, 964
	  	Methods for Selectively Stimulating Proliferation of T-Cells by Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, and Paul D. Rennert	  	06/03/94
			
	 USSN08/253, 751
	  	Methods for Selectively Stimulating Proliferation of T-Cells by Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert, and Gordon J. Freeman	  	06/03/94
			
	 USSN08/453, 925
 (Div. of USSN08/253, 751)
	  	Methods for Selectively .Stimulating Proliferation of T-Cells by Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert, and Gordon J. Freeman	  	05/30/95
			
	 USSN08/403, 253
	  	Methods for Selectively Stimulating Proliferation of T-Cells by Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, and Paul D. Rennert	  	03/10/95
			
	 USSN08/453, 816
	  	Methods for Selectively Stimulating Proliferation of T-Cells by Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, and Paul D. Rennert	  	05/04/95
			
	 USSN08/592, 711
	  	Methods for Selectively Stimulating Proliferation of T-Cells by Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, and Paul D. Rennert	  	01/02/96

					
	 Serial Number/
Patent Number

	  	 Title and Inventor(s)

	  	Filing
Date/Issue
Date

	 USSN08/245, 282
	  	Methods for Modulating T-Cell Activation by Manipulating CD-28-Associated Signal Transduction by Carl H. June	  	04/29/94
			
	 USSN08/435, 518
	  	Methods for Enhancing T-Cell Survival by Augmenting BCL-XL Protein Levels by Carl H. June and Craig B. Thompson	  	05/04/95
			
	 USSN08/481, 739
	  	Methods for Modulating T-Cell Survival by Modulating BCL-XL
Protein Level by Carl H. June and Craig B. Thompson	  	06/07/95
			
	 USSN08/435, 095
	  	Methods for Modulating Expression of Exogenous DNA in T-Cells by Carl H. June, Craig B. Thompson, and Suil Kim	  	05/04/95
			
	 USSN08/475, 136
	  	Improved Methods for Transfecting T-Cells by Carl H. June, Craig B. Thompson, and Suil Kim	  	06/07/95
			
	 06/07/95
	  	Methods for Selectively Stimulating Proliferation of T-Cells by Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, and Paul D. Rennert	  	06/03/95
			
	 70521/94
 Australia
	  	Methods for Selectively Stimulating Proliferation of T-Cells by Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, and Paul D. Rennert	  	06/03/94
			
	 2,164,226
 Canada
	  	Methods for Selectively Stimulating Proliferation of T-Cells by Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, and Paul D. Rennert	  	06/03/94
			
	 94 91 9346.0
 Europe
	  	Methods for Selectively Stimulating Proliferation of T-Cells by Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, and Paul D. Rennert	  	06/03/94

					
	 Serial Number/
Patent Number

	  	 Title and Inventor(s)

	  	Filing
Date/Issue
Date

	 501964/1995
 Japan
	  	Methods for Selectively Stimulating Proliferation of T-Cells by Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, and Paul D. Rennert	  	06/03/94
			
	 PCT/US94/13782
	  	Methods for Selectively Stimulating Proliferation of T - Cells by Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert, and Gordon F. Freeman	  	12/01/94
			
	 PCT/US95/05213
	  	Methods for Stimulating T-Cell Responses by Manipulating Intracellular Signal Transduction by Carl H. June	  	05/01/95
			
	 PCT/US96/06203
	  	Methods for Modulating T-Cell Survival by Augmenting BCL-XL
Protein Levels by Carl H. June and Craig B. Thompson	  	05/02/96
			
	 PCT/US96/06200
	  	Improved Methods for Transfecting T-Cells by Carl H. June, Craig B. Thompson, and Suil Kim	  	05/02/96

 Exhibit B 
  

Michigan Agreement 
  
  

 Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information
subject to the confidentiality request. Omissions are designated as [*]. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 
  
 LICENSE AGREEMENT 
  
 This is an Agreement dated as of the 28th day of May 1992 by and between Repligen Corporation, a Delaware corporation having its principal office at One
Kendall Square, Building 700, Cambridge, Massachusetts 02139 (hereinafter “Repligen”), and the Regents of the University of Michigan, a constitutional corporation of the State of Michigan having an office at 475 East Jefferson Street, Ann
Arbor, Michigan 48109-1248 (hereinafter “UM”). 
  
 WHEREAS, UM possesses certain intellectual property pertaining to immune regulation mediated by B7, [*] and CTLA-4; and 
  
 WHEREAS, Repligen desires to obtain licenses under said intellectual property rights; 
  
 NOW, THEREFORE, UM and Repligen agree as follows: 
  
 I. Definitions 
  
 1.1 “Parties, in singular or plural usage as required by the context,. means Repligen and/or UM. 
  
 1.2 The “Licensed Patents” means (i) UM’s ownership or license
interest in patent applications as listed in Appendix A hereof, as well as in all foreign equivalent patent applications, including Patent Cooperation Treaty filings, and all patents issuing therefrom in which UM has a property interest or under
which UM acquires licensing rights; and (ii) any divisions or continuations of the patents or patent applications set forth above, including any reissue, reexamination or extension of the above-described patents, any extended or restored term, and
any confirmation patent, registration patent, or patent of addition. UM shall notify Repligen, from time to time, as new patent applications are made or patents issued which fall within the definition of Licensed Patents and Appendix A shall be
appropriately updated to reflect such changes. 
  
 1.3 “Valid
Claim(s)” means any claim(s) pending in a patent application or in an unexpired patent included within the Licensed Patents which has not been held unenforceable, unpatentable, or invalid by a decision of a court or other governmental agency
‘of competent jurisdiction, unappealable or unappealed within, the time allowed for appeal, and which has not been admitted to be invalid or unenforceable through reissue or disclaimer. If in any country there should be two or more such
decisions conflicting with respect to the validity of the same claim, the decision of the higher or highest tribunal shall thereafter control; however, should the tribunals be of equal rank, then the decision or decisions upholding the claim shall
prevail when the conflicting decisions are equal in number, and the majority of decisions shall prevail when the conflicting decisions are unequal in number. 

 1.4 “Licensed Product” means any product in the Licensed Fields whose manufacture, use or sale
in any country would, but for either ownership of or a license under the Licensed Patents, comprise an infringement, including contributory infringement, of one or more Valid Claims in such country. 
  
 1.5 “Combination Product” means any Licensed Product sold in
combination with a second discrete product containing one or more active ingredients which are not Licensed Products. 
  
 1.6 “Sublicensee” means any person or entity (other than an Affiliate) sublicensed by Repligen to practice Licensed Patent(s) 
  
 1.7 “Net Sales” means the sum of all amounts received and all other
consideration received (when in a form other than cash or its equivalent, the fair market value thereof when received) by Repligen, its Affiliates or Sublicensees, as the case may be, from persons or entities who are not Affiliates or Sublicensees
by reason of the sale, distribution or use of Licensed Products, including Combination Products, less the following deductions and offsets but in the case of the deductions and offsets described in clauses (a)-(d) below only to the extent the monies
represented by such deductions and offsets have actually been included in the sum referred to above. 
  
 (a) trade and quantity discounts actually allowed and taken; 
  
 (b) returns, rebates and allowances when actually taken; 
  
 (c) retroactive price reductions, if any, when actually
credited; 
  
 (d) uncollected invoices for
Licensed Products, to the extent written off as uncollectible on Repligen’s, Affiliates’ or Sublicensees’ books, as the case may be; 
  
 (e) with regard to sales in the United States, four percent (4%) of the amount invoiced and paid to cover cash discounts, sales or excise
taxes, transportation and insurance charges; and with regard to sales outside the United States six percent (6%) to include the above and additional special packaging, duties, and other governmental charges. 
  
 1.8 “Territory” means all countries of the world. 
  
 1.9 “Affiliate(s)” means any individual, corporation, partnership,
proprietorship or other entity controlled by, controlling, or under common control with Repligen through equity ownership, ability to elect directors, or by virtue of a majority of overlapping directors, and shall include any individual,
corporation, partnership, proprietorship or other entity directly or indirectly owning, owned by or under common ownership with the party in question to the extent of fifty percent (50%) or more of the equity or voting shares, including shares owned
beneficially by such party. 
  

 -2- 

 1.10 “Royalty Quarters” means the three (3) months ending on the last day of March, June,
September and December of each year. 
  
 1.11 “Effective
Date” means the date upon which this Agreement has been entered into as mentioned in its introductory paragraph. 
  
 1.12 “Licensed Fields” means (i) immune stimulants in conjunction with vaccines, (ii) immunostimulation/suppression, and (iii) if the option
granted under Section 2.2 is exercised, the Option Fields. 
  
 1.13 “Option Fields” means all potential fields of use not) included in Licensed Fields, including (a) non-biological, chemically-synthesized drug compounds whose mode of action is intracellular and (b) non-biological,
chemically-synthesized drug compounds whose mode of action is extracellular. 
  
 II. License Grant 
  
 2.1 Subject
to the terms and conditions of this Agreement, UM grants to Repligen an exclusive license of UM’s interest under the Licensed Patents for the purpose of making, having made, manufacturing, using, marketing and selling Licensed Products, solely
within Licensed Fields, in the Territory, with the right to grant sublicenses to Affiliates and Sublicensees, neither of which shall be allowed to further sublicense the rights licensed hereunder 
  
 2.2 Subject to the terms and conditions of this Agreement, UM grants to
Repligen an exclusive option to include the Option Fields in the Licensed Fields. Such exclusive option shall be automatically exercised, and the Option Fields shall be included in the Licensed Fields on the first to occur of the following events:

  
 (a) the organization by Repligen of a separate corporate
entity to develop B7/[*]/CTLA-4 technology; 
  
 (b) demonstrated
intent by Repligen to obtain significant independent financing for the development of Licensed Products focusing on the B7/CTLA-4/[*] pathway; 
  
 (c) preparation of an IND (or similar application in any foreign country) acceptable for filing with respect to any product candidate in the Option
Fields; 
  
 (d) total documented expenditure by Repligen of five
million dollars ($5,000,000) on research relating to the development of Licensed Products focusing on the B7/CTLA-4/[*] pathway; 
  
 (e) execution of a development agreement or marketing agreement in the Licensed Fields or any Option Field between Repligen and any third party.

  

	[*]	Certain information on this page has been omitted and filed separately with the Securities & Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 -3- 

 If not sooner exercised, the exclusive option granted herein shall automatically expire if Repligen shall
fail to expend (and to document such expenditure annually, upon request) at least one million dollars ($1,000,000) on research relating to the development of Licensed Products focusing on the B7/CTLA-4/[*] pathway during any consecutive twelve (12)
month period ending on any anniversary of the Effective Date. Except as provided in the preceding sentence, such exclusive option shall remain in effect during the term of this Agreement. Unless and until such exclusive option expires, UM shall not
grant any rights in or to the Licensed Patents in the Option Fields, other than as provided in Section 2.3. 
  
 2.3 UM retains the right to grant to the Howard Hughes Medical Institute (“HHMI”) a non-exclusive, irrevocable, royalty-free license, without
the right to grant sublicenses, to the Licensed Patents, as required by UM’s Patent and Intellectual Property Agreement with HHMI. UM retains the right to use all aspects of the Licensed Patents, any means, solely for internal research and
education purposes. 
  
 III. Patent Protection
and Validity 
  
 3.1 UM represents and warrants to Repligen that:

  
 (a) UN is an owner of an undivided interest in the Licensed
Patents. (The Licensed Patents are jointly owned by UM and certain third parties); 
  
 (b) UM has the full right, power and authority to enter into this Agreement and to grant the licenses under Article II hereof; 
  

(c) UM is not aware of any pending or threatened litigation (and has not received any communication) which alleges that any Party’s activities in
the Licensed Fields or in the Option Fields have violated the intellectual property rights of any other person; 
  
 (d) UM is not aware of any unauthorized use, infringement or misappropriation of any of the Licensed Patents; and 
  
 (e) UM has not as of the Effective Date entered into any agreement with any
third party (other than an agreement with Bristol Myers Squibb regarding CTLA-4, the existence of which agreement has been disclosed to Repligen) concerning the transfer by UM or licensing by UM of, or grant by UN of a security interest in, any
rights to or under the Licensed Patents in the Licensed Fields or in the Option Fields. 
  
 In the event of any breach by UM of the representations and warranties set forth in this Section 3.1, any resulting liabilities, including legal and equitable, shall be limited to the sum of all payments received by
UM under Article VIII herein. 
  
 3.2 UM (and/or its joint owner
in the case of co-owned Licensed Patents including a licensee of such joint owner (“Joint Owner”)) shall control all aspects of prosecuting and 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities & Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 -4- 

 maintaining the Licensed Patents. UM shall not voluntarily relinquish its own right as a joint owner to participate in
the control of the prosecution and maintenance of the Licensed Patents. UM shall promptly notify Repligen of all information received by UN relating to the prosecution and maintenance of Licensed Patents, including without limitation any lapse,
revocation, surrender, invalidation or abandonment of any of the. Licensed Patents. 
  
 3.3 UM shall provide notice to Repligen of all reasonable and necessary expenses paid by UN to third parties in drafting, monitoring, filing, prosecuting and maintaining the Licensed Patents, and in maintaining or
asserting its inventorship or ownership interest in Licensed Patent(s), even as to the other Joint Owner, including without limitation fees paid to outside counsel or consultants; patent office fees for filing, prosecution, reissue, reexamination
and issue; maintenance fees; and reasonable travel expenses incurred by UM employees for the purpose of monitoring, prosecuting and maintaining the Licensed Patents, but not including any part of any UM employee’s salary. Upon receipt of such
notice, Repligen shall promptly reimburse UM for all such reasonable and necessary expenses except those expenses which are chargeable to Joint Owner. 
  
 3.4 UM and/or Joint Owner may in their/its sole discretion decide to refrain from or to cease prosecuting or maintaining any of the Licensed Patents. In
the event that both UM and Joint Owner make such decision, UN shall notify Repligen promptly and in sufficient time to permit Repligen at its sole discretion to continue such prosecution or maintenance at Repligen’s expense. If Repligen elects
to continue such prosecution or maintenance, UN shall execute such documents and perform such acts at Repligen’s expense as may be reasonably necessary for Repligen to so continue such prosecution or maintenance. 
  
 3.5 [*] of Repligen’s payments and expenses as described in Sections
3.3, 3.4, 3.10, 16.1 and 16.2 hereof, and [*] of .Repligen’s otherwise unrecovered expenses under Sections 3.6, 3.7 and 3.9 hereof shall be credited against earned royalties, subject to the limitations of Section 8.11, and amounts so credited
shall then be deemed recovered. 
  
 3.6 In the event either Party
shall learn of any potential infringement of a claim of any of the Licensed Patents, that Party shall immediately supply the other Party with written notice of such potential infringement. Provided this Agreement has not been terminated, Repligen
shall have the first right at its expense to institute and control all actions brought for infringement of any of the Licensed Patents when, in Repligen’s sole judgment, such action may be reasonably necessary, proper, and justified. In the
event Repligen declines within one year of its receipt of such notice of infringement to either (i) cause infringement to cease, or (ii) initiate legal proceedings against the infringer, UM may upon notice to Repligen initiate legal proceedings
against the infringer at UM’s expense. 
  
 3.7 In the event
either Party shall initiate or carry on legal proceedings to enforce any of the Licensed Patents against an alleged infringer, the other Party shall fully cooperate with, and supply all reasonable assistance requested by, the Party initiating or
carrying on such proceedings. Except as described in Section 3.11 below, the Party that institutes any suit to protect or enforce any of the Licensed Patents shall have sole control of that suit and shall bear 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities & Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 -5- 

 the reasonable expenses incurred by said other Party in providing such assistance and cooperation as is requested
pursuant to this section. 
  
 3.8 Any recovery obtained by either
UN or Repligen as the result of legal proceedings initiated and paid for by Repligen to enforce any of the Licensed Patents against an alleged infringer, whether obtained by settlement or otherwise, shall after payment of all otherwise unrecovered
expenses attributable to such action paid by Repligen or by UM or by both Repligen and UM, including without limitation fees paid to outside counsel or consultants, and reasonable travel expenses, but not including any part of any UM employee’s
salary or Repligen employee’s salary, be paid 75% to Repligen and 25% to UM. In the event that Repligen does not initiate the prosecution or defense of such action and maintain such action at its expense, UM shall retain 100% of its recovery
after payment to Repligen of any unrecovered expenses paid by Repligen at UM’s request to third parties in furtherance of such action. 
  
 3.9 Each Party shall immediately give notice to the other upon said Party’s receipt of any certification filed under the U.S. “Drug Price
Competition and Patent Term Restoration Act of 1984” claiming that any of the Licensed Patents is invalid or that infringement will not arise from the manufacture, use or sale of Licensed Products. If Repligen decides not to bring infringement
proceedings at its expense against the entity making such a certification, Repligen shall give notice to UM of its decision not to bring suit within twenty-one days after receipt of notice of such certification. At its expense, UM may then, but is
not required to, bring suit against the entity that filed the certification. Any suit by Repligen or UM shall either be in the name of Repligen or in the name of UM, or jointly by Repligen and UM, as may be required by law. For this purpose, the
party not bringing suit shall execute such legal papers necessary for the prosecution of such suit as may be reasonably requested by the party bringing suit. 
  
 3.10 The Parties shall cooperate with one another in gaining any patent term extension that may be applicable to the Licensed Patents. Any and all filings
for any such extension will be made by and at the expense of Repligen after consultation with UM. 
  
 3.11 Neither Party shall compromise or settle any claim or action regarding Licensed Patents in any manner that would affect the rights of the other Party
without the written consent of said other Party, which consent shall not be unreasonably withheld. 
  
 IV. Sublicenses 
  
 4.1 Repligen shall have the exclusive right under the license granted in Article II herein to grant sublicenses to Affiliates and Sublicensees under
Licensed Patents, provided: 
  
 (a) Repligen shall notify UM of
every sublicense agreement and each amendment thereto, within thirty (30) days after their execution, and indicate the name of the Sublicensee or Affiliate, territory of the sublicense, scope of the sublicense, and the nature, timing and amounts of
all fees and royalties to be paid thereunder; 
  
 (b) All
sublicenses shall attach a copy of this Agreement as an exhibit and shall be consistent with the terms of this Agreement; 
  

 -6- 

 (c) All sublicenses shall contain acknowledgements of the University’s disclaimer of warranty and
limitation on liability as provided by Section 12 below; and 
  
 (d) All sublicenses shall require the Sublicensee or Affiliate to accept duties equivalent to those accepted by Repligen herein in Sections 7.3, 9.3, 11, 17, 21 and 25. 
  
 4.2 Any sublicense granted by Repligen shall provide for its termination upon termination of this Agreement, provided,
however, that a sublicense granted to any Sublicensee may permit such Sublicensee, by written notice to UM within sixty (60) days of the Sublicensee’s receipt of written notice of such termination, to elect to continue its sublicense; subject
to the approval of UM of such continuation, which approval shall not be unreasonably withheld. No such election will be valid unless such Sublicensee agrees in writing at the time of election to assume in respect to UM all of the obligations
(including obligations for payment) contained in its sublicense agreement with Repligen. 
  
 V. License Rights; Future Ownership Rights 
  
 5.1 UM shall use continuing good faith efforts to obtain from the United States Navy an exclusive license, in accordance with the provisions of 37
CFR§404, to the United States Navy’s rights in U.S. Patent Application Serial No. 275,433. 
  
 5.2 Upon the date of the execution of this Agreement, Appendix A and the license granted in Section 3.1 shall not include license rights obtained by UM
pursuant to Section 5.1. By written agreement with Repligen, UM shall amend this Agreement and Appendix A hereto in order to include in Appendix A all license rights obtained by UM pursuant to Section 5.1, on the conditions that: 
  
 (a) any such amendment shall be subject to the express approval of the
United States Navy of this Agreement and such amendment; and 
  
 (b) such amendment shall include those terms or modifications of existing terms which may be required by 37CFR§404 or other applicable rules of the United States Government. 
  
 VI. Confidentiality and Publications 
  
 6.1 All technical information of either Party relating to the Licensed Patents or Licensed Products, which is disclosed to
the other Party during the term of this Agreement, in a writing marked “CONFIDENTIAL” (or, if initially orally disclosed, is confirmed in writing and designated as “CONFIDENTIAL” within thirty (30) days of such initial
disclosure), shall be maintained in confidence by the receiving Party for a period of three (3) years from receipt and shall not be disclosed by the receiving Party during that period to any other person, firm, or agency, governmental or private,
without the prior written consent of the disclosing Party, except to the extent that the information: 
  
 (a) is known at the time of its receipt as documented in written records, or 
  

 -7- 

 (b) is properly in the public domain, or 
  
 (c) is subsequently disclosed to the receiving Party by a third party who may lawfully do so, or 
  
 (d) is required to be disclosed to governmental agencies in order to gain
approval to sell Licensed Products, or 
  
 (e) is necessary to be
disclosed to agents, consultants, Affiliates, Sublicensees and/or other third parties for the research and development and/or marketing of Licensed Products under this Agreement, which entities first agree to-be bound by the confidentiality
obligations contained in this Agreement, or 
  
 (f) is required to
be disclosed by law or by court order. 
  
 (Such confidential
information to be maintained in confidence under this section is referred to below as “Confidential Information”.) 
  
 6.2 Repligen recognizes that under UM policy, research relating to Licensed Patents or Licensed Products must be publishable, subject to the terms set
forth herein. Repligen agrees that UM and HHMI researchers shall be permitted to present their results at symposia, national, or regional professional meetings, and to publish the results in journals, theses or dissertations, or otherwise of their
own choosing, provided, however, that Repligen shall have been furnished copies of any proposed publication or presentation relating to Licensed Patents or Licensed Products at least one month in advance of the submission of such proposed
publication or presentation to a journal, editor, or other third party. Repligen shall have one month after receipt of said copies, to object to such proposed presentation or proposed publication because there is patentable subject matter which
needs protection or because it contains Confidential Information of Repligen. 
  
 6.3 In the event that Repligen makes an objection under 6.2 above, said researcher(s) shall, as the case may be, remove Repligen’s Confidential Information from such publication, and refrain from making such
publication or presentation for a maximum of four (4) months from date of receipt of such objection in order for UM or Repligen to file patent application(s) with the United States Patent and Trademark Office or foreign patent office(s) directed to
the patentable subject matter contained in the proposed publication or presentation. 
  
 VII. Commercialization 
  
 7.1 It is understood that Repligen shall be responsible for obtaining any governmental approvals which may be necessary to manufacture and/or sell
Licensed Products. If Repligen decides in its sole discretion that it is feasible to manufacture and sell Licensed Products at an acceptable profit, Repligen shall use its best efforts to obtain such government approvals, and upon receipt thereof,
to cause Licensed Products to be manufactured and sold. For the purpose hereof, “best efforts” shall mean the usual practice followed by Repligen in pursuing commercialization of its products. In the event Repligen shall breach any
covenant set forth in 
  

 -8- 

 this Section 7.1, UM’s sole remedy with respect to such breach shall be to terminate this Agreement under Section
13.3. 
  
 7.2 Repligen shall keep UM informed, in writing of any
material developments with respect to Licensed Products. Repligen shall promptly inform UM of any patent applications, or similar applications, relating to Licensed Products or improvements thereon, filed by or on behalf of Repligen or Affiliates
anywhere in the world. 
  
 7.3 Repligen covenants to substantially
manufacture and require Affiliates and Sublicensees to substantially manufacture within the United States all of their Licensed Products. Where domestic manufacture is not commercially feasible, UM will cooperate with Repligen to obtain appropriate
waivers to this requirement from the United States Government. 
  
 VIII. Payments 
  
 8.1 The
license rights granted to Repligen herein are subject to Repligen’s payment of royalties to UN according to the provisions of this Article VIII. 
  
 8.2 Upon execution of this Agreement, Repligen shall pay eighty thousand dollars ($80,000) to UM. Upon receipt by UM of a license from the United States
Navy pursuant to Section 5.1 above, and the inclusion of such license rights in Appendix A pursuant to Section 5.2, Repligen shall pay an additional twenty thousand dollars ($20,000) to UM. 
  
 8.3 With respect to each Royalty Quarter, Repligen shall pay UM a royalty
equal to [*] of Repligen’s and Affiliates’ Net Sales of Licensed Products during such Royalty Quarter. 
  
 8.4 With respect to Combination Products, the fair market sales price of the active ingredient(s) of the discrete product(s) which are not themselves
Licensed Products shall be subtracted from the selling price used to calculate Net Sales with respect to such Combination Product; provided that in the case of a Combination Product which includes one or more Licensed Products which are also sold in
non-Combination Product form, the resulting Net Sales figure upon which UM’s royalty is based shall not be reduced to less than the normal aggregate Net Sales for such Licensed Product(s) when not sold as Combination Product. 
  
 8.5 The obligation to pay UM a royalty under this Article VIII is imposed
only once with respect to the same unit of Licensed Product regardless of the number of Valid Claims or Licensed Patents covering the same; however, for purposes of determination of payments due hereunder, whenever the term Licensed Product may
apply to a property during various stages of manufacture, use or sale, Net Sales’, as otherwise defined shall be derived from the sale, distribution or use of such Licensed Product by Repligen, Affiliates or Sublicensees, as ‘the case may
be, at the stage of its highest invoiced value to unrelated third parties. 
  
 8.6 With respect to each Royalty Quarter, Repligen shall pay UM [*] of any royalties received during such Royalty Quarter by Repligen or Affiliate(s) with respect to Net Sales of 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities & Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 -9- 

 Sublicensee(s), and no other royalties with respect to such Net Sales of Sublicensee(s), except that with respect to Net
Sales of Sublicensee(s) upon which Repligen or Affiliate(s) are themselves being paid a royalty by Sublicensee(s) of less than [*] of such Net Sales the following formula shall be applied to determine the royalty payment to UM: 
  
 UM’s royalty will be equal to such Net Sales of Sublicensee multiplied
by a royalty rate of “R” percent where R = [*] - [*]/[*]([*] - x) and “x” can be a maximum of [*] and a minimum of [*] and is the percentage rate of royalty paid by Sublicensee(s) to Repligen or Affiliate(s), as the case may be,
on the above described Net Sales. For example, if a particular Sublicensee is paying Repligen a royalty of [*] for Net Sales of a particular Licensed Product, then UM receives a royalty from Repligen equal to [*] of such Net Sales ([*] minus
one-eighth of the difference between [*] and [*]). The formula is intended to gradually reduce UM’s royalty below [*] for Net Sales of Sublicensee(s) who are themselves paying a royalty of less than [*] on such Net Sales, and it establishes [*]
as a minimum royalty rate to UM for such Net Sales by Sublicensee(s), including, if applicable, Net Sales of Combination Products as calculated in Section 8.4 above. 
  
 8.7 In addition, with respect to each Royalty Quarter, Repligen shall pay to UM [*] of any upfront or lump sum payments
which Repligen receives during such Royalty Quarter from any Sublicensee in consideration of the grant of its sublicense. For the purpose hereof, upfront or lump sum payments shall not include any payment made to Repligen as a royalty on Net Sales
of Sublicensee(s) or any Research Milestone Payment or Clinical Milestone Payment (as hereinafter defined). 
  
 8.8 (a) ”Research Milestone Payment” means any payment received by Repligen from any Sublicensee which is payable by reason of the attainment of
a research or development objective relating to technology described in Licensed Patent(s)’ or to Licensed Product(s) themselves. With respect to each Royalty Quarter, Repligen shall pay to UM [*] of each Research Milestone Payment received
during such Royalty Quarter. 
  
 (b) “Clinical Milestone
Payment” means any payment received by Repligen from any Sublicensee which is payable by reason of the attainment of a clinical objective relating to one or more Licensed Product(s). With respect to each Royalty Quarter, Repligen shall pay to
UM [*] of each Clinical Milestone Payment received during such Royalty Quarter. 
  
 (c) [*] of all amounts paid to UM under this Section 8.8 shall be credited against earned royalties, subject to the limitations contained in Section 8.11. 
  
 8.9 (a) If Repligen is required to pay an unrelated third party a royalty in a given country in order to sell the Licensed
Products in that country, then [*] of that royalty will be deducted from the royalty otherwise payable hereunder for Net Sales of such Licensed Products in that country, provided that in no event shall the royalty thus payable by Repligen be reduced
below [*] of Repligen’s or Affiliates’ Net Sales of Licensed Products in that country. Upon the 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities & Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 -10- 

 mutual agreement of the parties the royalty percentage for a particular Licensed Product may be reduced based on specific
indications and associated market size and conditions. 
  
 (b) If
Repligen is required to pay a royalty to the United States Navy or to HHMI in order to obtain the exclusive right as to the U.S. Navy, UM or HHMI, to practice any of the patents or patent applications included in Licensed Patents, in a given
country, then, in, addition to any amounts deducted under subparagraph (a) above, one-hundred percent (100%) of that royalty shall be deducted from the royalty otherwise payable hereunder for Net Sales of Licensed Products in that country, provided
that: (i) in no event shall the amounts deducted under this subparagraph (b) exceed’ one and [*] of the Net Sales of Licensed Products in that country; and (ii) in no event shall the royalty thus payable by Repligen, after all deductions under
this subparagraph (b) and subparagraph (a) above, be reduced below [*] of Repligen’s or Affiliates’ Net Sales of Licensed Products in that country. 
  
 8.10 Repligen agrees to pay minimum royalties to UM during the term of this Agreement on the following dates, for the following periods and in the
following amounts. 
  

				
	 Date

	  	Amount

	1. On January 1, 1995 for the calendar year beginning on that date, and on each January 1 thereafter, for each calendar year beginning on such date, but ceasing immediately prior to the date in
item 2 below.	  	$	10,000
		
	2. On the earlier of January 1, 1998 or the January 1 immediately following the initiation of Phase I Clinical Trials on the first Licensed Product, for the calendar date beginning on such date,
and on each January 1 thereafter, for each calendar year beginning on such date, but ceasing immediately prior to the date in item 3 below.	  	$	20,000
		
	3. On the January 1 immediately following the filing of a Product License Application for the first Licensed Product, for the calendar year beginning on such date.	  	$	50,000
		
	4. On the first and each subsequent anniversary of the payment in item 3 above, for the calendar year beginning on such date.	  	$	50,000

  
 All minimum royalties
paid for a given year which, are in excess of that year’s earned royalties shall be credited against future earned royalties otherwise payable under this Agreement, subject to the limitations in Section 8.11. 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities & Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 -11- 

 8.11 Notwithstanding anything to the contrary in this Agreement, the Parties agree that in no event shall
the aggregate reduction of earned royalties on account of credits allowed by UM to Repligen under this Agreement in any Royalty Quarter exceed [*] of the earned royalties otherwise payable under this Agreement for such Royalty Quarter. Any credits
in excess of these limitations shall be carried forward and applied against earned royalties in subsequent Royalty Quarters until fully credited or until termination of this Agreement. Upon termination of this Agreement, Repligen shall have no right
to recover unused credits except to the extent that they may continue to be credited against up to [*] of the royalties payable after termination, subject to the limitations set forth herein. 
  
 8.12 If at any time or from time to time an unrelated third party in any
country shall, under right of a compulsory license granted or ordered to be granted by a competent governmental authority, manufacture, use or sell any Licensed Product with respect to which royalties shall be payable pursuant to Section 8.3 herein,
then Repligen, upon notice to UM and during the period such compulsory license shall be effective, shall have the right to reduce such royalty to UM on each unit of Licensed Product sold in such country to an amount no greater than the amount
payable by said third party in consideration of its compulsory license. 
  
 8.13 Repligen agrees to refrain from any business dealing relating to Licensed Patents or Licensed Products in which a significant purpose or result would be to lower UM’s share of income or actual income resulting from this Agreement
or the sale, use or commercialization of Licensed Products. This Section 8.13 shall not be construed in such a way as to (i) enlarge Repligen’s obligations under Section 7.1 or (ii) provide any remedy to UM if Repligen terminates this Agreement
under Section 13.4. 
  
 IX. Reports 

 
 9.1 Within sixty (60) days after the close of each Royalty Quarter during
the term of this Agreement (including any Royalty Quarter which closes following any termination of this Agreement), Repligen shall report to UM all royalties or other payments accruing to UM under Article VIII during such Royalty Quarter. Such
quarterly reports shall indicate for each Royalty Quarter the gross sales and Net Sales of Licensed Products; such reports shall also indicate the source and amount of all other revenues with respect to which payments are due to UM and the amount of
such payments, as well as the various calculations used to arrive at said amounts, including the quantity, description. (nomenclature and type designation), country of sale and country of manufacture of Licensed Products. In case no payment is due
for any such period, Repligen shall so report. 
  
 9.2 Repligen
covenants that it will promptly establish and consistently employ a system of specific nomenclature and type designations for Licensed Products so that the various types can be identified and segregated. Repligen, Affiliates and Sublicensees will
consistently employ such system when rendering invoices thereon and henceforth agree to inform UN, or its auditors, when requested as to the details concerning such nomenclature system as well as to all additions thereto and changes therein.

  

	[*]	Certain information on this page has been omitted and filed separately with the Securities & Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 -12- 

 9.3 Repligen shall keep and it shall cause Affiliates and Sublicensees to keep, true and accurate records
and books of account containing data reasonably required for the computation and verification of payments to be made as provided by this Agreement, which records and books shall be open for inspection upon reasonable notice during business hours by
either UM auditor(s) or an independent certified accountant selected by UM, except one to whom Repligen has a reasonable objection, for the purpose of verifying the amount of payments due and payable. Said right of inspection may be exercised not
more than once in any calendar year, but will exist for four (4) years from the date of origination of any such record and this requirement and right of inspection shall survive any termination of this Agreement. UM shall be responsible for all
expenses of its auditor(s) or independent accountants associated with ‘such inspection. However, in the event that such inspection reveals an underpayment of royalties to UM in excess of ten percent (10%), then said inspection shall be at
Repligen’s expense and such underpayment shall become immediately due and payable to UM. If such inspection reveals an overpayment of royalties to UM, at Repligen’s election, UM shall promptly reimburse Repligen to the extent of such
overpayment or credit such overpayment against Repligen’s next royalty payment to UM. 
  
 9.4 The reports provided for hereunder shall be certified by an authorized representative of Repligen to be correct to the best of Repligen’s knowledge and information. 
  
 X. Time and Currencies of Payments 
  
 10.1 Payments accrued at the close of each Royalty Quarter shall be due and
payable in Ann Arbor, Michigan on the date each quarterly report, provided for under Article IX above, is due and shall be paid in United States dollars. Repligen agrees to make all payments due hereunder to UM by check made payable to the Regents
of the University of Michigan and sent by prepaid, certified mail, return receipt requested, to the address set forth in Article XVIII herein. 
  
 10.2 On all amount’s outstanding and payable to UM, interest shall accrue from the date such amounts are due and payable at a rate of two (2) points
above the prime lending rate as established by the Chase Manhattan Bank, N.A. in New York City, New York, or at such lower rate as may be required by law. 
  
 10.3 In the case of sales of Licensed Products transacted in foreign currency, such foreign currency shall be converted into its equivalent in United
States dollars at the exchange rate of such currency as reported (or if erroneously reported, as subsequently corrected) in the Wall Street Journal on the last business day of the Royalty Quarter during which such payments are received by Repligen,
Affiliates or Sublicenses, as the case may be (or if not reported on that date, as quoted by the Chase Manhattan Bank, N.A. in New York City, New York). 
  
 10.4 Except as provided in the definition of Net Sales, all royalty payment to UM under this Agreement shall be without deduction for sales, use, excise,
personal property or other similar taxes or other duties imposed on such payments by the government of any country or any political subdivision thereof; and any and all such taxes or duties shall be assumed by and paid by Repligen. Repligen shall
have no liability for any income taxes levied against UM on account 
  

 -13- 

 of royalties or other payments received by UN on account of royalties or other payments received by UM under this
Agreement. If laws or regulations require that any such taxes be withheld by Repligen, Repligen shall deduct such taxes from the payment due UM, pay the taxes so withheld to the taxing authority, and send proof of payment to UM within sixty (60)
days following such payment. 
  
 XI. Product
Liability 
  
 11.1 Repligen, Affiliates and Sublicensees assume
all risk of damage or injury to persons or property arising out of the clinical testing, manufacture, use, distribution or sale of the Licensed Products by them or authorized by them and shall hold harmless and indemnify UM, its officers and
employees from and against any and all personal injury, property damage, product liability or similar claims, losses and liabilities arising out of Repligen’s, Affiliates’ or Sublicensees’ (or any business associates of any of these)
clinical testing, manufacture, use, distribution or sale of the Licensed Products, including reasonable attorneys fees and other costs or defense. UM shall, promptly upon receipt of any claim that may be subject to indemnification hereunder, give
written notice to Repligen of such claim, and Repligen shall assume the defense thereof, including the employment of counsel reasonably satisfactory to UM. UM shall have the right to employ separate counsel in any such action and to participate in
the defense thereof, but the fees and expenses thereof shall be at UM’s expense. Repligen shall not be liable for any settlement of any such claim, action or proceeding effected without its written consent. 
  
 11.2 Repligen shall purchase and maintain, and require Affiliates and
Sublicensees to purchase and maintain, in effect a policy of product liability insurance covering all claims with respect to any Licensed Products used, manufactured, sold, licensed or otherwise distributed by Repligen within the term of this
Agreement, and shall specify UM as an additional insured. Repligen shall furnish a certificate of such insurance to UM, upon request. 
  
 XII. No Warranty; Limitations of Liability 
  
 12.1 EXCEPT AS PROVIDED IN SECTION 3.1, UM MAKES NO REPRESENTATIONS, EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT
LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND ASSUMES NO RESPONSIBILITIES WHATEVER WITH RESPECT TO DESIGN, DEVELOPMENT, MANUFACTURE, USE, SALE OR OTHER DISPOSITION BY REPLIGEN OR AFFILIATES OR
SUBLICENSEES OF LICENSED PRODUCTS. 
  
 12.2 THE ENTIRE RISK AS TO
PERFORMANCE OF LICENSED PRODUCTS IS ASSUMED BY REPLIGEN AND AFFILIATES AND SUBLICENSEES. In no event shall UM be responsible or liable for any direct, indirect, special, incidental, or consequential damages or lost profits to Repligen, Affiliates,
Sublicensees, users or any other individual or entity regardless of legal. theory. The above limitations on liability apply even though UM may have been advised of the possibility of such damage. 
  

 -14- 

 12.3 Repligen, Affiliates and Sublicensees shall make no statements, representations or warranties or
accept any liabilities or responsibilities whatsoever to or with regard to any person or entity which are inconsistent with any disclaimer or limitation included in this Article XII. 
  
 XIII. Term and Termination 
  
 13.1 Upon any termination of this Agreement, and except as provided herein to the contrary, all rights and obligations of
the Parties hereunder shall cease, except as follows: 
  
 13.1.1 Obligations to pay royalties and other sums accruing hereunder up to the day of such termination; 
  
 13.1.2 The right to complete the manufacture and sale of Licensed Products which qualify as “work in process” under generally
accepted cost accounting standards or which are in stock at the date of termination, and the obligation to pay royalties on Net Sales of such Licensed Products; 
  
 13.1.3 Obligations for record keeping and accounting reports for so long as Licensed Products are sold
pursuant to Paragraph 13.1.2 above. At such time after termination of this Agreement when sales or other dispositions of Licensed Products have ceased, Repligen shall render a final report and royalty payment, if required; 
  
 13.1.4 UM’s rights to inspect books and records as
described in Article IX; 
  
 13.1.5 Obligations
of defense and indemnity under Article XI; 
  
 13.1.6 Any cause of action or claim of Repligen or UN accrued or to accrue because of any breach or default by the other Party hereunder; 
  
 13.1.7 All other terms, provisions, representations, rights and obligations contained in this Agreement that by their sense and context
are intended to survive until performance thereof by either or both Parties. 
  
 13.2 This Agreement will become effective on its Effective, Date and, unless terminated under another specific provision of this Agreement, will remain in effect until, and terminate upon, the expiration of the last
to expire of Licensed Patents. 
  
 13.3 Upon any material breach
by either Party under this Agreement, the other Party may terminate this Agreement by ninety (90) days’ written notice to the breaching Party, specifying the material breach, default or other defect. Without limiting the generality of the
foregoing, any default by Repligen in the payment of any royalty or the making of any report hereunder, or the insolvency of Repligen shall be deemed to be a material breach. The termination shall become effective at the end of the ninety day period
unless the breaching Party cures the breach during the ninety (90) day period. 
  

 -15- 

 13.4 Notwithstanding anything in this Agreement to the contrary, Repligen may terminate’ this
Agreement by giving UM a notice of termination, which shall include a statement of the reasons, whatever they may be, for such termination and the termination date established by Repligen, which date shall not be sooner than ninety (90) days after
the date of the notice. Such notice shall be deemed by the Parties to be final and, immediately upon receipt of such notice of termination, UM shall have the right to begin negotiations, and enter into agreements, with others for the manufacture,
sale, and use of Licensed Products, and may, at its option, disclose to said others any and all information related to Licensed Products which UM, in its sole discretion, deems appropriate, other than information which is subject to confidentiality
under any agreement between UM and Repligen. During the period of time from the notice of termination until termination pursuant to this provision, Repligen shall continue any efforts ongoing immediately prior to the termination notice to
manufacture and sell Licensed Products. 
  
 XIV.
Governing Law and Venue 
  
 This Agreement and the relationships
between the Parties shall be governed in all respects by the law of the State of Michigan (notwithstanding any provisions governing conflict of laws under such Michigan law to the contrary), except that questions affecting the construction and
effect to any patent shall be determined by the law of the country in which the patent has been granted. The Parties understand and expressly agree that any claims, demands, or actions asserted against the Regents of the University of Michigan, its
agents or employees, shall be brought in the appropriate court of the State of Michigan. 
  
 XV. Assignment and Non-Pledge for Security 
  
 Due to the unique relationship between, the Parties, this Agreement shall not be assignable by either Party without the prior written consent of the other
Party, which consent shall not be unreasonably withheld; and any attempt to assign this Agreement without such consent shall be void from the beginning. Notwithstanding the foregoing, Repligen may assign this Agreement without UM’s consent to
any assignee or purchaser of all or substantially all of Repligen’s business provided the intended assignee agrees in writing to accept all of the terms and condition of this Agreement. Further, Repligen shall refrain from pledging any of the
license rights granted in this Agreement as security for any creditor. 
  
 XVI. Registration or Recordation 
  
 16.1 If the terms of this Agreement, or any assignment or license under this Agreement are or become such as to require that the Agreement or license or any part thereof be registered with or reported to a national or supranational agency
of any area in which Repligen, Affiliates or Sublicensees would do business, Repligen will, at its expense, undertake such registration or report. Prompt notice and appropriate verification of the act of registration or report of any agency ruling
resulting from it will be supplied by Repligen to UM. 
  
 16.2 Any
formal recordation of this Agreement or any license herein granted which is required by the law of any country as a prerequisite to enforceability of the Agreement or license in the courts of any such country or for other reasons shall also be
carried out by Repligen at its expense, and appropriately verified proof of recordation shall be promptly furnished to UM. 
  

 -16- 

 XVII. Export Laws and Regulations of the United States 
  
 17.1 The Export Regulations of the United States Department of Commerce
prohibit the exportation from the United States of certain types of technical data and commodities (listed in the Export Administration Regulations), unless the exporter (e.g., Repligen, Affiliates or Sublicensees) has received the required General
License or Validated License, whichever is applicable. In addition, the exporter may be required to obtain certain, written assurances regarding re-export from the foreign importer for certain types of technical data and commodities. Prior to its
engaging in any export activity, Repligen has advised UM that it will receive a copy of the then current Export Administration Regulations of the United States Department of Commerce and will arrange for a subscription under which it will receive
Supplementary Bulletins from the United States Department of Commerce upon their issuance. Should the Export Administration Regulations apply to the activities contemplated under this Agreement, Repligen hereby agrees to comply with, and to require
Affiliates to comply with the Export Administration Regulations of the United States Department of Commerce and Repligen hereby gives UM the assurances called for in the Export Administration Regulations, including the assurances called for in Part
779.4 and any successor provisions of such regulations. 
  
 17.2
This Agreement shall by subject to all United States Government laws and regulations now or hereafter applicable to the subject matter of this Agreement. 
  
 XVIII. NOTICES 
  
 Any notice, request, report, or payment required or permitted to be given or made under this Agreement by any Party shall be given by sending such notice
by certified mail, return receipt requested, to the address set forth below or such other address as such party shall have specified by written notice given in conformity herewith. Any notice not so given shall not be valid unless and until actually
received, and any notice given in accordance with the provisions of this section shall be effective when mailed to: 
  
 Notices to Repligen shall be addressed to: 
  
 Repligen Corporation 
 One Kendall Square

 Building 700 
 Cambridge,
Massachusetts 02139 
 Attention:        Mr. Sandford D. Smith 
  

 -17- 

 (with a copy to:) 
  
 Choate, Hall & Stewart 
 Exchange Place 
 53 State Street 
 Boston, Massachusetts 02139 
 Attention:        John M. Cornish, Esq. 
  
 Notices to UM shall be addressed to: 
  
 The University of Michigan 
 Intellectual Properties Office 
 475 East Jefferson Street, Room 2354 
 Ann
Arbor, Michigan 48109-1248 
 Attention:        File #377 
  
 XIX. Invalidity 
  
 In the event that any term, provision, or covenant of this Agreement shall
be determined by a court of competent jurisdiction to be invalid, illegal, or unenforceable, that term will be curtailed, limited, or deleted, but only to the extent necessary to remove such invalidity, illegality, or unenforceability, and the
remaining terms, provisions, and covenants shall not in any way be affected or impaired thereby. In the event that the time period of any covenant shall be held unenforceable as a matter of law, said covenant will be interpreted to be effective for
an enforceable time period. 
  
 XX. Entire
Agreement and Amendment 
  
 This Agreement contains the entire
understandings of the Parties with respect to the matter contained herein, and supersedes all prior agreements, oral or written, and all other communication between them relating to the subject matter hereof. The Parties hereto may, from time to
time during the continuance of this Agreement, modify, vary or alter any of the provisions of this Agreement, but only by an instrument duly executed by authorized officials of both Parties hereto. 
  
 XXI. Publicity 
  
 21.1 Each Party agrees to refrain from using (and in the case of Repligen to
require Affiliates and Sublicensees to refrain from using) the name of the other Party in publicity or advertising without the prior written approval of the other Party. Reports in scientific literature and presentations of joint research and
development work are not considered publicity. If a Party wishes to use the name of the other Party in financial disclosures, such Party must obtain prior written approval from the other Party, which approval will not be unreasonably withheld.

  
 21.2 Any announcements or similar publicity with respect to
this Agreement or the transactions contemplated herein shall be at such time and in such manner as UM and Repligen shall mutually agree, provided that nothing herein shall prevent either Party upon notice to the other from making such public
announcements as such party’s legal obligations require. 
  

 -18- 

 XXII. Bankruptcy 
  
 The parties hereto intend that the Agreement shall not be deemed an executory contract under the United States Bankruptcy
Code. If during the term of this Agreement, Repligen shall make an assignment for the benefit of creditors, or if proceedings in voluntary or involuntary bankruptcy shall be instituted in behalf of or against Repligen, and not be dismissed within
sixty (60) days after such proceedings are instituted, or if a receiver or trustee shall be appointed for the property of Repligen, UM may, at its option, terminate this Agreement and revoke the license herein granted by written notice to Repligen.

  
 XXIII. Financing Statements 
  
 Repligen agrees to cooperate with UM in the execution and filing (not
earlier than 120 days after execution of this Agreement) of financial statements under the Uniform Commercial Code, and of similar statements, providing notice of this License Agreement, in the United States Patent and Trademark Office, or other
federal agency or court as deemed appropriate by UM. 
  
 XXIV. Force Majeure 
  
 No failure or omission by the
Parties hereto in the performance of any obligation of this Agreement shall be deemed a breach of this Agreement or create any liability if the same shall arise from any cause or causes beyond the control of the Parties, including, but not limited
to, the following: act of God; acts or Omissions of any government; any rules, regulations or orders issued by any governmental authority or by any officer, department, agency or instrumentality thereof; fire; storm; flood; earthquake; accident;
war; rebellion; insurrection; riot; invasion; strikes, and lockouts and provided that such failure or omission resulting from one of the above causes is cured as soon as is practicable after the occurrence of one or more of the above-mentioned
causes. 
  
 XXV. Product Marking 
  
 Repligen agrees to mark, and to require Affiliates and Sublicensees to mark,
Licensed Products with the appropriate patent notice as approved by UM, such approval not to be unreasonably withheld. 
  
 XXVI. Non-Waiver 
  
 No waiver, other than as agreed to in writing by the Parties, no matter how long continuing or how many times extended, by either Party of a breach of any
term or condition of this Agreement shall be considered as a permanent waiver or as an amendment to this instrument. 
  

 -19- 

 XXVII. Article Headings 
  
 The Article headings herein are for purposes of convenient reference only and shall not be used to construe or modify the
terms written in the text of this Agreement. 
  
 XXVIII. No Agency Relationship 
  
 Except as clearly and
specifically provided under the terms and provisions of this Agreement, neither Party shall be deemed to be an agent of the other in connection with the exercise of any rights hereunder, and neither shall have any right or authority to assume or
create any obligation or responsibility on behalf of the other. 
  
 XXVIX. Repligen Represents and Warrants 
  
 Repligen represents and warrants to UM that it has not entered into any agreement with any third party in connection with the Licensed Patents, and that in future it will not enter into any’ such agreement which
conflicts or interferes with the terms of this Agreement. 
  
 IN
WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly authorized representatives as of the date first written above. 
  

									
	 FOR REPLIGEN CORPORATION
	 	 	 	 FOR THE REGENTS OF THE UNIVERSITY OF MICHIGAN

					
	 By
	 	 /s/ Sandford D. Smith

	 	 	 	 By
	 	 /s/ Anne C. Di Sante

	 	 	       (authorized representative)
	 	 	 	 	 	       (authorized representative)

					
	 Typed Name
	 	 Sandford D. Smith
	 	 	 	 Typed Name
	 	 Anne C. Di Sante

	 Title
	 	 President & CEO
	 	 	 	 Title
	 	 Acting Director, Intellectual Properties

	 Date
	 	 May 28, 1992
	 	 	 	 Date
	 	 May 28, 1992

  

 -20- 

 Appendix A 
 to License Agreement 
 (5/28/92) 
 UM/Repligen 
  
 APPENDIX A

  
 LICENSED PATENTS 
  

					
	UM’s joint ownership interest in U.S. Patent Application Serial Number 275,433	  	—  	  	 Immunotherapy Involving
 CD28 Stimulation

	  	  
	  	  
			
	UM’s joint ownership interest in the Continuation—in-Part filed as U.S. Patent Application Unofficial Serial, Number 07/864,805	  	—  	  	 CD28 Pathway Immunoregulation

	  	  
	  	  
	  	  
			
	UM’s joint ownership interest in the Continuation-in-Part filed as U.S. Patent Application Unofficial. Serial Number 07/864, 866	  	—  	  	 Enhancement of CD28-Regulated
 Immune Response

	  	  
	  	  
	  	  

  

 -21- 

 Exhibit C 
  

Dana Farber Cancer Institute Agreement 
  
  

 Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information
subject to the confidentiality request. Omissions are designated as [*]. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 
  
 LICENSING AGREEMENT 
  
 Agreement (“AGREEMENT”), effective as of July 20, 1993 (“Effective Date”) between REPLIGEN CORPORATION, a Delaware corporation, with
its principal place of business at One Kendall Square, Building 700, Cambridge, Massachusetts 02139 (hereinafter referred to as “Repligen”) and the DANA-FARBER CANCER INSTITUTE, INC., a Massachusetts non-profit corporation, with its
principal place of business at 44 Binney Street, Boston, Massachusetts, 02115 (hereinafter referred to as “DFCI”). 
  
 WITNESSETH: 
  
 WHEREAS, DFCI is the owner of certain rights in technology as later defined herein, subject only to (i) a royalty-free, nonexclusive license heretofore
granted to the United States Government, and (ii) certain rights granted to Coulter Corporation which are described herein; 
  
 WHEREAS, DFCI desires to have its rights utilized to promote the public interest by granting a license thereunder; 
  
 WHEREAS, Repligen has represented to DFCI that Repligen is experienced in the
development and production of products similar to the technology which is the subject of this AGREEMENT and has the financial capacity and strategic commitment to facilitate the transfer of such technology for the public interest; and 
  
 WHEREAS, Repligen desires to obtain a license to said rights upon the terms
and conditions hereinafter set forth. 
  
 NOW THEREFORE, in
consideration of the mutual covenants herein contained and intending to be legally bound hereby, the parties hereto agree as follows: 
  
 ARTICLE I - Definitions 
  
 1.1 “Inventions” shall mean all discoveries, inventions, concepts, ideas or tangible property in which DFCI has any proprietary interest,
whether patentable or not, made, conceived or reduced to practice pursuant to the Research Agreement, including, but not limited to processes, methods, formulas, techniques, antibodies, vectors, plasmids and host cells. 
  
 1.2 “Technical Information” shall mean all Inventions not covered
by Patent Rights. 
  
 1.3 “Patent Rights” shall mean (i)
the patents and patent applications listed in Appendix A, (ii) any other existing or future patent or patent application arising from any 

 Invention, and (iii) all foreign equivalent patents and patent applications, including Patent Cooperation Treaty filings,
and all patents issuing therefrom, any divisions, continuations, or continuations-in-part of the patents or patent applications set forth above, including any reissue, reexamination or extension, any extended or restored term, and any confirmation
patent, registration patent or patent of addition. DFCI shall promptly notify Repligen, from time to time as new patent applications are made or patents issued which fall within the definition of Patent Rights and Appendix A shall be appropriately
updated to reflect such changes. 
  
 1.4 “Licensed
Products” shall mean any product whose manufacture, use or sale in any country would, but for either ownership of or a license under the Patent Rights, comprise an infringement of one or more Valid Claims in such country. 
  
 1.5 “Territory” shall mean all countries of the world. 

 
 1.6 “Net Sales” shall mean the gross income derived by Repligen
or its Affiliates from the sales of Licensed Products to independent third parties less: 
  
 (a) Transportation and insurance charges or allowances actually paid or granted; 
  
 (b) Trade, quantity, cash or other discounts and brokers’ or agents’ commissions, if any, allowed and paid by Repligen or its Affiliates to
independent parties in arms-length transactions; 
  
 (c) Credits
or allowances made or given on account of rejects, returns or retroactive price reductions; 
  
 (d) Any tax, customs duty or governmental charge directly on sale or transportation, use or delivery of products paid by Repligen or its Affiliates and not recovered from the purchaser; 
  
 (e) Uncollected invoices for Licensed Products to the extent written off as
uncollectible by Repligen or its Affiliates; 
  
 (f) The cost of
devices for dispensing or administering Licensed Products or of diluents or similar exogenous materials which accompany Licensed Products when sold; and 
  
 (g) The cost of special packaging of Licensed Products. 
  
 Licensed Products shall be considered “sold” when invoiced. 
  

 -2- 

 1.7 “Sublicensee” shall mean any corporation, partnership or business organization which is not
an Affiliate and which is sublicensed by Repligen to practice the Patent Rights. 
  
 1.8 “Affiliate” shall mean any corporation or other business entity controlled by, controlling, or under common control with Repligen. For this purpose “control” means direct or indirect beneficial
ownership of at least a fifty percent (50%) interest in the income or stock of such corporation or other business. 
  
 1.9 “Valid Claims” shall mean any claim(s) pending in a patent application or in an unexpired patent included within the Patent Rights which has
not been held unenforceable, unpatentable, or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has not been admitted to be invalid or
unenforceable through reissue or disclaimer. If in any country there should be two or more such decisions conflicting with respect to the validity of the same claim, the decision of the higher or highest tribunal shall thereafter control; however,
should the tribunals be of equal rank, then the decision or decisions upholding the claim shall prevail when the conflicting decisions are equal in number, and the majority of decisions shall prevail when the conflicting decisions are unequal in
number. 
  
 1.10 “Research Agreement” shall mean the
Collaborative Research, Research Support, and License Option Agreement between DFCI and Repligen effective as of February 15, 1992, as amended and as the same may be hereafter amended. 
  
 1.11 “Field” shall mean (i) all therapeutic and prophylactic applications, and (ii) all diagnostic applications
and research reagent applications which are included in the Field pursuant to Section 9.3 of this AGREEMENT. 
  
 1.12 “Coulter” shall mean Coulter Corporation, a corporation with offices at 440 West 20th Street, Hialeah, Florida. 
  
 ARTICLE II - Grant 
  
 2.1 DFCI hereby grants to Repligen, subject to all the terms and conditions
of this AGREEMENT including the nonexclusive license heretofore granted to the United States Government, an exclusive right and license in the Field under the Patent Rights to make, have made, use, lease and sell the Licensed Products in the
Territory for the term of this AGREEMENT unless this grant is sooner terminated according to the terms hereof. DFCI also hereby grants to Repligen an exclusive royalty-free right and license in the Field under the Technical Information to make, have
made, use, lease and sell products of any nature in the Territory for the term of this AGREEMENT unless this grant is sooner terminated according to the terms hereof. 
  

 -3- 

 2.2 Notwithstanding the provisions of Section 2.1, DFCI shall retain the right to use and practice the
Patent Rights and Technical Information for its own non-commercial, basic research purposes. 
  
 2.3 Repligen agrees that Licensed Products leased or sold in the United States shall be manufactured substantially in the United States. 
  
 2.4 (a) Repligen shall have the right, subject to the terms of this Section, to enter into sublicensing agreements with any
entity other than an Affiliate for the rights, privileges and licenses granted hereunder at royalty rates not less than those delineated in Section 4.2 hereof. DFCI shall be informed by written notice of the identity of any prospective Sublicensee.

  
 (b) Repligen agrees that any sublicenses granted by it shall
provide that the obligations to DFCI contained in this AGREEMENT shall be binding upon the Sublicensee. Repligen further agrees to attach a copy of this AGREEMENT to sublicense agreements. 
  
 (c) From any royalties received from its Sublicensee, Repligen shall pay DFCI
an amount equivalent to [*] of such royalties, except that with respect to Net Sales of Sublicensee(s) upon which Repligen is being paid a royalty by Sublicensee(s) of less than [*] of such Net Sales, the following formula shall be applied to
determine the royalty payment to DFCI. DFCI’s royalty will be equal to such Net Sales of Sublicensee multiplied by a royalty rate of “R” percent where R = [*] - [*] * ([*] - x) and “x” can be a maximum of [*] and a minimum
of [*] and is the percentage rate of royalty paid by Sublicensee(s) to Repligen on the above described Net Sales. For example, if a particular Sublicensee is paying Repligen a royalty of [*] for Net Sales of a particular Licensed Product, then DFCI
receives a royalty from Repligen equal to [*] of such Net Sales ([*] minus one-eighth of the difference between [*] and [*]). The formula is intended to gradually reduce DFCI’s royalty below [*] for Net Sales of Sublicensee(s) who are
themselves paying a royalty of less than [*] on such Net Sales, and it establishes [*] as a minimum royalty rate to DFCI for such Net Sales by Sublicensee(s). Reporting and payment of such royalties shall be made in accordance with the provision of
Article IV and V. 
  
 (d) In addition, in the case of any
sublicense agreement executed pursuant to Section 2.4(a) within two (2) years of the Effective Date, if the payments received by Repligen in consideration for the grant of such sublicense exceed Repligen’s total investment in the rights so
sublicensed, Repligen shall pay to DFCI an amount equal to [*] of such excess. For the purpose hereof, payments received in consideration for the 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities & Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 -4- 

 grant of a sublicense shall not include earned royalty payments, payments in consideration for the performance of
services or the transfer of tangible property or payments due upon the achievement of research, clinical, or development milestones, and shall include payments received in consideration of the issuance of Repligen stock to the Sublicensee
simultaneously with the grant of such sublicense only to the extent that the issue price exceeds [*] of the then market price of Repligen stock. 
  
 (e) Repligen agrees to forward to DFCI a copy of any and all fully executed sublicense agreements, and further agrees to forward to DFCI annually a copy
of such reports received by Repligen from its Sublicensees during the preceding twelve (12) month period under the sublicenses as shall be pertinent to a royalty accounting under said sublicense agreements. 
  
 (f) Repligen hereby agrees that every sublicensing agreement to which it
shall be a party and which shall relate to the rights, privileges and license granted hereunder shall contain a statement setting forth the date upon which Repligen’s exclusive rights, privileges and license hereunder shall terminate.

  
 ARTICLE III - Due Diligence 
  
 3.1 Repligen agrees to use its best efforts to bring one or more Licensed
Products to the marketplace through a diligent program of development, production and distribution. For the purpose hereof, “best efforts” shall mean the usual practice followed by Repligen in pursuing commercialization of its products.
Repligen shall be deemed to have satisfied its obligation under this Section 3 in each year that it expends (or its Sublicensees expend) at least $1,000,000 on the research, development or commercialization of Licensed Products. 
  
 3.2 Repligen’s failure to perform in accordance with Section 3.1 shall
be grounds for DFCI to terminate pursuant to Section 7.5 of this AGREEMENT. It is understood that termination shall be DFCI’s sole and exclusive remedy for any such failure to perform. 
  
 3.3 Upon written request from DFCI, Repligen shall provide an annual report
on its development efforts, which report shall cite specific goals and objectives in commercializing the Licensed Products and progress in meeting these goals and objectives. 
  
 3.4 If DFCI believes that one or more Licensed Product candidates could be pursued by Repligen in one or more portions of
the Field, and Repligen is not actively 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities & Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 -5- 

 pursuing such candidates in such portions of the Field, DFCI may by notice to Repligen request that Repligen pursue such
candidates in such portions of the Field. If Repligen does not comply with DFCI’s request, Repligen and DFCI will discuss the sublicensing of such candidate to a third party in such portion of the Field. However, the decision as to whether to
grant any such sublicense shall be made by Repligen alone, and Repligen shall have no obligation to pursue or sublicense such candidate provided that Repligen is in compliance with its obligations under Section 3.1. 
  
 ARTICLE IV - Payments 
  
 4.1. In partial consideration for the license granted hereunder, Repligen is
to make certain payments to DFCI under the Research Agreement. 
  
 4.2 In partial consideration for the license, granted hereunder, Repligen shall pay royalties to DFCI equal to five percent (5%) of Net Sales. 
  
 4.3 Upon termination of the last to expire Patent Right covering a Licensed Product, Repligen’s obligation to pay royalties will terminate.

  
 4.4 In the event that a Licensed Product under this AGREEMENT
is sold in a combination product, package or kit containing other active products, then Net Sales for purposes of determining royalty payments on such combination product or package, shall be calculated using the following method, but in no event
shall the royalties payable to DFCI be reduced to less than [*] of that provided for in Section 4.2 hereof: By multiplying the net selling price of that combination product or package by the fraction A/A+B, where A is the gross selling price during
the royalty-paying period in question of the Licensed Product sold separately, and B is the gross selling price during the royalty period in question of the other active products sold separately. If no separate sales are made of the Licensed Product
or of any of the active products in such combination product or package during the royalty-paying period in question, A shall be the gross cost of producing the Licensed Product component of the package, and B shall be the gross cost of producing
all other active products in the package. 
  
 4.5 (a) If Repligen
or an Affiliate is required to pay an unrelated third party a bona fide royalty in a given country in order to sell a Licensed Product in that country, then [*] of that royalty will be deducted from the royalty otherwise payable hereunder for Net
Sales of such Licensed Product in that country. In addition, in the event that after the reductions set forth above, the aggregate royalties payable by Repligen and its Affiliates to third parties (including DFCI) with respect to any Licensed
Product in any country exceeds [*], then the royalty payable to DFCI hereunder shall be further reduced so that 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities & Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 -6- 

 the cumulative royalty percentage for such Licensed Product does not exceed [*]; provided, however, that the royalty
payable to DFCI hereunder shall be reduced on a pro rata basis with all other royalties with respect to such Licensed Product which can be so reduced, so that the total cumulative royalty will equal [*], and in no case shall DFCI’s royalty due
under Section 4.2 be reduced due to this Section 4.5 by more than [*]. Upon the mutual agreement of the parties, the royalty percentage for a particular Licensed Product may be reduced based on specific indications and associated market size and
conditions. 
  
 (b) Repligen shall permit DFCI to review the
economic substance of all arrangements pursuant to which Repligen owes any royalty described in Section 4.5(a). If DFCI believes that any such royalty is not bona fide or the result of arms-length bargaining, it may dispute the same by notice to
Repligen. If Repligen and DFCI are unable to resolve such dispute, it shall be arbitrated under Article XI. 
  
 4.6 If at any time or from time to time an unrelated third party in any country shall, under right of a compulsory license granted or ordered to be
granted by a competent governmental authority, manufacture, use or sell any Licensed Product with respect to which royalties shall be payable pursuant to Section 4.2 hereof, then Repligen, upon notice to DFCI and during the period such compulsory
license shall be effective, shall have the right to reduce such royalty to DFCI on each unit of Licensed Product sold in such country to an amount no greater than the amount payable by said third party in consideration of its compulsory license.

  
 4.7 Payment of royalties specified in Section 4.2 shall be
made by Repligen to DFCI within forty-five (45) days after March 31, June 30, September 30 and December 31 each year during the term of this AGREEMENT covering the quantity of Licensed Products sold by Repligen during the preceding calendar quarter.
The last such payment shall be made within forty-five (45) days after termination of this AGREEMENT. 
  
 4.8 All payments to be made under this Article shall be paid in United States dollars in Boston, Massachusetts, or at such other place and in such other
way, as DFCI may reasonably designate, without deduction of exchange, collection or other charges. 
  
 4.9 Only a single royalty shall be paid with respect to any Licensed Product irrespective of the number of claims of Patent Rights utilized. 

 

	[*]	Certain information on this page has been omitted and filed separately with the Securities & Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 -7- 

 4.10 In the event that any payment due hereunder is not made when due, the payment shall accrue interest
beginning on the first day following the due date as herein specified, calculated at the annual rate of the sum of (a) [*] plus (b) the prime interest rate quoted by the Bank of Boston on the date said payment is due, the interest being compounded
on the last day of each calendar quarter, provided that in no event shall said annual rate exceed the maximum legal interest rate in Massachusetts. The payment of such interest shall not foreclose DFCI from exercising any other rights it may have as
a consequence of the lateness of any payment. 
  
 4.11 The parties
acknowledge that at some future time Repligen may wish to purchase from DFCI all of DFCI’s right to receive future payments under this Article IV (other than this Section 4.11) (the “Future Payments”). If Repligen desires to purchase
the Future Payments, it will give notice to DFCI. Thereupon, the parties will negotiate in good faith with respect to the price and other terms of such purchase, it being understood that the price will be the fair market value of the Future Payments
as determined by agreement between the parties. The purchase price may be paid entirely in cash, partly in cash and partly in shares of Repligen common stock as the parties may agree. If the parties are unable to agree upon the price or other terms
of the purchase, neither party shall have any liability or obligation to the other as a result of the failure to consummate the purchase of the Future Payments. 
  

ARTICLE V - Reports and Records 
  
 5.1 Repligen shall keep true books of account containing, an accurate record of all data necessary for the determination of the amounts payable under
Article IV hereof. Said records shall be kept at Repligen’s principal place of business or the principal place of business of the appropriate division of Repligen to which this AGREEMENT relates. Said records shall be available for inspection
at DFCI’s sole expense by a certified public accountant selected by DFCI and reasonably acceptable to Repligen during regular business hours for five (5) years following the end of the calendar year to which they pertain in order for DFCI to
ascertain the correctness of any report and/or payment made under this AGREEMENT. There shall be no more than one (1) such inspection in any calendar year. The provisions of this Section 5.1 shall survive termination of this Agreement. 

 
 5.2 Within forty-five (45) days after March- 31, June 30, September 30 and
December 31, of each year in which this AGREEMENT is in effect, commencing with the first year in which a Licensed Product is sold for commercial purposes, Repligen shall deliver to DFCI full, true and accurate reports of its activities and those of
its 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities & Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 -8- 

 Sublicensee(s), if any, relating to this AGREEMENT during the preceding three month period. These reports shall include
at least the following: 
  
 (a) Number of Licensed Products
manufactured and sold; 
  
 (b) Total billings for Licensed
Products sold, where applicable; 
  
 (c) Deductions applicable to
a determination of Net Sales; and 
  
 (d) Total royalties due.

  
 5.3 With each such report, Repligen shall pay to DFCI the
royalties due and payable as provided for in Section 4.7. If no royalties are due, Repligen shall so report. 
  
 ARTICLE VI - Patent Prosecution and Infringement 
  
 6.1 Repligen shall have primary responsibility for the preparation, filing, prosecution and maintenance of all patent applications and patents included in
the Patent Rights with patent counsel selected by Repligen. Repligen shall furnish to DFCI copies of all documents relevant to the preparation, filing, prosecution or maintenance of the Patent Rights sufficiently in advance of filing to permit
review and comment by DFCI. DFCI shall cooperate fully with Repligen in the preparation, filing, prosecution .and maintenance of the Patent Rights, including, without limitation, the execution of all documents necessary for filing with governmental
authorities. 
  
 6.2 Payment of all fees and costs relating to the
filing, prosecution and maintenance of all Patent Rights shall be the responsibility of Repligen whether such fees and costs were incurred before or after the date of this AGREEMENT, provided that Repligen shall have no liability for such fees and
costs incurred after the date of this Agreement to the extent properly allocable to Patent Rights licensed to Coulter pursuant to Section 9.3 (a). 
  
 6.3 (a) If at any time during the term of this AGREEMENT either party received or obtains evidence of an infringement of a patent included in the Patent
Rights, it shall give notice thereof to the other party. Thereupon, Repligen shall have the right, but not the obligation, at its sole expense, to cause such infringement to terminate or to bring a suit or action to compel termination. If Repligen
brings such suit, payment of fifty percent (50%) of the royalties which are payable under Article IV hereof shall be waived so long as such infringement continues. 
  
 (b) If Repligen fails to cause such infringement to terminate or to bring a suit or action to compel termination within six
(6) months of the notice provided under Section 6.3(a), or if before said six (6) months expires Repligen notifies DFCI that it does not intend to take any such action, DFCI shall have the right, but not the obligation, at its sole expense to bring
such suit or action to compel termination. 
  

 -9- 

 (c) No settlement, consent judgment or other voluntary final disposition of any suit under Section 6.3(a)
or (b) may be entered into without the consent of DFCI and Repligen, which consent shall not unreasonably be withheld. Any damages recovered by such suit or action shall be first used to reimburse each party hereto for the cost of such suit or
action (including attorney’s fees) actually paid by each party hereto as the case may be, then to reimburse DFCI for any royalties waived under Section 6.3(a). The residue, if any; of any suit or action under this Section 6.3 shall be paid
seventy-five percent (75%) to the party that initiated such suit or action, and twenty-five percent (25%) to the other party. 
  
 6.4 In the event that a declaratory judgment-action alleging invalidity or non-infringement of any of the Patent Rights shall be brought against DFCI,
Repligen at its sole option, shall have the right, within thirty (30) days after commencement of such action, to intervene and take over the sole defense of the action at its own expense. 
  
 6.5 In any infringement suit as either party may institute to enforce the Patent Rights pursuant to this AGREEMENT, the
other party hereto shall, at the request and expense of the party initiating such suit, be joined as a party to such suit and cooperate in all respects and, to the extent possible, have its employees testify when requested and make available
relevant records, papers, information, samples and the like. 
  
 ARTICLE VII - Term and Termination 
  
 7.1 Unless earlier
terminated as hereinafter provided, this AGREEMENT shall remain in full force and effect for the life of the last to expire patent issued under the Patent Rights; provided, however, that with respect to any products incorporating Technical
Information, the AGREEMENT shall extend for so long as any such products are sold by Repligen, its Affiliates or Sublicensees. 
  
 7.2 If Repligen shall cease to carry on its business with respect to LICENSED PRODUCTS, the AGREEMENT shall terminate upon notice by DFCI. 
  
 7.3 Should Repligen fail to pay DFCI such royalties as are due and payable
hereunder, DFCI shall have the right to terminate this AGREEMENT on forty-five (45) days written notice, unless Repligen shall pay DFCI within the forty-five (45) notice period, all such royalties and interest that are due and payable. Upon the
expiration of the forty-five (45) day period, if Repligen shall not have paid all such royalties and interest due and payable, DFCI, at its sole option, may immediately terminate this AGREEMENT and all rights, privileges and license hereunder
granted. 
  

 -10- 

 7.4 Repligen shall have the right to terminate this AGREEMENT at any time upon six (6) months written
notice to DFCI, and upon payment of all amounts due DFCI through the effective date of termination. Upon any material breach or default of this AGREEMENT by DFCI, Repligen shall have the right to terminate this AGREEMENT upon ninety (90) days
written notice to DFCI. Such termination shall become effective immediately at the conclusion of such notice period unless DFCI shall have cured any such breach or default prior to the expiration of such ninety (90) day period. 
  
 7.5 Upon any material breach or default of this AGREEMENT by Repligen, other
than those delineated in Sections 7.2 and 7.3 which shall always take precedence in that order over any material breach or default referred to in this Section 7.5, DFCI shall have the right to terminate this AGREEMENT and the rights, privileges and
license hereunder granted upon ninety (90) days written notice to Repligen. Such termination shall become effective immediately at the conclusion of such notice period unless Repligen shall have cured any such breach or default prior to the
expiration of the ninety (90) day period. 
  
 7.6 Upon termination
of this AGREEMENT for any reason, nothing herein shall be construed to release either party from any obligation that matured prior to the effective date of such termination. Repligen and any Sublicensee thereof may, after the effective date of such
termination, sell all Licensed Products which are in inventory at the time of termination, and complete the production of and sell Licensed Products which Repligen can clearly demonstrate were in the process of manufacture at the time of such
termination, provided that Repligen shall pay to DFCI the royalties thereon as required by Article IV of this AGREEMENT and shall submit the reports required by Article V hereof on the sales of Licensed Products. 
  
 7.7 Upon termination of this AGREEMENT for any reason, any sublicense not
then in default shall continue in full force and effect except that DFCI shall be substituted in place of the sublicensor. 
  
 ARTICLE VIII - Indemnification and Insurance 
  
 8.1 Repligen shall indemnify, defend and hold harmless DFCI and its trustees, officers, medical and professional staff, employees, and agents and their
respective successors, heirs and assigns (the “Indemnitees”), against any liability, damage, loss or expense (including reasonable attorneys’ fees and expenses of litigation) incurred by or, imposed upon the Indemnitees, or any one of
them, in connection with any claims, suits, actions, demands or judgments (a) arising out of the design, production, manufacture, sale, use in commerce, lease, or promotion by Repligen or by a Sublicensee, Affiliate or agent of Repligen, of any
product, process or service relating to, or developed pursuant to this AGREEMENT or (b) arising out of any other activities to be carried out pursuant to this AGREEMENT. 
  

 -11- 

 8.2 Repligen’s indemnification under 8.1 shall not apply to any liability, damage, loss or expense
to the extent that it is attributable to (a) the negligent activities of the Indemnitees, or (b) the intentional wrongdoing or intentional misconduct of the Indemnitees. 
  
 8.3 At such time as any product, process or service relating to, or developed pursuant to, this AGREEMENT is being
commercially distributed or sold (other than for the purpose of obtaining regulatory approvals) by Repligen or by a Sublicensee, Affiliate or agent of Repligen,.Repligen shall, at its sole cost and expense, procure and maintain policies of product
liability insurance in amounts not less than $2,000,000 per incident and $2,000,000 annual aggregate and naming DFCI as an additional insured. If Repligen elects to self-insure all or part of the limits described above (including deductibles or
retentions which are in excess of $250,000 annual aggregate), such self-insurance program must be acceptable to the DFCI and the DFCI’s associated Risk Management Foundation. The minimum amounts of insurance coverage required under these
provisions shall not be construed to create a limit of Repligen’s liability with respect to its indemnification obligation under Section 8.1 of this AGREEMENT. 
  
 8.4 Repligen shall provide DFCI with written evidence of such insurance upon request of DFCI. Repligen shall provide DFCI
with written notice at least fifteen (15) days prior to the cancellation, non-renewal or material change in such insurance; if Repligen does not obtain replacement insurance providing comparable coverage within such fifteen (15) day period, or a
self-insurance program described in Section 8.3 DFCI shall have the right to terminate this AGREEMENT effective at the end of such fifteen (15) day period upon notice to Repligen. 
  
 8.5 Repligen shall maintain such product liability insurance beyond the expiration or termination of this AGREEMENT during
(a) the period that any product, process, or service, relating to, or developed pursuant to, this AGREEMENT is being commercially distributed or sold (other than for the purpose of obtaining regulatory approvals) by Repligen or by a licensee,
affiliate or agent of Repligen and (b) a reasonable period after the period referred to in 8.5(a) above which in no event shall be less than fifteen (15) years. 
  

8.6 In the event any such action is commenced or claim made or threatened against DFCI or other Indemnitees as to which Repligen may be obligated to
indemnify it (them) or hold it (them) harmless, DFCI or the other Indemnitees shall promptly notify Repligen of such event. Repligen shall assume the defense of, and may settle with counsel of its own choice and at its sole expense, that part of any
such claim or action commenced or made against DFCI (or other Indemnitees) which relates to Repligen’s indemnification, and Repligen may take such other steps as may be necessary to protect itself. Any Indemnitee may participate in the defense
of any such claim or action with counsel of its own choice, but the fees and expenses of such counsel shall be borne solely 
  

 -12- 

 by such indemnitee. Repligen shall not be liable to DFCI or other Indemnitees on account of any settlement of any such
claim or litigation effected without Repligen’s prior written consent. The right and obligation of Repligen to assume the defense of any action shall be limited to that part of the action commenced against DFCI and/or Indemnitees which relates
to Repligen’s obligation of indemnification and holding harmless. Any other part of any such action shall be defended by the Indemnitee at its own cost and expense. 
  
 8.7 This Article VIII shall survive expiration or termination of this AGREEMENT. 
  
 ARTICLE IX - Representations, Warranties and Other Agreements 
  
 9.1 DFCI represents and warrants to Repligen that (i) DFCI is the owner of
the Patent Rights and the Technical Information free and clear of claims by any third party except as expressly provided in Section 2.1 and Section 9.2, (ii) DFCI has the full right, power and authority to execute and deliver this AGREEMENT, to
grant the licenses provided hereunder, and to perform its obligations hereunder, and (iii) the terms of this AGREEMENT do not conflict with any other agreement, order or judgment to which DFCI is a party or by which it is bound. 
  
 9.2 DFCI further represents and warrants to Repligen that Coulter has
unconditionally and irrevocably waived any and all rights that it may have to any and all therapeutic and prophylactic applications of the Patent Rights and the Technical Information. In consideration for such waiver, DFCI and Coulter have agreed
that (i) Coulter shall have a right to license from DFCI for a limited period of time any B7 related diagnostic product or research reagent product (a) developed, or which could be developed, from the Patent Rights or Technical Information as they
exist as of the Effective Date, or (b) developed by DFCI under the Research Agreement, (ii) Coulter shall pay to DPCI a [*] royalty on Coulter’s and its affiliates’ net sales of any diagnostic products or research reagent product described
in clause (i), and (iii) Repligen shall pay to Coulter $250,000 upon the commencement by Repligen of Phase III clinical trials in the United States for each B7 therapeutic product covered by the Patent Rights as they exist on the Effective Date, but
in no event more than $1,000,000 in the aggregate. 
  
 9.3 In
order to effectuate and carry out the terms of the agreement between DFCI and Coulter, DFCI and Repligen agree as follows: 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities & Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 -13- 

 (a) DFCI shall promptly notify Coulter each time that a patent application is filed covering any B7
related diagnostic product or research reagent product described in clause (i) of Section 9.2, and of Coulter’s right to obtain a license under the same for such product. If DFCI and Coulter fail for any reason to enter into a license agreement
under such Patent Rights for such product within six months following Coulter’s receipt of such notice from DFCI, Coulter’s right to obtain such license for such product shall automatically terminate, and such diagnostic or research
reagent product shall automatically be included in the Field and exclusively licensed to Repligen pursuant to the terms of this Agreement. 
  
 (b) In the event that Coulter shall enter into any license agreement pursuant to Section 9.3(a), DFCI shall provide a copy of such license agreement to
Repligen. DFCI shall pay to Repligen an amount equal to [*] of all payments which DFCI is entitled to receive pursuant to each such license agreement, including, without limitation, all upfront, milestone and royalty payments, but excluding any
payments for research services rendered by DFCI or out-of-pocket expenses incurred by DFCI, and specifically reimbursed by Coulter. 
  
 (c) In the event that Repligen (i) develops any B7 therapeutic product covered by the Patent Rights as they exist on the Effective Date, and (ii)
commences Phase III clinical trials in the United States for such product, Repligen shall within sixty days after the commencement of such trials pay to Coulter the sum of $250,000. Repligen’s obligations under this Section 9.3(c) shall
terminate when payments hereunder have been made with respect to four such products. 
  
 9.4 EXCEPT AS EXPRESSLY PROVIDED ABOVE, DFCI MAKES NO WARRANTY, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR OF FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO ANY
PATENT, TRADEMARK, SOFTWARE, NON-PUBLIC OR OTHER INFORMATION, OR TANGIBLE RESEARCH PROPERTY, LICENSED OR OTHERWISE PROVIDED TO REPLIGEN HEREUNDER AND HEREBY DISCLAIMS THE SAME. 
  
 9.5 DFCI DOES NOT WARRANT THE VALIDITY OF THE PATENT RIGHTS LICENSED HEREUNDER AND MAKES NO REPRESENTATION WHATSOEVER WITH
REGARD TO THE SCOPE OF THE LICENSED PATENT RIGHTS OR THAT SUCH PATENT RIGHTS MAY BE EXPLOITED BY LICENSEE, AFFILIATE OR SUBLICENSEE WITHOUT INFRINGING OTHER PATENTS. IF BIOLOGICAL MATERIALS ARE LICENSED HEREUNDER, DFCI MAKES NO REPRESENTATION THAT
SUCH MATERIALS OR THE METHODS USED IN 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities & Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 -14- 

 MAKING OR USING SUCH MATERIALS ARE FREE FROM LIABILITY FOR PATENT INFRINGEMENT. 
  
 ARTICLE X - Notices 
  
 10.1 Reports, notices and other communications from Repligen to DFCI as
provided hereunder shall be sent to: 
  
 Dr. Bernard W. Janicki

 Director for Research 
 Dana-Farber Cancer Institute 
 44 Binney Street 
 Boston, MA 02115 
  
 or other
individuals or addresses as shall hereafter be furnished by written notice to Repligen. 
  
 10.2 Reports, notices and other communications from DFCI to Repligen as provided hereunder shall be sent to: 
  
 Repligen Corporation 
 One Kendall Square

 Building 700 
 Cambridge, MA
02139 
 Attention:        President 
  
 with a copy to: 
  
 John M. Cornish, Esq. 
 Choate, Hall &
Stewart 
 Exchange Place, 53 State Street 
 Boston, MA 02109 
  
 or other
individuals or addresses as shall hereafter be furnished by written notice to DFCI. 
  
 ARTICLE XI - Arbitration 
  
 11.1
Any controversy or claim arising out of, or relating to, any provisions of this AGREEMENT or the breach thereof which cannot otherwise be resolved by good faith negotiations between the parties shall be resolved by final and binding arbitration in
Boston, Massachusetts under the rules of the American Arbitration Association, or the Patent Arbitration Rules if applicable, then obtaining. The arbitration shall be subject to the following terms: 
  

 -15- 

 (a) The number of arbitrators shall be one (1). 
  
 (b) The arbitrator shall be an independent, impartial third party having no
direct or indirect personal or financial relationship to any of the parties to the dispute, who has agreed to accept the appointment as arbitrator on the terms set out in this Section 11.1. 
  
 (c) The arbitrator shall be an active or retired attorney, law professor, or
judicial officer with at least five (5) years experience in general commercial matters and a familiarity with the laws governing proprietary rights in intellectual property. 
  
 (d) The arbitrator shall be selected as follows: 
  
 (i) Each party shall submit a description of the matter to be arbitrated to the American Arbitration
Association at its Regional Office in Boston, Massachusetts. Said Association shall submit to the parties a list of the arbitrators available to arbitrate any dispute between them. Thereafter, each party shall select, in numerical order, those
persons on said list acceptable as arbitrators and return the same to the Association. The first arbitrator acceptable to both parties shall be deemed the selected arbitrator with respect to the dispute then at issue under this AGREEMENT. In the
event of a failure to select a mutually agreeable arbitrator, the Association shall be requested to submit as many subsequent lists of arbitrators as shall be necessary to effect a mutual selection. 
  
 (ii) If the method of selection set out in paragraph (d)(i)
fails for any reason, then either party may petition any state or federal court in Massachusetts having jurisdiction for appointment of the arbitrator in accordance with applicable law, provided that the arbitrator must satisfy the requirements of
(b) and (c) above. 
  
 (e) The arbitrator shall announce the award
in writing accompanied by written findings explaining the facts determined in support of the award, and any relevant conclusions of law. 
  
 (f) Unless otherwise provided in this Section 11.1 or extended by agreement of the parties, each party shall submit an initial request for designation of
an arbitrator within thirty (30) days after any request for arbitration, the dispute shall be submitted to the arbitrator within ninety (90) days after the arbitrator is selected, and a decision shall be rendered within thirty (30) days after the
dispute is submitted. 
  
 (g) The fees of the arbitrator and any
other costs and fees associated with the arbitration shall be paid in accordance with the decision of the arbitrator. 
  

 -16- 

 (h) The arbitrator shall have no power to add to, subtract from, or modify any of the terms or conditions
of this AGREEMENT. Any award rendered in such arbitration may be enforced by either party in either the courts of the Commonwealth of Massachusetts or in the United States District Court for the District of Massachusetts, to whose jurisdiction for
such purposes DFCI and Repligen each hereby irrevocably consents and submits. 
  
 11.2 Notwithstanding the foregoing, nothing in this Article shall be construed to waive any rights or timely performance of any obligations existing under this AGREEMENT. 
  
 ARTICLE XII - Restrictions on Use of Names 
  
 12. Repligen shall not use the names of DFCI, its related entities and its
employees, or any adaptations thereof, in any advertising, promotional or sales literature, or in any reports required by the Securities and Exchange Commission (except to the extent that such use is required under applicable securities laws or the
rules and regulations thereunder), without the prior written consent of DFCI in each case; provided, however, that Repligen (a) may refer to publications by employees of DFCI in the scientific literature or (b) may state that a license from DFCI has
been granted as herein provided. 
  
 ARTICLE XIII - Independent
Contractor 
  
 13. For the purpose of this AGREEMENT and all
services to be provided hereunder, both parties shall be, and shall be deemed to be, independent contractors and not agents or employees of the other. Neither party shall have authority to make any statements, representations or commitments of any
kind, or to take any action, that will be binding on the other party. 
  
 ARTICLE XIV - Severability 
  
 14. If any one or more of
the provisions of this AGREEMENT shall be held to be invalid, illegal or unenforceable, the validity, legality or enforceability of the remaining provisions of this AGREEMENT shall not in any way be affected or impaired thereby. 
  
 ARTICLE XV - Assignability 
  
 15. Neither this AGREEMENT nor any part hereof shall be assignable by either
party without the express written consent of the other. Any attempted assignment without such consent shall be void. Notwithstanding the foregoing, Repligen may assign this Agreement without DFCI’s consent to any Affiliate, to any entity
(whether or not an Affiliate) formed or availed of to facilitate the research, development, manufacture, use, 
  

 -17- 

 or sale of Licensed Products or the financing of the same, or to any assignee or purchaser of all or substantially all of
Repligen’s business provided the intended assignee agrees in writing to accept all of the terms and conditions of this Agreement. 
  
 ARTICLE XVI - Entire AGREEMENT 
  
 16. This instrument and the Research Agreement contain the entire AGREEMENT between the parties hereto with respect to the subject matter hereof. No
verbal agreement, conversation or representation between any officers, agents, or employees of the parties hereto either before or after the execution of this AGREEMENT shall affect or modify any of the terms or obligations herein contained.

  
 ARTICLE XVII - Modifications in Writing 
  
 17. No change, modification, extension, termination or waiver of this
AGREEMENT, or any of the provisions herein contained, shall be valid unless made in writing and signed by a duly authorized representative of each party. 
  
 ARTICLE XVIII - Governing Law 
  
 18. The validity and interpretation of this AGREEMENT and the legal relations of the parties to it shall be governed by the laws of the Commonwealth of
Massachusetts. 
  
 ARTICLE XIX - Captions 
  
 19. The captions are provided for convenience and are not to be used in
construing this AGREEMENT. 
  
 ARTICLE XIX - Construction

  
 20. The parties agree that they have participated equally in
the formation of this AGREEMENT and that the language herein should not be presumptively construed against either of them. 
  
 IN WITNESS WHEREOF, the parties hereto have caused this AGREEMENT to be executed in quadruplicate by their duly authorized representatives as of the date
first above written. 
  

									
	 DANA-FARBER CANCER INSTITUTE (DFCI)
	 	 	 	 REPLIGEN CORPORATION

					
	 By:
	 	  

	 	 	 	 By:
	 	  

					
	 Title:
	 	  

	 	 	 	 Title:
	 	  

			
	 WITNESSED BY:
	 	 	 	 WITNESSED BY:

	
	 	 	 	

  

 -18- 

 APPENDIX A 
  
 PATENT RIGHTS 
  
 U.S. Patent Appl. No. 591,300, DNA Encoding B7, a New Member of the IGG Superfamily with Unique Expression on Activated and Neoplastic B Cells, filed on October 1, 1990

  
 U.S. Patent Appl. No. 751,306, a Continuation-in-Part Application involving
the same subject matter as No. 591,300, filed on August 28, 1991 
  

 -19- 

 Exhibit D 
  

Patents 
  

			
	 Serial No.

	  	 Title/misc

	 07/864,807
	  	“Immunotherapy involving stimulation of THCD28 lymphokins production”
	 07/902,467
	  	“Immunotherapy involving CD28 stimulation”
	 08/073,223
	  	“Methods for selectively stimulating proliferation of T cells”
	 08/253,964
	  	“Methods for selectively stimulating proliferation of T cells”
	 08/253,751
	  	“Methods for selectively stimulating proliferation of T cells”
	 PCT/US94/06255
	  	“Methods for selectively stimulating proliferation of T cells”
	 PCT/US94/06701
	  	“CD28 pathway immunosuppression”
	 08/403,253
	  	“Methods for selectively stimulating proliferation of T cells”
	 08/435,095
	  	“Methods for Modulating Expression of Exogenous DNA in T cells”
	 08/453,925
	  	“Methods for selectively stimulating proliferation of T cells”
	 08/475,136
	  	“Improved methods for Transfecting T Cells
	 08/435,816
	  	“Methods for selectively stimulating proliferation of T cells”
	 08/477,165
	  	“Immunotherapy Involving Stimulation of THCD28 Lymphokine Production”
	 08/476,818
	  	“Methods for selectively stimulating proliferation of T cells”
	 08/435,518
	  	“Methods for enhancing T cells survival by augmenting bci-XL, protein level”
	 08/481,739
	  	“Methods for enhancing T cells survival by augmenting bci-XL, protein level”
	 PCT/US94/13782
	  	“Methods for selectively stimulating proliferation of T cells”
	 PCT/US96/06203
	  	“Methods for enhancing T cells survival by augmenting bci-XL, protein level”
	 PCT/US96/06200
	  	“Improved Methods for transfecting T cells”
	 08/592,711
	  	“Methods for selectively stimulating proliferation of T cells”

  

 Schedule 6.1 
  
 Exceptions to Patents Warranty 
  
 None

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00061-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00061-of-00352.parquet"}]]